

HA2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/31134 A2

(51) International Patent Classification⁷: **C12N 9/64**

(21) International Application Number: **PCT/US01/31874**

(22) International Filing Date: 12 October 2001 (12.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/240,117 12 October 2000 (12.10.2000) US

(71) Applicant (for all designated States except US): **FER-RING BV** [US/US]; Polaris Avenue 144, NL-2132 JX Hoofddorp (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **QI, Steve** [GB/US]; 11034 West Ocean Air Drive, Apt. 24B, San Diego, CA 92130 (US). **AKINSANYA, Karen, O.** [GB/US]; 7675 Palmilla Drive, Apt. 642B, San Diego, CA 92122-5094 (US). **RIVIERE, Pierre, J.-M.** [FR/US]; 3993 Via Can-grejo, San Diego, CA 92130 (US). **JUNIEN, Jean-Louis** [FR/FR]; Ferring SAS, F-75507 Paris (FR).

(74) Agents: **SAMPLES, Kenneth, H.** et al.; Fitch, Even, Tabin & Flannery, 120 South LaSalle Street, Suite 1600, Chicago, IL 60603 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/31134 A2

(54) Title: NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

(57) Abstract: Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.

Novel Serine Protease Genes Related to DPPIV

Field of the Invention

The present invention relates to novel serine proteases related to dipeptidyl peptidase IV (DPPIV), and to isolated nucleic acids coding for these proteases, all of which are useful for the discovery of new therapeutic agents, for measuring protease activity, and for determining the inhibitory activity of compounds against these proteases.

Background of the Invention

Proteases and peptidases are enzymes that catalyse the hydrolysis of peptidic amide bonds. Proteases play an important role in the regulation of biological processes in almost every life-form from bacteria to virus to mammals. They perform critical functions in, for example, digestion, blood clotting, apoptosis, activation of immune responses, zymogen activation, viral maturation, protein secretion and protein trafficking. They can be classified according to a number of criteria, such as site of action, substrate preference, and mechanism. So, for example, aminopeptidases act preferentially at the N-terminal residues of a peptide, while carboxypeptidases act preferentially at the C-terminus and endopeptidases act at sites removed from the two termini. Among the carboxy- and aminopeptidases, peptidyl peptidases cleave a single amino acid residue from the substrate, dipeptidyl peptidases cleave a dipeptide unit (two amino acids) from the substrate, and tripeptidases cleave three amino acids from the substrate. Substrate preference is frequently expressed in terms of the amino acid residue immediately N-terminal to the cleavage site. For example, trypsin-like peptidases will preferentially cleave a peptide next to a basic amino acid (arginine or lysine), i.e. where the bond hydrolysed is the Arg/Lys-Xaa bond. As another example, the chymotrypsin-like family of peptidases preferentially hydrolyse peptides adjacent to an aromatic residue. Mechanistically, peptidases are classified as being serine-dependent, cysteine-dependent, aspartic acid-dependent or zinc-dependent.

Because peptidases and proteases are involved in the regulation of many physiological processes, they are attractive targets for the development of therapeutic agents. Protease and peptidase inhibitors are, for example, used in the treatment of hypertension, coagulation disorders, and viral infection.

Proteolytic enzymes that exploit serine in their catalytic activity are ubiquitous, being found in viruses, bacteria and eukaryotes. Over 20 families (denoted S1 - S27) of serine protease have been identified; these are grouped into 6 clans (SA, SB, SC, SE, SF

and SG) on the basis of structural similarity and other functional evidence. Structures are known for four of the clans (SA, SB, SC and SE); these appear to be totally unrelated, suggesting at least four evolutionary origins of serine peptidases and possibly many more, Rawlings and Barrett, Meth. Enzymol. 244: 19-61 (1994).

5 The prolyl oligopeptidase family consists of a number of evolutionarily related peptidases whose catalytic activity seems to be provided by a charge relay system similar to that of the trypsin family of serine proteases, but which evolved by independent convergent evolution. A conserved serine residue has been shown experimentally (in *E. coli* protease II as well as in pig and bacterial PE) to be necessary for the catalytic
10 mechanism. This serine, which is part of the catalytic triad (Ser, His, Asp), is generally located about 150 residues away from the C-terminal extremity of these enzymes (which are all proteins that contains about 700 to 800 amino acids).

 One of the most intensively studied prolyl oligopeptidases is dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5), a type II glycoprotein, which is the only well characterised
15 dipeptidyl aminopeptidase known to be located on the outer side of plasma membranes. As indicated above, dipeptidyl aminopeptidases are characterised by their ability to cleave N-terminal dipeptides from a variety of small peptides. Dipeptidyl aminopeptidases show different substrate specificities and cellular localisation, suggesting different functions of each activity in peptide processing. DPPIV is characterised by its capacity to cleave N-
20 terminal dipeptides containing proline or alanine as the penultimate residue. The DPPIV gene spans approximately 70 kb and contains 26 exons, ranging in size from 45 bp to 1.4 kb. The nucleotide sequence (3,465 bp) of the cDNA contains an open reading frame encoding a polypeptide comprising 766 amino acids. The nucleotides that encode the active site sequence (G-W-S-Y-G) are split between 2 exons. This clearly distinguishes
25 the genomic organisation of the prolyl oligopeptidase family from that of the classic serine protease family.

 DPPIV is widely distributed in mammalian tissues and is found in great abundance in the kidney, intestinal epithelium and placenta (Yaron, A. and Naider, F., Critical Reviews in Biochem. Mol. Biol. 1993 [1], 31). In the human immune system,
30 the enzyme is expressed almost exclusively by activated T-lymphocytes of the CD4⁺ type where the enzyme has been shown to be synonymous with the cell-surface antigen CD26. Although the exact role of DP-IV in human physiology is still not completely understood, recent research has shown that the enzyme clearly has a major role in human physiology and pathophysiology.

On human T cells, DPPIV expression appears late in thymic differentiation and is preferentially restricted to the CD4⁺ helper/memory population, and CD26 can deliver a potent co-stimulatory T-cell activation signal. DPPIV, also known as T-cell activation antigen CD26, therefore plays an important role in the immune response via association with CD45 tyrosine phosphatase and, through its ability to bind adenosine deaminase (ADA) to the T-cell surface, protects the T-cell from adenosine-mediated inhibition of proliferation. Furthermore, the regulation of the function of chemokines by CD26/DPPIV appears to be essential for lymphocyte trafficking and infectivity of HIV strains. DPPIV has been associated with numerous functions including involvement in T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells, Pethiyagoda et al., Clin. Exp. Metastasis 2000;18(5):391-400. DPPIV is also implicated in the endocrine regulation and metabolic physiology. More particularly, DPPIV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Glucagon-like peptide-1 (GLP-1), an incretin that induces glucose-dependent insulin secretion, is rapidly degraded by DPPIV, and since the half-life for DPPIV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10- fold) is anticipated from DPP-IV inhibition. Inhibitors of DPPIV are currently being studied in the clinic as potential therapeutic agents for type 2 diabetes and impaired glucose tolerance.

Various different inhibitors of DPPIV were known in 1993. One of these is a suicide inhibitor N-Ala-Pro-O-(nitrobenzoyl-) hydroxylamine. Another is a competitive inhibitor: e-(4-nitro) benzoxycarbonyl-Lys-Pro, and another is a polyclonal rabbit anti-porcine kidney DPPIV immunoglobulin. Others have since been developed and are described in detail in U.S. Patents Nos. 5,939,560, 6,110,949m 6,011,155 and 5,462,928.

In addition to, but independent of, its serine type catalytic activity, DPPIV binds closely to the soluble extracellular enzyme adenosine deaminase (ADA), acting as a receptor and is thought to mediate signal transduction. DPPIV structure is characterized by two extracellular domains, an α/β fold hydrolase domain and a 7-blade beta-propeller domain consisting of repeated beta sheets of about 50 amino acids. Recently it has been shown that, besides selecting substrates by size, the beta-propeller domain, containing 10 of the 12 highly conserved cysteine residues, contributes to catalysis of the peptidase domain. In addition, the cysteine-rich domain is responsible for DPPIV-binding to collagen I and to extracellular ADA. DPPIV is also reported to play a role in fibronectin-

mediated interactions of cells with extracellular matrix. Recent studies show that the protease activity of DPPIV is not required for its anti-invasive activity because mutants of DPPIV that lack the extracellular serine protease activity maintain such activity.

A number of proteins that share similarities with DPPIV have been reported in the literature. Several of these proteins have been cloned including DPP-I, DPP-II, DPP-III, DPP-X and fibroblast activation protein (FAP). These have been identified and characterised either by molecular cloning and functional studies of expressed proteins or as biochemical activities in tissue extracts. DPPIV-beta and other novel peptidases with functional similarities to DPPIV are not yet cloned. The identification, characterization and/or appropriate classification of further members of the family of prolyl oligopeptidases, the elucidation of their physiological (and particularly pathophysiological) role, and the application of that knowledge to the development of new therapeutic agents are significant challenges.

Summary of the Invention

The present invention provides proteins with prolyl oligopeptidase (post-proline cleaving) activities that constitute three novel members of a family of proteins related to DPPIV, including the full-length proteins, alternative splice forms, subunits, and mutants, as well as nucleotide sequences encoding the same. The present invention also provides methods of screening for substrates, interacting proteins, agonists, antagonists or inhibitors of the above proteins, and furthermore to pharmaceutical compositions comprising the proteins and/or mutants, derivatives and/or analogues thereof and/or ligands thereto.

These novel proteins having significant sequence homology to DPPIV are termed dipeptidyl peptidase IV-related protein-1, 2 & 3 (DPRP-1, DPRP-2 and DPRP-3). The amino acid sequences of DPRP-1, DPRP-2 and DPRP-3 are given in SEQ. ID NOS:1, 3 and 5 respectively. Further disclosed are nucleic acid sequences coding for these proteins (SEQ. ID NOS:2, 4 and 6). Table 1 illustrates the homology (i.e. similarity) between the novel proteins DPRP-1, DPRP-2 and DPRP-3 and other known serine proteases.

Table 1 – Comparison of the sequences of these three novel proteins with DPPIV and other Clan SC, Family S9 members and Subfamily B members

	Protease Family	Protease name	No. of a.a.	Homology with DPPIV	TM region	Ser-Asp-His Triad	Gene location	Optimal pH
5	Clan CA, Family C1	DPPI	463	N	N	N	11q14.1-q14.3	-
	Clan SC, Family S28	DPPII	500	N	Y	N	-	4.5-6.0
		QPP	492	N	N	N	-	4.5-7.5
		PCP	496	N	N	N	-	-
	Unassigned	DPPIII	737	N	N	N	-	-
	Clan SC, Family S9, Subfamily B	DPPIV	766	100	Y	Y	2q24.3	7.5-8.0
		DPPVI	865	52	Y	Mutation	7	-
		FAP	760	70	Y	Y	2q23	7.5-8.0
10		DPRP-1	882	41	N	Y	15q22.1-15q22.2	7.5-8.0
		DPRP-2	864	39	N	Y	19p13.3	7.5-8.0
		DPRP-3	796	54	Y	Mutation	2q12.3-2q14.1	-

The greatest homology between DPRP-1, DPRP-2 and DPPIV is seen in the C-terminal sequences. On the basis of sequence homology with DPPIV (see Figure 1), one might predict that these DPRP proteins would have functions that include, but are not limited to, roles as enzymes. Cloning, expression, biochemical and molecular characterization have confirmed this hypothesis.

The expression pattern of DPRPs and the localization to specialized epithelial cells and plasma cells (Leydig cells, prostate epithelial cells, lymphocytes, B cells) is consistent with a role in differentiation, proliferation and inflammation. The localization of the DPRP-1 gene in hormone sensitive cancers (breast, prostate, testicular), tissues regulated by testosterone and the abundant expression in poorly differentiated cancers, demonstrate that DPRP-activating or inhibiting molecules will have numerous therapeutic applications in the treatment of disorders characterized by dysregulated growth, differentiation and steroid or polypeptide hormone synthesis and degradation. Data disclosed herein supports the hypothesis that DPRP-1 and DPRP-2 are involved in the regulation of proliferation of *in vitro* models of prostate and testis cancer well known to those skilled in the art.

DPRP-1 and DPRP-2 activities described herein and their expression patterns are compatible with their having functional roles as physiological regulators of the immune and neuroendocrine systems through the enzymatic modification of biochemical mediators like peptides and chemokines. The numerous functions previously described

for DPPIV based upon the use of inhibitors may be due in part to its action and that of similar proteins, like the DPRPs. Therefore, the discovery of selective and potent inhibitors of DPPIV, of the DPRPs and of other related proteases like FAP is considered central to achieving effective and safe pharmaceutical use of these and any newly
5 identified serine protease inhibitors, as well as other active compounds that modify the function(s) of such proteins.

The invention thus provides novel proteins or polypeptides, the nucleic acids coding therefor, cells which have been modified with the nucleic acid so as to express these proteins, antibodies to these proteins, a screening method for the discovery of new
10 therapeutic agents which are inhibitors of the activity of these proteins (or which are inhibitors of DPPIV and not of the proteins), and therapeutic agents discovered by such screening methods. The novel proteins and the nucleic acids coding therefor can be used to discover new therapeutic agents for the treatment of certain diseases, such as for example, reproductive, inflammatory and metabolic disorders and also in the preparation
15 of antibodies with therapeutic or diagnostic value.

In accordance with one aspect of the present invention, there are provided novel, mature, biologically active proteins, principally of human origin. Such proteins may be isolated in small quantities from suitable animal (including human) tissue or biological fluids by standard techniques; however, larger quantities are more conveniently prepared
20 in cultures of cells genetically modified so as to express the protein.

In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding polypeptides of the present invention including mRNAs, DNAs, cDNAs, genomic DNAs thereof.

In accordance with a further aspect of the present invention, nucleic acid probes
25 are also provided comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.

In accordance with a still further aspect of the present invention, processes utilizing recombinant techniques are provided for producing such polypeptides useful for *in vitro* scientific research, for example, synthesis of DNA and manufacture of DNA
30 vectors. Processes for producing such polypeptides include culturing recombinant prokaryotic and/or eukaryotic host cells that have been transfected with DNA vectors containing a nucleic acid sequence encoding such a polypeptide and/or the mature protein under conditions promoting expression of such protein and subsequent recovery of such protein or a fragment of the expressed product.

In accordance with still another aspect, the invention provides methods for using DPRP polypeptides and polynucleotides, including the treatment of infections, such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2, pain, diabetes, precocious puberty, infertility, obesity, anorexia, bulimia, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, stroke, ulcers, asthma, allergies, benign prostatic hypertrophy, cancers including hormone-sensitive and androgen-independent cancers, migraines, vomiting, psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, dementia, and severe mental retardation, and dyskinesias, hereinafter collectively referred to as "the Diseases".

In accordance with yet another aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for the discovery of compounds that inhibit the biological activity of the mature proteins thereof, e.g. by cleaving an N-terminal dipeptide, and such inhibitors are thus also provided.

In accordance with a more specific aspect, the invention provides isolated nucleic acid which encodes (a) a polypeptide which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function, or which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6, or which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b), or which is complementary to any one of the foregoing.

In accordance with another specific aspect, the invention provides a polypeptide which may be optionally glycosylated, and which (a) has the amino acid sequence of a mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

In accordance with still another specific aspect, the invention provides a method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of the invention, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of a test

compound, and selecting the test compound or compounds that reduce the enzymatic activity, and it also provides a method for screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one mature protein and a suitable substrate in the presence of one or more inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

These and other aspects of the present invention should be apparent to those skilled in the art from the detailed description which follows.

Brief Description of the Drawings

FIGS. 1A and 1B show the co-linear alignment of DPRP-1, DPRP-2, DPRP-3 and DPPIV, with shading being supplied to indicate the same (black) or similar (gray) amino acid residues at a particular location.

FIG. 2 is similar to FIG. 1 and shows co-linear alignment of human and mouse DPRP-2.

FIG. 3 is a graph which shows the effects of various tetrapeptide amide inhibitors on dipeptidyl peptidase enzyme activity.

FIGS. 4A-4C show the effects of three inhibitor compounds on the proliferation of PC3 prostate cancer cell lines at various doses.

Detailed Description of the Preferred Embodiments

In accordance with an aspect of the present invention, there are provided isolated nucleic acid sequences (polynucleotides), which encode the mature polypeptides having the deduced amino acid sequences of the three DPRP's (SEQ ID NOS:1, 3 and 5).

The polynucleotides of this invention were discovered using a human testis cDNA library (DPRP-1), a human colon library (DPRP-2) and a human hypothalamus cDNA library (DPRP-3). Isolated nucleic acid for DPRP-1 contains an open reading frame encoding a protein of approximately 882 amino acids in length which is structurally related to human DPPIV, showing 26% identity, and 41% similarity over the entire human DPPIV protein sequence. Isolated nucleic acid for DPRP-2 contains an open reading frame encoding for a protein of approximately 864 amino acids, which is 39% similar to the entire DPPIV amino acid sequence. Analysis of DPRP-1 and DPRP-2 primary amino acid sequence using hydrophobicity plots predicts that these two proteins do not have a transmembrane domain. Despite this fact, it is possible that these intracellular serine proteases are secreted upon cellular activation. Quiescent cell proline

dipeptidase (QPP) is a serine protease that is targeted to intracellular vesicles that are distinct from lysosomes (Chiravuri M, et al., J. Immunol. 2000 Nov 15;165(10):5695-702). This hypothesis expands the potential site(s) and scope of DPRP-1 and DPRP-2 involvement in mechanisms for post-translational regulation of chemokines, cytokines, peptides and polypeptides. The full length DPRP-3 sequence contains 796 amino acids, a signal peptide from 1 to 48, and a transmembrane domain between 34 and 56. The mature protein is predicted to be a type II membrane protein and may be cleaved to produce a soluble form. The amino acid sequence is set forth in SEQ ID NO:5 , which was deduced from SEQ ID NO:6 and has 54% similarity with DPPIV.

Amino acid sequence alignments of these polypeptides with members of the prolyloligopeptidase enzyme subfamily S9B show that all three DPRP proteins have overall sequence and structural homology to DPPIV and FAP. DPRPs are predicted to be a members of the enzyme Clan SC (Serine nucleophile) with catalytic residues in the order Ser, Asp, His and the active site sequence (G-W-S-Y-G).

Table 2. Homology (i.e. similarity) between DPRP-1, DPRP-2, DPRP-3 and members of the prolyl oligopeptidase family S9B enzymes.

DPPIV					
41	DPRP-1				
39	74	DPRP-2			
54	39	40	DPRP-3		
70	41	39	52	FAP	
52	40	42	68	54	DPPVI

DPRP-1, DPRP-2 and DPRP-3 do not exhibit sequence similarity with any members of the classical serine protease families, chymotrypsin and subtilisin. The order of the catalytic triad residues is different in the three main related SC clan families: His-Asp-Ser in chymotrypsin, Asp-His-Ser in subtilisin and Ser-Asp-His in the prolyl oligopeptidases.

As shown in Table 2, DPRP-3 has the highest homology with DPPVI (68% homology and 51% identity). Wada et al isolated cDNA clones for DPPVI, a DPPIV-related protein, from bovine, rat (Wada et al., *Proc. Nat. Acad. Sci.* 89: 197-201. (1992)) and human (Yokotani et al., *Hum. Molec. Genet.* 2:1037-1039 (1993)) brain libraries. They demonstrated that, unlike DPPIV, the catalytic triad in DPPVI does not have the first serine residue. In DPRP-3 two of the amino acids in the catalytic triad

characteristic of the serine protease family are conserved. However, the serine residue itself is replaced by glycine. While the absence of the serine residue is likely to prevent protease activity at this site, it is possible that multiple other functions mediated by other functional domains of the protein remain intact.

5 As briefly described above, DPPIV is a multifunctional molecule that exerts important functions depending on the expressed cells and tissues, in addition to its catalytic activity as a peptidase. DPRP-3 and DPPVI are also likely to maintain multiple functions despite the absence of an intact catalytic triad. For example, DPPVI has been implicated in the regulation of neuronal plasticity. DPPVI is highly expressed in the
10 hippocampus, thalamus, hypothalamus and striatum. In addition, developmental arrest and embryonic lethality of *rump white* *Rw/Rw* embryos is thought to be due to disruption of the DPPIV gene. *Rw* mutation is associated with a chromosomal inversion spanning 30 cM of the proximal portion of mouse chromosome 5. Genomic analysis of the DPPVI gene on the *Rw* chromosome places the inversion breakpoint in the coding region
15 resulting in loss of a significant fraction of the C-terminal region, Hough R.B. et al., Proc. Nat. Acad. Sci., 95, 13800-13805 (1998).

 The human DPRP-1 gene, predicted to be 32668bp in length, has at least 22 exons and eight transcripts. It maps to chromosome 15 (NT_010265) at position 15q21.1 – 15q22.1. The lengths of predicted alternative splice variant transcripts vary
20 between 602bp and 4523bp (see SEQ ID NOS: 7-22). This is in agreement with the multiple transcripts observed by Northern blot analysis (See Example 2). ESTs representing the transcripts were found in numerous tissues including senescent fibroblasts, T-lymphocytes, germinal center B-cells, germ cell seminoma, testis, melanocytes, uterus, ovary breast, multiple sclerosis lesions, pancreas and placenta.

25 Human DPRP-2 belongs to a gene with at least 27 exons and nine splice variants (see SEQ ID NOS:23-40). One SNP was observed in the 3' UTR. (88% (37) C vs. 12% (5) T). The DPRP-2 gene maps to region 19p13.3 of chromosome 19. This location is host to a number of disease markers and is associated with various disorders including hypocalciuric hypercalcemia, type II cerebellar ataxia, muscular dystrophy, convulsions,
30 susceptibility to atherosclerosis, psoriasis, ectodermal dysplasia, and acute myeloid leukemia. In agreement with the ubiquitous distribution of the mRNA observed by Northern blot analysis (see Example 2), DPRP-2 was expressed in a wide variety of tissues upon examination of EST's coverage (e.g. over 64 EST's expressed in liver, spleen, muscle, melanocytes, heart, lung, placenta, skin, pancreas, stomach, brain
35 parathyroid gland).

Human DPRP-3 belongs to a gene with at least 23 exons and two splice variants (see SEQ ID NOS:41-44). The gene maps to chromosome 2 (NT_005445) at position 2q12.3-2q14.1. Transcripts for DPRP-3 did not show as wide a distribution as DPRP-1 and DPRP-2. As shown by Northern blot in Example 2, DPRP-3 expression is restricted to brain and pancreas. ESTs representing the DPRP-3 mRNA were abundant in tissue derived from multiple sclerosis lesions, hypothalamus, whole brain and nerves, with a few transcripts being found in uterus and colon.

The relationships among human and rodent proteases in clan SC, including DPRP-1 DPRP-2 and DPRP-3, were analyzed using Neighbor Joining method (NJ), see Saitou and Nei, *Mol. Biol. Evol.*, 4, 406-525 (1987). Phylogenetic analysis shows that among the S9 proteases, DPRP-1 and DPRP-2, both lacking a transmembrane domain, are distinguished from DPPIV and its closely related proteins like FAP. Similarity is shown however between DPPIV and FAP and between DPRP-3 and DPPVI, which are all type II membrane proteins.

A database search for additional DPRP-related genes revealed the presence of a murine sequence related to DPRP-1. Alignment of this mouse sequence with the novel human proteases shows that the mDPRP-1 displays considerable homology with its human counterpart (FIG. 2). One skilled in the art will readily recognize that the novel mouse protease gene can be isolated using the sequence information disclosed herein and can be readily incorporated into one of the routinely used expression constructs which are well known in the art. Use of this disclosed sequence by those skilled in the art to generate a transgenic mouse model will employ development of gene-targeting vectors, for example, that result in homologous recombination in mouse embryonic stem cells. The use of knockout mice in further analysis of the function of DPRP genes is a valuable tool.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA; DNA should be understood to include cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded and, if single-stranded, may be the coding strand or non-coding (antisense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in SEQ ID NOS:2, 4 and 6 respectively, or it may be a different coding sequence encoding the same mature polypeptide, as a result of the redundancy or degeneracy of the genetic code or a single nucleotide polymorphism. For example, it may also be an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.

The polynucleotides which encode the mature proteins of SEQ ID NOS:1, 3, 5, respectively, may include but are not limited to the coding sequence for the mature protein alone; the coding sequence for the mature polypeptide plus additional coding sequence, such as a leader or secretory sequence or a proprotein sequence; and the
5 coding sequence for the mature protein (and optionally additional coding sequence) plus non-coding sequence, such as introns or a non-coding sequence 5' and/or 3' of the coding sequence for the mature protein.

Thus, the term "polynucleotide encoding a polypeptide" or the term "nucleic acid encoding a polypeptide" should be understood to encompass a polynucleotide or nucleic
10 acid which includes only coding sequence for the mature protein as well as one which includes additional coding and/or non-coding sequence. The terms polynucleotides and nucleic acid are used interchangeably.

The present invention also includes polynucleotides where the coding sequence for the mature protein may be fused in the same reading frame to a polynucleotide
15 sequence which aids in expression and secretion of a polypeptide from a host cell; for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell may be so fused. The polypeptide having such a leader sequence is termed a preprotein or a preproprotein and may have the leader sequence cleaved, by the host cell to form the mature form of the protein. These
20 polynucleotides may have a 5' extended region so that it encodes a proprotein, which is the mature protein plus additional amino acid residues at the N-terminus. The expression product having such a prosequence is termed a proprotein, which is an inactive form of the mature protein; however, once the prosequence is cleaved an active mature protein remains. Thus, for example, the polynucleotides of the present invention
25 may encode mature proteins, or proteins having a prosequence, or proteins having both a prosequence and a presequence (leader sequence).

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptides of the present invention. The marker sequence may be a polyhistidine tag, a hemagglutinin
30 (HA) tag, a c-myc tag or a V5 tag when a mammalian host, e.g. COS-1 cells, is used. The HA tag would correspond to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., *Cell*, 37:767 (1984)), and the c-myc tag may be an epitope from human Myc protein (Evans, G.I. et al., *Mol. Cell. Biol.* 5: 3610-3616 (1985)).

The term "gene" means the segment of DNA involved in producing a polypeptide
35 chain; it includes regions preceding and following the coding region (leader and trailer)

as well as intervening sequences (introns) between individual coding segments (exons). The term "significant sequence homology" is intended to denote that at least 25%, preferably at least 40%, of the amino acid residues are conserved, and that, of the non-conserved residues, at least 40% are conservative substitutions.

5 Fragments of the full-length genes of the present invention may be used as a hybridization probe for a cDNA library to isolate full-length cDNA as well as to isolate other cDNAs which have significant sequence homology to the gene and will encode proteins or polypeptides having similar biological activity or function. By similar biological activity or function, for purposes of this application, is meant the ability to
10 cleave an N-terminal dipeptide having Ala or Pro as the penultimate residue or other amino acids. Such a probe of this type has at least 14 bases (at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 or 6), preferably at least 30 bases, and such may contain, for example, 50 or more bases. Such probe may also be used to identify a
15 cDNA clone corresponding to a full-length transcript and/or a genomic clone or clones that contains the complete gene, including regulatory and promoter regions, exons, and introns. Labelled oligonucleotides having a sequence complementary to that of the gene of the present invention are useful to screen a library of human cDNA, genomic DNA or mRNA to locate members of the library to which the probe hybridizes. As an example, a known DNA sequence may be used to synthesize an oligonucleotide probe which is then
20 used in screening a library to isolate the coding region of a gene of interest.

 The present invention is considered to further provide polynucleotides which hybridize to the hereinabove-described sequences wherein there is at least 70%, preferably at least 90%, and more preferably at least 95% identity or similarity between the sequences, and thus encode proteins having similar biological activity. Moreover, as
25 known in the art, there is "similarity" between two polypeptides when the amino acid sequences contain the same or conserved amino acid substitutes for each individual residue in the sequence. Identity and similarity may be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue,
30 Madison, WI 53705). The present invention particularly provides such polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means conditions which permit hybridization between polynucleotides sequences and the polynucleotide sequences of SEQ ID NOS:2, 4 and 6 where there is at least about 70% identity.
35 Suitably stringent conditions can be defined by, e.g., the concentrations of salt or

formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, by increasing the concentration of formamide, and/or by raising the hybridization temperature.

5 For example, hybridization under high stringency conditions may employ about 50% formamide at about 37°C to 42°C, whereas hybridization under reduced stringency conditions might employ about 35% to 25% formamide at about 30°C to 35°C. One particular set of conditions for hybridization under high stringency conditions employs 42°C, 50% formamide, 5x. SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured
10 salmon sperm DNA. For hybridization under reduced stringency, similar conditions as described above may be used in 35% formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions
15 are well known in the art. Preferably, hybridization should occur only if there is at least 95%, and more preferably at least 97%, identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which exhibit substantially the same biological function or activity as the mature protein encoded by one of the cDNAs of
20 SEQ ID NOS:2, 4 and 6.

As mentioned, a suitable polynucleotide probe may have at least 14 bases, preferably 30 bases, and more preferably at least 50 bases, and will hybridize to a polynucleotide of the present invention which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides
25 may be employed as a probe for hybridizing to the polynucleotides of SEQ ID NOS:2, 4 and 6 respectively, for example, for recovery of such a polynucleotide, or as a diagnostic probe, or as a PCR primer. Thus, the present invention includes polynucleotides having at least a 70% identity, preferably at least a 90% identity, and more preferably at least a 95% identity to a polynucleotide which encodes the polypeptides of SEQ ID NOS:1, 3
30 and 5 respectively, as well as fragments thereof, which fragments preferably have at least 30 bases and more preferably at least 50 bases, and to polypeptides encoded by such polynucleotides.

As is well known in the art, the genetic code is redundant in that certain amino acids are coded for by more than one nucleotide triplet (codon), and the invention
35 includes those polynucleotide sequences which encode the same amino acids using a

different codon from that specifically exemplified in the sequences herein. Such a polynucleotide sequence is referred to herein as an "equivalent" polynucleotide sequence. The present invention further includes variants of the hereinabove described polynucleotides which encode for fragments, such as part or all of the mature protein, 5 analogs and derivatives of one of the polypeptides having the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5 respectively. The variant forms of the polynucleotides may be a naturally occurring allelic variant of the polynucleotides or a non-naturally occurring variant of the polynucleotides. For example, the variant in the nucleic acid may simply be a difference in codon sequence for the amino acid resulting 10 from the degeneracy of the genetic code, or there may be deletion variants, substitution variants and addition or insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides that does not substantially alter the biological function of the encoded polypeptide.

15 The present invention further includes polypeptides which have the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5, as well as fragments, analogs and derivatives of such polypeptides. The terms "fragment," "derivative" and "analog", when referring to the polypeptides of SEQ ID NOS:1, 3 and 5, means polypeptides that retain essentially the same biological function or activity as such polypeptides. An 20 analog might, for example, include a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature protein. The polypeptides of the present invention may be recombinant polypeptides, natural polypeptides or synthetic polypeptide; however, they are preferably recombinant polypeptides, glycosylated or unglycosylated.

25 The fragment, derivative or analog of a polypeptide of SEQ ID NOS:1, 3 and 5 respectively, may be (i) one in which one or more of the amino acid residues is substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid 30 residues includes a substituent group, or (iii) one in which additional amino acids are fused to the mature protein, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art to provide upon the basis of the teachings herein.

The polypeptides and polynucleotides of the present invention should be in an isolated form, and preferably they are purified to substantial homogeneity or purity. By substantial homogeneity is meant a purity of at least about 85%.

The term "isolated" is used to mean that the material has been removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not considered to be isolated, but the same polynucleotide or polypeptide, when separated from substantially all of the coexisting materials in the natural system, is considered isolated. For DNA, the term includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Further included is recombinant DNA which includes a portion of the nucleotides shown in one of SEQ ID NO:2,4 or 6 which encodes an alternative splice variant of the DPRP. Various alternative splice variants are exemplified in SEQ ID NOS:8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 and 46.

The polypeptides of the present invention include any one of the polypeptide of SEQ ID NOS:1, 3 and 5 (in particular the mature protein), as well as polypeptides which have at least 70% similarity (e.g. preferably at least 60% and more preferably at least 70% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, more preferably at least 90% similarity (e.g. preferably at least 90% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, and most preferably at least 95% similarity (e.g. preferably at least 95% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5. Moreover, they should preferably include exact portions of such polypeptides containing a sequence of at least 30 amino acids, and more preferably at least 50 amino acids.

Fragments or portions of the polypeptides of the present invention may be employed as intermediates for producing the corresponding full-length polypeptides by peptide synthesis. Fragments or portions of the polynucleotides of the present invention may also be used to synthesize full-length polynucleotides of the present invention.

The present invention also includes vectors which include such polynucleotides, host cells which are genetically engineered with such vectors and the production of polypeptides by recombinant techniques using the foregoing. Host cells are genetically

engineered (transduced or transformed or transfected) with such vectors which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those commonly used with the host cell selected for expression, as well known to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotides may be included in any one of a variety of expression vectors for expressing polypeptides. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by any of a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures well known in the art, which procedures are deemed to be within the scope of those skilled in this art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli*. lac or trp, the phage lambda P.sub.L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector should also contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin-resistance for eukaryotic cell culture, or such as tetracycline- or ampicillin-resistance in *E. coli*.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells, such as

Drosophila S2 and Spodoptera Sf9; animal cells, such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

Synthetic production of nucleic acid sequences is well known in the art as is
5 apparent from CLONTECH 95/96 Catalogue, pages 215-216, CLONTECH, 1020 East Meadow Circle, Palo Alto, Calif. 94303. Thus, the present invention also includes expression vectors useful for the production of the proteins of the present invention

The present invention further includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs may comprise a
10 vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The
15 following vectors are provided by way of example: Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pDR540 and pRIT5 (Pharmacia); and Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other suitable plasmid or
20 vector may be used as long as it is replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol acetyl transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P.sub.R, P.sub.L and trp. Eukaryotic
25 promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

Components of the expression vector may generally include: 1) a neomycin phosphotransferase (G418), or hygromycin B phosphotransferase (hyg) gene as a
30 selection marker, 2) an E. coli origin of replication, 3) a T7 and SP6 phage promoter sequence, 4) lac operator sequences, 5) the lactose operon repressor gene (lacIq) and 6) a multiple cloning site linker region. Such an origin of replication (oriC) may be derived from pUC19 (LTI, Gaithersburg, Md.).

A nucleotide sequence encoding one of the polypeptides SEQ ID NOS:2,4 and 6
35 having the appropriate restriction sites is generated, for example, according to the PCR

protocol described in Example 1 hereinafter, using PCR primers having restriction sites for KpnI (as the 5' primer) and NotI or SacI (as the 3' primer) for DPRP-1, or sites for HindIII (as the 5' primer) and NotI or BamHI (as the 3' primer) for DPRP-2. The PCR inserts are gel-purified and digested with compatible restriction enzymes. The insert and
5 vector are ligated according to standard protocols.

In a further embodiment, the present invention provides host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell
10 can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

Such constructs in host cells are preferably used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the
15 polypeptides of the invention can be synthetically produced by conventional peptide synthesizers or by chemical ligation of suitable fragments thus prepared.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of
20 the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989).

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector.
25 Enhancers include cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin-resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes, such as 3-
35 phosphoglycerate kinase (PGK), alpha-factor, acid phosphatase, or heat shock proteins,

among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion
5 protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
10 The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desired, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of
15 choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example,
20 pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, Wis., U.S.A.). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g.,
25 temperature shift or chemical induction), and cells are cultured for an additional period. Cells are typically harvested by centrifugation and then disrupted by physical or chemical means, with the resulting crude extract being retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption and use of
30 cell-lysing agents; such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express a recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981). Other cell lines capable of expressing a compatible vector include, for example, the C127, 3T3,
35 CHO, HeLa and BHK cell lines. Mammalian expression vectors will generally comprise

an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to
5 provide required nontranscribed genetic elements.

The polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography
10 and lectin chromatography. Recovery can be facilitated if the polypeptide is expressed at the surface of the cells, but such is not a prerequisite. Recovery may also be desirable of cleavage products that are cleaved following expression of a longer form of the polypeptide. Protein refolding steps as known in this art can be used, as necessary, to complete configuration of the mature protein. High performance liquid chromatography
15 (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be purified natural products, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect or mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the
20 present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

In a preferred embodiment, the proteins of the invention are isolated and purified so as to be substantially free of contamination from other proteins. For example, the proteins of the invention should constitute at least 80% by weight of the total protein
25 present in a sample, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 98% by weight of the total protein.

These proteins may be in the form of a solution in water, another suitable solvent, such as dimethyl sulfoxide (DMSO) or ethanol, or a mixture of suitable solvents. Examples of mixtures of solvents include 10% (by weight) ethanol in water and 2% (by
30 weight) DMSO in water. A solution may further comprise salts, buffering agents, chaotropic agents, detergents, preservatives and the like. Alternatively, the proteins may be in the form of a solid, such as a lyophilised powder or a crystalline solid, which may also comprise a residual solvent, a salt or the like.

As used herein, the term "antibodies" includes polyclonal antibodies,
35 affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding

fragments, such as F(ab')₂ and Fab' proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human
5 CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through
10 humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans should be reduced.

Alternative techniques for generating or selecting antibodies useful herein include in vitro exposure of lymphocytes to human prohormone DPRP protein or a peptide therefrom, and selection of antibody display libraries in phage or similar vectors
15 (for instance, through use of immobilized or labeled human DPRP protein or peptide). Genes encoding polypeptides having potential human DPRP polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding such polypeptides can be obtained in a number of ways well known in this art.

20 As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice and rats, with a human DPRP polypeptide or a fragment thereof. The immunogenicity of a human prohormone DPRP polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or
25 Freund's complete or incomplete adjuvant, or surface active substances, such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH or dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially preferable. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of DPRP or a portion
30 thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "haptten-like", such portion may be advantageously joined or linked to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid, for immunization. Antibodies to DPRP may
35 also be generated using methods that are well known in the art. Such antibodies may

include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library.

Neutralizing antibodies (i.e., those which block or modify interactions at the active sites) are especially preferred for therapeutic use.

- 5 For the production of antibodies, binding proteins, or peptides which bind specifically to DPRP, libraries of single chain antibodies, Fab fragments, other antibody fragments, non-antibody protein domains, or peptides may be screened. The libraries could be generated using phage display, other recombinant DNA methods, or peptide synthesis (Vaughan, T. J. et al. Nature Biotechnology 14: 309-314 (1996)). Such
10 libraries would commonly be screened using methods which are well known in the art to identify sequences which demonstrate specific binding to DPRP.

- It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DPRP have an amino acid sequence consisting of at least about 5 amino acids and, more preferably, of at least about 10 amino acids. It is also preferable that
15 these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DPRP amino acids may also be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

- Monoclonal antibodies to DPRP may be prepared using any well known
20 technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique, although monoclonal antibodies produced by hybridoma cells may be preferred.

- In addition, techniques developed for the production of "chimeric antibodies",
25 such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used, see Neuberger, M.S. et al. Nature 312: 604-608 (1984). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DPRP-specific single chain antibodies. Antibodies with related
30 specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (Burton D. R. Proc. Natl. Acad. Sci. 88: 11120-11123 (1991)).

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly

specific binding reagents as disclosed in the literature. (Orlandi, R. et al. Proc. Natl. Acad. Sci. 86: 3833-3837 (1989)).

Antibody fragments which contain specific binding sites for DPRP may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse, W. D. et al. Science 254: 1275-1281 (1989)).

10 Various immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DPRP and its specific antibody. A two-site, monoclonal-based
15 immunoassay utilizing monoclonal antibodies reactive to two non-interfering DPRP epitopes is preferred, but a competitive binding assay may also be employed.

As earlier mentioned, the DPRPs can be used in treatment of the Diseases. Pharmaceutical compositions suitable for use in this aspect of the invention include compositions wherein the active ingredients are contained in an effective amount to
20 achieve the intended purpose relating to one of the Diseases. The determination of a therapeutically effective dose is well within the capability of those skilled in the art and can be estimated initially either in cell culture assays, e.g. of neoplastic cells, or in animal models, usually mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration, which
25 information is then commonly used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, e.g. a DPRP or fragment thereof, antibodies of DPRP, or an agonist, antagonist or inhibitor of DPRP, which ameliorates particular symptoms or conditions of the Disease. For
30 example, the amount to be administered may be effective to cleave a desired target substrate upon contact therewith. Therapeutic efficacy and toxicity may likewise be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED50 (the dose therapeutically effective in 50% of the population) or LD50 (the dose lethal to 50% of the population) statistics. The dose
35 ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the

LD50/ED50 ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the
5 ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

An exact dosage will normally be determined by the medical practitioner in light of factors related to the subject requiring treatment, with dosage and administration being adjusted to provide a sufficient level of the active moiety or to maintain a desired
10 effect. Factors to be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or even once every two weeks, depending
15 on the half-life and clearance rate of the particular formulation.

Yet another aspect of the invention provides polynucleotide molecules having sequences that are antisense to mRNA transcripts of DPRP1, DPRP2 and DPRP-3 polynucleotides. Administration of an antisense polynucleotide molecule can block the production of the protein encoded by DPRP-1, DPRP2 or DPRP-3. The techniques for
20 preparing antisense polynucleotide molecules and administering such molecules are known in the art. For example, antisense polynucleotide molecules can be encapsulated into liposomes for fusion with cells.

In particular, the expression of DPRP-1, DPRP-2 and DPRP-3 in specialized epithelial cells, immune cells (lymphocytes and B cells), astrocytic tumors, and in
25 various hormone sensitive cancers provides evidence of a potential role in the pathophysiology of cancer, metaplasia and metastasis. Therefore in a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate DPRP activity or expression levels. Antibodies that specifically bind DPRP may be used for the diagnosis of disorders characterized by expression of DPRP, or in assays to
30 monitor patients being treated with DPRP or with agonists or antagonists (inhibitors) of DPRP. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for DPRP include methods that utilize the antibody and a label to detect DPRP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and they
35 may be labeled by covalent or non-covalent joining with a reporter molecule. A wide

variety of reporter molecules are known in the art. Recombinant DPRP proteins that have been modified so as to be catalytically inactive can also be used as dominant negative inhibitors. Such modifications include, for example, mutation of the active site.

A variety of protocols for measuring DPRP, including ELISAs, RIAs and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of DPRP expression. Normal or standard values for DPRP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to DPRP under conditions suitable for complex formation. The method for detecting DPRP in a biological sample would comprise the steps of: a) providing a biological sample; b) combining the biological sample and an anti-DPRP antibody under conditions which are suitable for complex formation to occur between DPRP and the antibody; and c) detecting complex formation between DPRP and the antibody, thereby establishing the presence of DPRP in the biological sample. The amount of complex formation then may be quantified by various methods, preferably by photometric means. Quantities of DPRP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding DPRP are used for diagnostic purposes, which polynucleotides may include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. These polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of DPRP may be correlated with one of the Diseases. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of DPRP and to monitor regulation of DPRP levels during therapeutic intervention. Moreover, pharmacogenomic, single nucleotide polymorphisms (SNP) analysis of the DPRP genes can be used as a method to screen for mutations that indicate predisposition to disease or modified response to drugs.

DPRP polynucleotide and polypeptide sequences, fragments thereof, antibodies of DPRPs, and agonists, antagonists or inhibitors of DPRPs can be used to as discovery tools to identify molecular recognition events and therefore proteins, polypeptides and peptides that interact with DPRP proteins. A specific example is phage display peptide libraries where greater than 10⁸ peptide sequences can be screened in a single round of panning. Such methods as well as others are known within the art and can be utilized to identify compounds that inhibit or enhance DPRP-1, DPRP-2 or DPRP-3 activity. Coupled links represent functional interactions such as complexes or pathways, and

proteins that interact with DPRPs can be identified by a yeast two-hybrid system, proteomics (differential 2D gel analysis and mass spectrometry) and genomics (differential gene expression by microarray or serial analysis of gene expression SAGE). Proteins identified as functionally linked to DPRPs and the process of interaction form
5 the basis of methods of screening for inhibitors, agonists and antagonists and modulators of these DPRP-protein interactions.

The term "antagonist," as it is used herein, refers to an inhibitor molecule which, when bound to DPRP, decreases the amount or the duration of the effect of the biological or immunological activity of DPRP, e.g. decreasing the enzymatic activity of
10 the peptidase to cleave the N-terminal dipeptide. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of DPRP; for example, they may include small molecules and organic compounds that bind to and inactivate DPRPs by a competitive or non-competitive type mechanism. Specific examples of DPRP tetrapeptide peptidic enzyme activity inhibitors are
15 described in Example 6 and 7. Inhibitors can be, for example, inhibitors of the DPRP protease activity, or alternatively inhibitors of the binding activity of the DPRP to proteins with which they interact. Specific examples of such inhibitors can include, for example, anti-DPRP antibodies, peptides, protein fragments, or small peptidyl protease inhibitors, or small non-peptide, organic molecule inhibitors which are formulated in a
20 medium that allows introduction into the desired cell type. Alternatively, such inhibitors can be attached to targeting ligands for introduction by cell-mediated endocytosis and other receptor mediated events. Such methods are described further below and can be practiced by those skilled in the art given the DPRP nucleotide and amino acid sequences described herein.

25 A further use for DPRPs is for the screening of potential antagonists for use as therapeutic agents, for example, for inhibiting binding to DPRP, as well as for screening for agonists. DPRP, its immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds which are prospective agonists or antagonists in any of a variety of drug screening techniques. The fragment employed in such screening
30 may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DPRP and the agent being tested is then measured. Other assays to discover antagonists that will inhibit DPRP are apparent from the disclosures of U.S. Patents Nos. 6,011,155, 6,107,317, 6,110,949, 6,124,305 and 6,166,063, which describe inhibitors of DPPIV. Another worthwhile use

of these DPRPs is the screening of inhibitors of DPPIV to show that they will not have undesired side effects by also inhibiting one or more of the DPRPs.

A method provided for screening a library of small molecules to identify a molecule which binds DPRP generally comprises: a) providing a library of small molecules; b) combining the library of small molecules with the polypeptide of either
5 SEQ ID NOS: 1, 3 or 5, or with a fragment thereof, under conditions which are suitable for complex formation; and c) detecting complex formation, wherein the presence of such a complex identifies a small molecule which binds DPRP.

One method for identifying an antagonist comprises delivering a small molecule
10 which binds DPRP into extracts from cells transformed with a vector expressing DPRP along with a chromogenic substrate (e.g. Ala-Pro-AFC or Ala-Pro-AMC) under conditions where cleavage would normally occur, and then assaying for inhibition of cleavage by the enzyme by monitoring changes in fluorescence, or UV light absorption, by spectrophotometry to identify molecules that inhibit cleavage. A reduced rate of
15 reaction or total amount of fluorescence or UV light absorption, in the presence of the molecule, establishes that the small molecule is an antagonist which reduces DPRP catalytic/enzymatic activity. Once such molecules are identified, they may be administered to reduce or inhibit cleaving by a DPRP.

The term "agonist," as used herein, refers to a molecule which, when bound to
20 DPRP, increases or prolongs the duration of the effect of DPRP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules that bind to and modulate the effect of DPRP. Although it is less likely that small molecules will prove to be effective DPRP agonists, a method for identifying such a small molecule, which binds DPRP as an agonist, comprises delivering a chromogenic form of a small molecule that
25 binds DPRP into cells transformed with a vector expressing DPRP and assaying for fluorescence or UV light absorption changes by spectrophotometry. An increased amount of UV absorption or fluorescence would establish that the small molecule is an agonist that increases DPRP activity.

Another technique for drug screening which may be used provides for high
30 throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with DPRP, or with fragments thereof, and then washed. Bound DPRP is then detected by methods well
35 known in the art. Purified DPRP can also be coated directly onto plates for use in the

aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DPRP specifically compete with a test
5 compound for binding DPRP. In this manner, antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with DPRP.

As indicated above, by investigating the binding sites, ligands may be designed that, for example, have more interactions with DPRP than do its natural ligands. Such antagonist ligands will bind to DPRP with higher affinity and so function as competitive
10 ligands. Alternatively, synthetic or recombinant proteins homologous or analogous to the ligand binding site of native DPRP may be designed, as may other molecules having high affinity for DPRP. Such molecules should also be capable of displacing DPRP and provide a protective effect.

As indicated above, the knowledge of the structures of DPRP enables synthetic
15 binding site homologues and analogues to be designed. Such molecules will facilitate greatly the use of the binding properties to target potential therapeutic agents, and they may also be used to screen potential therapeutic agents. Furthermore, they may be used as immunogens in the production of monoclonal antibodies, which antibodies may themselves be used in diagnosis and/or therapy as described hereinbefore.

20 Given the ubiquitous expression of several members of the prolyl oligopeptidase S9B family, cell lines in which targeted gene disruption of DPPIV, DPRP-1, DPRP-2, DPRP-3, FAP and DPPVI to establish the null phenotype will be of great value to assist screening for selective and potent compounds. Accordingly, the invention provides such cell lines engineered with Lox-Neo IRES tk cassette and GFP-IRES-Neo Knock-in/out
25 cassette DNA element for constructing somatic gene targeting vectors.

Example 1

Cloning and Expression of DPRP genes Using the Mammalian Expression System

DNA fragments encoding the full-length polypeptide DPRP-1 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene,
30 i.e. SEQ ID NO:45 and NO:46. In addition, DNA fragments encoding the full length polypeptide DPRP-2 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ ID NO:50 and NO:51. Furthermore, DNA fragments encoding the full length polypeptide DPRP-3 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ
35 ID NO:55 and NO:56.

The three amplified sequences were respectively isolated from a 0.7% agarose gel using commercially available kit (GFX PCR DNA and Gel Band Purification Kit, Amersham Pharmacia Biotech Inc., Piscataway NJ, USA). The fragments were then ligated into cloning vector, pGEM-7Zf(-) (Promega Corporation, Madison WI, USA) and sequenced. The corresponding cloning constructs were respectively designated pGEM7-DPRP1, pGEM7-DPRP2 and pGEM7-DPRP3. The DNA sequences encoding the truncated DPRP-1 or DPRP-2 or DPRP-3 were amplified using pGEM7-DPRP1 or pGEM7-DPRP2 or pGEM7-DPRP3 as a template and PCR oligonucleotide primers. SEQ ID NO:45 and NO:47 were used for DPRP-1; SEQ ID NO:50 and NO:52 were used for DPRP-2; and SEQ ID NO:57 and NO:58 for DPRP-3. The amplified sequences were again isolated from a 0.7% agarose gel using the same purification kits and sub-cloned into pGEM-7Zf(-). The resulting constructs were designated pGEM7-DPRP1f, pGEM7-DPRP2f and pGEM7-DPRP3f.

To make the DPRP-1 mammalian expression construct, pGEM7-DPRP1 was digested with the restriction enzymes KpnI and NotI to release the full length DPRP-1 gene. The DNA fragment carrying the DPRP-1 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-1 expression construct, which was designated pcDNA-DPRP1. pGEM7-DPRP1f was digested with the restriction enzymes XbaI and HindIII to release the truncated DPRP-1f gene. The DNA fragment carrying the DPRP-1f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His A (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-1 expression construct pcDNA-MycHis-DPRP1.

To make the DPRP-2 mammalian expression construct, pGEM7-DPRP2 was digested with the restriction enzymes HindIII and BamHI to release the full length DPRP-2 gene. The DNA fragment carrying the DPRP-2 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-2 expression construct, which was designated pcDNA-DPRP2. pGEM7-DPRP2f was digested with the restriction enzymes EcoRI and BamHI to release the truncated DPRP-2f gene. The DNA fragment carrying the DPRP-2f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-2 expression construct designated pcDNA-MycHis-DPRP2.

To make the DPRP-3 mammalian expression construct, pGEM7-DPRP3 was digested with the restriction enzymes EcoRI and XhoI to release the full length DPRP-3

gene. The DNA fragment carrying the DPRP-3 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-3 expression construct designated pcDNA-DPRP3. pGEM7-DPRP3f was digested with the restriction enzymes NheI and ApaI to release the truncated DPRP-3f gene. The DNA fragment carrying the DPRP-3f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-3 expression construct pcDNA-MycHis-DPRP3.

Example 2

Expression Pattern of DPRP genes in human tissues

Quantitative PCR analysis was carried out to examine the levels of expression of the mRNAs for the polypeptides of the present invention in human tissues. RT PCR was also carried out on a number of human cell lines including but not limited to prostate cancer cells (LNCaP, PC3, DU145), the MLTC-1 line (mouse testis), and MDA-MB231 cells (breast cancer). Bands of the expected sizes for DPRP-1, DPRP-2 and DPPIV were all expressed in the various cancer cells lines, with FAP also being expressed at very low levels.

Northern Blot Analysis

Northern blot analysis was performed with 2µg poly(A)⁺ RNA isolated from eight different tissues using DPRP probes. Specifically, a human Multiple Tissue Northern (MTN) blot (Clontech, Palo Alto, Calif.) was probed with a 1 kb N-terminal fragment that had been radioactively labeled by random priming in the presence of a ³²PdCTP (A. P. Feinberg et al., *Anal. Biochem.*, 132, 6 (1983)). Hybridization was performed at 68°C overnight in ExpressHybTM hybridization solution (Clontech, Palo Alto, Calif.). The blots were first washed at room temperature in 2 times SSC and 0.05% SDS, and then washed at 60°C (DPRP-1 & DPRP-2) and 50°C (DPRP-3) in 0.1 times SSC and 0.1% SDS.

Northern analysis showed expression of DPRP-1 in several tissues with the most abundant signal being in testis, prostate, muscle and brain. Testis showed 3 transcripts approximately 7.5, 4.5 and 2.5 kb in length. The shorter mRNA species was very abundant in testis but negligible in the other tissues tested. DPRP-2 was ubiquitously expressed in every tissue with highest levels in liver and muscle and a predominant transcript at 5kb. DPRP-3 expression was limited to brain and pancreas. Further analysis was conducted for the three proteases in specific brain regions (cerebellum, cortex, medulla, spinal cord, occipital lobe, frontal lobe temporal lobe and putamen).

DPRP-1 was expressed in all regions with low levels present in the spinal cord, while DPRP-2 was expressed in all brain regions tested.

Oligonucleotide primers SEQ ID NO:48 and NO:49 were used for DPRP-1 quantitative PCR, whereas oligonucleotide primers SEQ ID NO:53 and NO:54 were
5 used for DPRP-2 quantitative PCR. Human Multiple Tissue cDNA (MTC™) Panel I and Panel II (Clontech, Palo Alto CA, USA) were used as normalized cDNA templates. 0.5 ng of each cDNA were used in a 25 µl PCR reaction, with each primer at a final concentration of 300 nM. The PCR reaction was performed using a SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City CA, USA) and detected with an
10 Applied Biosystems GeneAmp 5700 sequence detection system. Manufacturer's recommended thermal cycling parameter, e.g. 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min was used. Data obtained shows relatively high rates of expression for both DPRP-1 and DPRP-2 in the pancreas, ovary and testis, and a particularly high rate for DPRP-2 in the liver.

15 **Example 3 – Production of DPRP Polyclonal Antibodies and Western Blotting**

The amino acid sequence deduced from the cDNA encoding DPRP-1 was analyzed using DNASTAR software (DNASTAR, Inc.) to determine regions of high immunogenicity, and a corresponding oligopeptide was synthesized and used to raise anti-DPRP-1 antibodies. The procedure was repeated for DPRP-2 and DPRP-3. The
20 selection of appropriate peptide sequences and the techniques for antibody production are methods well known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is well known in this art.

Typically, oligopeptides that are about 15 to 20 residues in length, e.g. SEQ ID NO:59 for DPRP-1, SEQ ID NO:60 for DPRP-2 and SEQ ID NO:61 for DPRP-3, were
25 synthesized using an Applied Biosystems Peptide Synthesizer Model 431 A. Fmoc-chemistry was used and the 19- or 15-residue peptides were respectively coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). Rabbits were immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting
30 antisera were tested for antipeptide activity, e.g., by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Western blotting was performed using normal human protein samples (Protein Medley) obtained from Clontech (about 36 µg of total proteins). Proteins were
35 fractionated through 10% SDS-polyacrylamide gels, and transferred to 0.45 mm

nitrocellulose membranes. Membranes were blocked in Tris-buffered saline (TBS) with 0.05% Tween 20 and 1% BSA. Anti DPRP-1 or DPRP-2 specific antibodies were used as primary antibodies and were diluted 1:5,000 in Tris-buffered saline with 0.05% Tween 20 (TBST) and the Alkaline Phosphatase (AP) conjugated goat anti-Rabbit IgG (Promega) was diluted 1: 5,000 in the same buffer before use. The positive reaction was visualized by incubating the membrane in Western Blue Stabilized Substrate (Promega) for AP until the bands of interest have reached the desired intensity. DPRP-1 and DPRP-2 proteins were detected in brain, muscles, kidney, prostate, testis and ovary tissues. DPRP-1 and DPRP-2 were synthesized as approximately 101kDa and 100kDa forms, respectively, which are in good agreement with the molecular masses estimated from their primary structure as shown in Table 3.

Table 3. Predicted Molecular Weight, Number of potential N-linked glycosylation sites (Asn residues) and predicted pI values of DPRP-1, DPRP-2 and DPRP-3, based on sequence analysis using the method developed by Hopp and Woods, Proc. Nat. Acad. Sci. 78:3824-3828 (1981).

	M.W. (Da.)	No. of Asn	pI
DPRP1	101422	26	5.39
DPRP2	98263	27	6.01
DPRP3	90914	33	6.11

Several additional bands of similar molecular weight were observed. These are thought to be due to the presence of post-translational glycosylation of the proteins. Table 3 also shows the number of potential N-glycosylation sites for the DPRP proteins. The presence of glycosylated and unglycosylated forms of the proteins was evaluated using tunicamycin, an inhibitor of the oligosaccharide synthesis. It is evident that the smaller forms were unglycosylated forms. The correlation between mRNA (Northern analysis) and protein quantity (Western analysis) for DPRP-1 is shown in Table 4.

Table 4. Correlation of mRNA and protein expression of DPRP-1 in human tissues

	Heart	Brain	Placenta	Muscles	Kidney	Prostate	Testis	Ovary
Northern	++	+++	+	+++	++	+++	++++	+
Western	-	++++	-	+	++	+	+++	+++

Example 4**Immunohistochemical localization of DPRP proteins in human tissues**

Four-micron sections were prepared from a number of different formalin-fixed, paraffin-embedded human tissues. Tissue sections were deparaffined through 4 immersions in xylenes for 5 minutes, followed by a graded alcohol series to distilled water. Steam heat induced epitope recovery (SHIER) was used with several different SHIER solutions with and without enzyme digestion tissue in two different concentrations (Ladner et al, Cancer Res.; 60, p 3493-3503, 2000). The treatments and antibody dilutions employed are outlined below.

1. Blocking Reagent for 15 minutes (Normal Goat Serum)
2. Primary Antibody for 25, 60 min or overnight incubation
3. Secondary Antibody for 25 minutes (Biotinylated Goat-anti-rabbit IgG)
4. Endogenous Peroxidase Blocking for 3 x 1.5 minutes
5. ABC (avidin-biotin complex) / Horse Radish Peroxidase for 25 minutes
6. DAB Chromogen for 3 x 5 minutes (Brown reaction product)
7. Light Hematoxylin Counter Stain 1 minute

Positive controls were run to assure the detection chemistries and antigen pretreatments were working appropriately. Rabbit IgG was run as a negative control. An avidin-biotin based tissue staining system was used for the detection of the DPRP-1 antibody. Horseradish peroxide was used as a reporter enzyme with DAB as chromogen. After staining, slides were dehydrated through an alcohol series to absolute ethanol followed by xylene rinses. Slides were permanently coverslipped with glass coverslips and permount. Digital images of representative staining, where positive staining was indicated by a dark brown chromogen (DAB-HRP reaction product), were captured using a video camera from Olympus. Hematoxylin counterstain provides a blue nuclear stain to assess cell and tissue morphology.

DPRP-1 rabbit polyclonal antibody labels formalin-fixed, paraffin-embedded human tissues, including normal testis, prostate glands, endometrial glands, tonsils and pancreas. It was also present in endothelial cells of normal ovary, bladder and kidney. Staining was localized in the cytoplasm in epithelial and some stromal cells such as fibroblasts, endothelial cells and lymphocytes. Interestingly in normal testis tested with DPRP-1 antibodies, there was distinctive expression in Leydig cells and multinucleated macrophages found in interstitial tissue, which is the space surrounding the seminiferous tubules. Tonsil B cells were stained with DPRP-1 antibody.

Example 5

Mammalian and Insect Cell Expression of DPRP Proteins and Purification

Plasmid DNA of pcDNA-DPRP1, pcDNA-MycHis-DPRP1, pcDNA-DPRP-2 or pcDNA-MycHis-DPRP2 was transfected into PEAK (EdgeBioSystems, Gaithersburg MD, USA) or COS-1 (ATCC CRL-1650) using LipofectAmine (Life Technologies, Gaithersburg MD, USA) method recommended by the manufacturer. Transfected cells were maintained in DMEM with 5% FBS at 37°C with 5% CO₂ for 48 hours. Cells were then collected and used for recombinant protein extraction. Cells were harvested 48 hours after transfection, homogenized and then spun at 18,000 x g for 40 min. The supernata were collected as cytosolic fractions. This fraction was loaded on TALON spin column (Clontech), and His-tagged proteins were eluted with 50mM PBS, 150mM imidazole, pH 7. Recombinant proteins were then detected by western blotting with anti-myc antibody and visualized using a ProtoBlot II AP system (Promega). Recombinant affinity purified fusions of the DPRP-1 and DPRP-2 were detected by western blot, and DPRP-1 and DPRP-2 were synthesized as 112kDa and 109kDa forms as predicted.

Naturally occurring or recombinant DPRP proteins were substantially purified by immunoaffinity chromatography using antibodies specific for DPRP-1, DPRP-2 or DPRP-3. An immunoaffinity column was constructed by covalently coupling DPRP antibodies to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin was blocked and washed according to the manufacturer's instructions.

Media or cell extracts containing DPRP proteins were passed over the immunoaffinity column, and the column was washed under conditions that allow the preferential absorbance of DPRPs (e.g., high ionic strength buffers in the presence of detergent). The column was eluted under conditions that disrupt antibody/DPRP binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and purified DPRP was collected.

Example 6

Enzymatic Activity of DPRP proteins and Methods of Screening for Inhibitors

The kinetic properties of recombinant DPRP-1 and DPRP-2 were determined in a continuous fluorimetric assay. Buffer, pH and temperature dependence optimization led to the following assay conditions: Enzyme assays were performed in 50mM PBS, pH 7.4. 50 µl (50 µg/ml) of purified enzymes were mixed with 1 µl of different concentration of Ala-Pro-AMC (Enzyme Systems). Plates were then incubated at 37°C for 30 min, and

fluorescence was detected using a Wallac 1420 Fluorimeter with λ_{ex} 40355 and λ_{em} 535. The K_m values of DPRP-1 and DPRP-2 were similar (208 and 161 μ M respectively).

Further biochemical characterization reveals that DPRP-1 and DPRP-2 have similar profiles to DPPIV. The two purified proteases and DPPIV were preincubated with inhibitors at room temperature for 30 min. Substrate, Ala-Pro-AMC (100 μ M), was then added, and the fluorescence intensity was recorded as 60 readings during a 60 min period. The irreversible serine protease inhibitor AEBSF was the only inhibitor tested that showed strong inhibition of all three enzymes (Table 5). This confirms the structural and domain analysis prediction that these proteins belong to the serine protease superfamily.

Table 5. Inhibition of DPRP-1 and DPRP-2 by Protease Inhibitors

Inhibitor	Inhibitor Property	Concentration	Residual activity (% of control)		
			DPRP-1	DPRP-2	DPPIV
AEBSF	serine, irreversible	5mM	29.6	23.9	21.1
Aprotinin	serine, reversible	5 μ g/ml	77.5	63.2	80.2
Pepstatin	aspartic, reversible	2 μ g/ml	97.3	95.0	93.5
DTT	cysteine	2mM	100.1	94.8	98.3
B-Mercaptoethonal	cysteine	100mM	93.2	84.0	98.0
EDTA	metallo, reversible	2mM	91.5	86.0	93.5
Leupeptin	serine, reversible	50 μ g/ml	91.1	90.4	90.7

In addition to Ala-Pro-AMC, additional substrates tested also confirmed that DPRP-1 and DPRP-2 are dipeptidyl peptidases. The data were derived by determining the fluorescence change following a 30-minute incubation of the substrates (125 μ M) with enzymes as a percentage of the fluorescence measured at Ala-Pro-AMC and Gly-Pro-AMC were the only good substrates among those tested.

Table 6. DPRP-1 and DPRP-2 are dipeptidyl peptidases.

Substrate	% Change in Fluorescence at 30 minutes		
	DPRP-1	DPRP-2	DPPIV
Ala-Pro-AMC	239.0	127.5	379.0
Gly-Pro-AMC	341.5	205.0	444.0
Ala-Pro-pNA	45.5	44.0	29.5
Pro-pNA	-1	-2.5	0.0
Gly-Arg-pNA	-4.5	-0.5	0.0
Lys-Ala-pNA	2.5	0.5	0.5
Ala-Phe-Pro-pNA	-4	-0.5	2.0

Additional natural and non-natural amino acid di-, tri- and tetra-peptides were tested in order to find an optimal substrate for testing each of the DPRP proteins that will also show reduced activity when incubated DPPIV.

The enzyme assay method described here is one of a number of methods that can be utilized to screen for peptide and non-peptide inhibitors of the DPRP enzymes. Libraries of tetrapeptide inhibitors were tested to discover inhibitors of enzyme activity. Candidate inhibitors were prepared as 10-20 mM stock solutions in DMSO and stored at -20°C. Dilutions were made in assay buffer. Inhibition was determined by comparing the changes in fluorescence of the inhibited enzyme to the change in fluorescence of the control (vehicle) enzyme. $100 - (\text{fl units of sample} / \text{fl units of control} \times 100)$ gives percent inhibition value. The percent inhibition and the inhibitor concentration at which the enzyme was 50% inhibited (IC_{50}) was ascertained by plotting percent inhibition vs. inhibitor concentration on the log scale. As shown in Figure 3, several tetrapeptides amides inhibited enzyme activity, wherein data are expressed as the % of activity in the presence of vehicle (0.02% DMSO) alone. Compounds were added at 1 mM. Most interesting was the apparent differential activity of some tetrapeptides for DPRP-1 and DPRP-2, compared to DPPIV. While all three enzymes were inhibited by Peptide-1, only DPRP-1 and DPRP-2 were significantly inhibited by Peptide-4 and Peptide-5. This demonstrates that selective inhibition of the purified enzymes is achievable.

The assay described in this example can also be used to screen additional synthetic or naturally occurring compound libraries, including macromolecules, for agents that either inhibit or enhance DPRP activity. The DPRP-1 and DPRP-2 polypeptides to be used in the assay can be obtained by, for example, *in vitro* translation, recombinant expression (see Example 5) or biochemical procedures. Methods other than those described here can also be used to screen and identify compounds that inhibit DPRP-1, DPRP-2 or DPRP-3, which methods can include, for example, binding assays such as ELISAs and RIAs.

Example 7

Effect of DPRP Inhibitors on the Proliferation of Human Cancer Cells In Vitro

In an attempt to assess the effect that several inhibitors of DPRP-1 and DPRP-2 activity may have on the proliferation of human cancer cells, LNCap, PC3 and Du145, mouse testis line MLTC-1 and MDA-MB231 breast cancer cells were plated (10^4 per well) in 96-well tissue culture plates and allowed to grow and attach for 24 hours at 37°C in a CO₂ incubator. Compounds at various dilutions (final dilutions: 0.1 nM – 10 μ M) were then added to the wells for various incubation periods from 24 hours to 96 hours,

with fresh compound being replaced each day. Addition of the diluent DMSO alone served as the control. Following incubation with these compounds in triplicate, proliferation of the cells was determined using an XTT cell proliferation assay (Roche 1-465-015). The plates were read at 490 and 650nm 5 hours after the XTT mix was added.

- 5 An increase in cell proliferation was observed with three of the inhibitors at concentrations equal to 0.1, 1, 10 and 100 x IC₅₀, and the results are shown in FIGS. 4A, 4B and 4C for PC3 cells.

Overall, the DPRPs are expressed in a wide variety of tissues as has been demonstrated by mRNA amplification, western blotting and immunohistochemistry.

- 10 DPRP-1 was most abundant in the testis by Northern blot and western blot. The large number of expressed sequence tags (ESTs) from testis cDNA sources that are homologous to DPRP-1 also confirms abundant expression of DPRP-1 in testis. Example 4 describes the immunohistochemical localization of DPRP-1 protein in human testis using a specific DPRP-1 antibody. DPRP-1 is strongly expressed in epitheloid
15 Leydig cells, and Leydig cells are the primary source of testicular androgens (male steroid hormones) in the mammalian male. In the interstitium of the testis, Leydig cells and macrophages are in close association with "digitation" of Leydig cell process extending onto macrophage surface. Multinucleated cells in close proximity to the Leydig cells were also stained with DPRP-1 antibody suggesting that the protease was
20 also expressed in macrophages, and macrophages in the testis play an important role in the paracrine regulation of Leydig cells. Cytokines secreted by the testicular macrophages are mitogenic to Leydig cells and play an important role in the differentiation of mesenchymal progenitor cell into mature Leydig cells. A clearer understanding of the proteins and pathways involved in the maturation of the testis is
25 important for the discovery of new treatments for precocious puberty. In addition, Leydig cells cause tumors such as sex cord-stromal tumors via sexual steroid production (predominantly testosterone). Testosterone is associated with several neoplasia and diseases such as breast carcinoma and uterine cancers, ovarian carcinoma and androgenic alopecia (hair loss). Further examination of the localization of DPRP
30 proteins in other glands in the body (e.g. adrenal glands) that produce testosterone and other androgenic hormones are currently under investigation. The possible association of DPRP-1 with steroid and polypeptide hormone biosynthetic pathways functions is being investigated, and Example 7 is relevant to understanding the role of DPRP proteins in prostate, testis and breast in vitro cell models.

Immunohistochemical analysis also localized DPRP-1 to endometrial glands in the uterus (see Example 4), pancreatic acini, glomeruli of the kidney, plasma cells in the bladder, a subset of B-cells in the tonsils, columnar epithelial cells of the prostate and poorly differentiated prostate squamous metaplasia, Gleason grade 4 prostatic carcinoma, and hyperplastic glands in benign prostatic hyperplasia. Positive staining in breast carcinoma, as well as in seminoma and prostate squamous metaplasia, suggests a general association of DPRP-1 with hormone-sensitive tissues, particularly in cells that become poorly differentiated. The presence of the DPRP-1 in specialized epithelial cells and in inflammatory plasma cells (lymphocytes) is also of interest. Inflammatory breast carcinoma has an abundance of infiltrating lymphocytes and an overall bad prognosis. DPRP-1 and other DPRP proteins appear in medullary carcinomas that typically have a constant infiltrating lymphoplasmacytic component at the periphery of the tumor, which is thought to represent a reaction of the host tissues to the neoplasm. Most of the lymphocytes are T Cells, and most of the plasma cells are of the IgG-producing type. Several antigens are abundant on B cells, a subgroup of breast-cancer cells, and other epithelial cancer cells, and these antigens are targets for a new class of therapeutic monoclonal antibodies with some notable success having been achieved with a humanized monoclonal antibody against the B-cell-specific antigen CD20. Accordingly, monoclonal antibodies to DPRP proteins are felt to be useful to diagnose and treat diseases in which they are involved, including cancer.

The expression of DPRP-1 in specialized epithelial cells of a number of tissues suggests that DPRP-1 and other DPRP proteins may be involved in growth and differentiation thereof. Testing using inhibitors described in Example 6 in *in vitro* models of prostate and testis cancer (Example 7) showed that DPRP-1/DPRP-2 inhibitors caused a 50-60% increase in proliferation of PC3 cells at nM concentrations as shown in FIGS. 4A-4C.

Although the invention has been described in accordance with its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that changes and modifications as would be obvious to those skilled in this art may be made without departing from its scope which is set forth in the claims appended hereto. For example, although the disclosure focuses on DPRP-1 and DPRP-2 in certain instances, DPRP-3 and its fragments are considered to be similarly useful, as are nucleic acids encoding same. Particular features of the invention are emphasized in the claims that follow.

CLAIMS:

1. Isolated nucleic acid
which encodes (a) a polypeptide, which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function;
or which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6; or
which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b) ; or
which is complementary to any one of the foregoing.
2. The isolated nucleic acid of claim 1 which is DNA or RNA.
3. The isolated nucleic acid of claim 1 which is a DNA transcript that includes the entire length of any one of SEQ ID NOS:2, 4 and 6 or which is complementary to the entire coding region of one of SEQ ID NOS:2, 4 and 6.
4. An antisense oligonucleotide directed against the DNA of claim 3.
5. The isolated nucleic acid of claim 1 which is an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.
6. The isolated nucleic acid of claim 1 which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6.
7. A polypeptide encoded by the nucleic acid of claim 6.
8. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 90% similar to one of SEQ ID NOS:1, 3 and 5.
9. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 95% similar to one of SEQ ID NOS:1, 3 and 5.
10. The isolated nucleic acid of claim 1 which encodes a polypeptide that has at least about 90% identity with one of SEQ ID NOS:1, 3 and 5.
11. A nucleic acid probe according to claim 1 comprising at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 and 6.
12. An isolated recombinant polynucleotide molecule comprising nucleic acid according to claim 1 plus expression-controlling elements linked operably with said nucleic acid to drive expression thereof.
13. An expression vector comprising the nucleic acid of claim 1 encoding a polypeptide having the entire amino acid sequence set forth in any one of SEQ ID NOS:1, 3 and 5 operably linked to a promoter, said expression vector being present in a compatible host cell.

14. A mammalian, insect or bacterial host cell that has been genetically engineered by the insertion of nucleic acid according to claim 1 which codes for at least the mature protein portion of the amino acid sequence of SEQ ID NO:1, 3 or 5.
15. A process for producing a polypeptide which includes the mature protein portion of one of SEQ ID NOS:1, 3 and 5, which process comprises culturing the host cell of claim 11 under conditions sufficient for the production of said polypeptide.
16. The process of claim 15 wherein said polypeptide is expressed at the surface of said cell and further includes the step of recovering the polypeptide or a fragment thereof from the culture.
17. A polypeptide
which may be optionally glycosylated, and
which (a) has the amino acid sequence of a mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).
18. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).
19. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).
20. The polypeptide according to claim 14 having the amino acid sequence of the mature protein of one of SEQ ID NOS:1, 3 and 5, or is a fragment thereof which exhibits the same biological function as the respective mature protein.
21. A DPRP antagonist which inhibits the biological function of one of said mature proteins of claim 17, 18 and 19.
22. An antibody that recognizes a polypeptide or a fragment according to claim 17.
23. The antibody of claim 22 which recognizes a polypeptide having an amino acid sequence of SEQ ID NO:1 or 3 or 5.
24. A method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of claim 17, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the

absence of a test compound, and selecting the test compound or compounds that reduce the enzymatic activity.

25. A method for the screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one of the mature proteins of claim 20, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

DPP4 1MTPVVL...AA...YT
 DPRP1 1 MAAAMETEQLGMEFFETDCENIESDRPKPEPYEAYSSEISKLEDRKHYM
 DPRP2 1ATTGPAAGGDAATDDPAARFQ...HSIDGAS...H...S...V
 DPRP3 1NQT...SVSHIKCPSKTEKELGSPPO...W...AIALLVILVCS

DPP4 20 MITVPVVLNNGP...ATADSRRTYTD...LKE...TIRLKLY...RWE...HEYLA...N
 DPRP1 61 AKAP...D...F...N...PDGPH...D...Y...MSGENDER...LYSEIP...NRA...VIMIS...PLL
 DPRP2 50 NKAP...D...Q...F...K...D...SGPH...H...Y...Y...MPYGS...N...LYSEIP...K...KEAL...L...ML
 DPRP3 48 MITMSVILLSP...DELTSN...ETRLS...ED...L...KE...VLHD...PEARWIN...TD...V...N

DPP4 75 ...ALVFNA...YNS...FLNST...DEF...H...IND...S...SID...Q...LLE...Y...K...H...SY
 DPRP1 121 ...EQAT...L...Y...S...R...E...E...L...R...R...R...I...S...T...V...G...I...A...S...Y...D...H...O...G...S...S...T...H...F...O...A...G...S...G...P...V...G...G...P
 DPRP2 110 ...HFOATPHHS...Y...S...R...E...E...L...R...R...R...R...L...S...V...E...G...I...S...Y...L...H...S...E...S...L...E...L...F...O...A...S...I...S...L...C...G...G...K
 DPRP3 101 GH...IKLN...T...NAT...L...L...L...E...N...T...T...V...I...F...K...S...R...H...S...I...D...L...K...Y...L...L...A...V...K...O...I...Y...S...Y

DPP4 130 ...S...D...I...Y...D...N...K...R...I...E...E...R...I...N...N...T...Q...W...V...T...W...S...P...V...G...H...K...I...A...N...N...D...Y...K...I...E...P...N...L...P...S...Y
 DPRP1 179 QGNTQCP...N...L...M...E...S...C...P...N...I...D...P...R...E...C...P...A...P...D...I...F...H...S...N...D...A...S...N...I...R...E...R...R...E
 DPRP2 168 NG...S...T...L...K...I...Q...C...S...G...P...D...P...I...C...P...A...P...A...F...E...I...N...S...I...A...N...E...I...G...E...R...R...I
 DPRP3 155 ...S...L...N...L...T...R...E...V...W...E...I...N...P...P...E...V...E...D...S...V...Q...Y...A...A...W...G...V...Q...Q...I...I...E...N...Y...Q...P...D...K...S...S...L...R...L

DPP4 187 ...G...K...I...Y...N...I...T...D...W...V...Y...E...V...I...S...A...Y...S...L...H...S...N...T...E...L...A...Y...A...O...N...E...S...V...P
 DPRP1 235 ...V...H...E...I...A...M...E...D...A...R...S...G...V...A...T...V...L...Q...E...E...F...D...R...Y...S...Y...W...C...H...K...A...T...T...P...S...G...G...I...K...I...L...Y...E...N...E...S
 DPRP2 224 ...C...H...O...G...S...I...V...L...D...P...K...S...A...G...V...A...T...V...I...Q...E...E...F...D...R...Y...S...Y...W...C...H...K...A...T...T...P...S...G...G...I...K...I...L...Y...E...N...E...S
 DPRP3 215 ...S...G...K...I...Y...N...I...T...D...W...V...Y...E...V...I...S...A...Y...S...L...H...S...N...T...E...L...A...Y...A...O...N...E...S...V...P

DPP4 235 ...L...Y...S...F...Y...D...E...S...I...Y...P...K...T...V...R...V...P...Y...P...R...A...G...A...V...N...E...I...R...F...E...V...V...N...T...D...S...L...S...S...T...N...A...T...S...I...O...T...A...P...A...S
 DPRP1 294 ...E...V...E...I...H...V...T...S...P...L...T...R...A...D...S...R...Y...P...K...T...A...N...P...K...Y...I...E...R...S...E...M...I...D...A...E...G...I...D...V...I...D...K...E...I...P...O...P...E
 DPRP2 284 ...E...V...E...I...H...V...P...S...E...A...L...H...E...R...K...T...D...S...Y...R...Y...E...T...S...K...N...P...I...A...K...A...E...F...O...T...D...S...O...S...I...S...T...O...K...E...I...P...O...P...E
 DPRP3 263 ...T...V...P...K...T...G...A...Y...P...G...K...O...P...Y...P...R...A...G...A...V...N...E...I...R...F...E...V...V...N...T...D...S...L...S...S...T...N...A...T...S...I...O...T...A...P...A...S

DPP4 293 ...I...G...D...H...I...C...D...V...T...A...Q...E...R...I...S...P...O...R...I...O...N...
 DPRP1 354 ...L...I...E...G...V...E...Y...I...A...R...A...W...T...P...E...C...K...Y...A...S...L...L...D...R...S...T...R...L...C...V...I...E...S...E...L...F...I...V...E...D...V...M...E...R...O...R...L...I...E...S
 DPRP2 344 ...S...L...E...P...K...V...E...Y...I...A...R...A...W...T...P...E...C...K...Y...A...S...L...L...D...R...P...O...S...W...L...O...V...I...P...P...A...L...F...I...E...S...T...N...E...E...Q...L...A...S...A...R...A
 DPRP3 314 ...F...K...S...R...E...Y...T...M...V...K...E...V...E...N...T...K...T...V...R...L...Y...R...P...O...N...

DPP4 322 ...Y...S...V...I...D...D...Y...J...G...R...N...C...I...V...A...R...O...L...E...M...S...T...W...V...G...R...F...R...P...S...E...H...F...T...L...D...G...N...S...F...Y...K...I...S...N...E...
 DPRP1 414 ...H...D...S...V...T...I...I...Y...E...F...I...D...A...W...I...N...H...D...I...E...F...F...P...O...S...H...E...E...E...F...A...S...E...C...K...I...G...F...R...L...Y...K...I...T...S...L...H...E
 DPRP2 404 ...E...R...N...O...Y...V...V...E...E...V...I...N...W...I...N...H...D...I...E...F...F...P...O...S...E...D...E...L...C...E...R...A...N...E...C...K...I...G...F...C...H...L...Y...K...I...T...S...L...H...E
 DPRP3 343 ...I...S...T...E...T...E...T...T...G...A...C...S...K...Y...E...M...T...S...T...W...L...S...Q...O...N...E...E...V...F...S...R...D...G...S...E...F...M...T...V...P...K...O...G

FIG. 1A

DPP4 379 E.....SRRICYQIDK.....CTETIKETWV.....EETSSEYLYYISKEY
 DPRP1 473 S...KRSSGCLTAPSEPCPI.....EEIATSGEWELGRHGNTQVDIVRLVYIEST
 DPRP2 464 QGNDWEPFSGEDPCPI.....EEIATSGEWELGRHGNTQVDIVRLVYIEST
 DPRP3 394 G.....ETHEAMLIQSSEQITVRHLTSNNEIK.....IAYDTQKEILSE

 DPP4 424 GMGGKNIKQLSDYTKVICH...ELNPER...QYSV...FKE...KY...S...GL...TH
 DPRP1 529 DSPEHILYVVSIVNPGEVIR...DR...HSCCIS...HCD...SKYS...H...S...YK...S
 DPRP2 520 DPPEHILYVVSIVNPGEVIR...DR...HSCCIS...HCD...SKYS...H...S...YK...S
 DPRP3 445 SSURGHOLISA...TLLNRQCA...NFMKEQ...FDA...F...P...NOHFL...F...EGRVIVS...H

 DPP4 484 SSVN...KGL...DNSA...DKMLON...VOM...SKKLD...I...N...T...F...Y...O...IL...PHFDKSK...
 DPRP1 588 SPEDDUTCTKEIWA...AGPLPDYTPPEISSEST...GTLYGM...YK...H...L...PGK...Y
 DPRP2 579 GEIDDLH...QPRWA...E...ASCPEDY...PPEI...H...R...V...LY...M...YK...H...L...PGK...Y
 DPRP3 505 STNPAKYF...LSNSM...K...ILKKKIGK...E...I...H...D...E...P...L...S...L...FMDRNO...A

 DPP4 542 LLDV...AGCS...KATV...LN...ATYLA...ENI...VASF...DGRSG...Q...D...IMHAIN...S...
 DPRP1 648 TML...YGGPOVOLVNS...FK...KY...RLNTLASIG...V...V...N...G...CH...R...L...F...E...Y...
 DPRP2 639 TML...YGGPOVOLVNS...FK...KY...RLNTLASIG...V...V...N...G...CH...R...L...F...E...Y...
 DPRP3 563 LLDV...DEEG...G...T...L...ID...DSVL...DMDNV...ARF...DGRSG...Q...D...ILQ...E...

 DPP4 600 TFE...EDC...F...ARQ...F...M...F...N...K...A...I...W...S...Y...G...G...Y...S...V...G...G...S...G...V...F...O...I...A...V...A...R...
 DPRP1 708 QLE...DD...D...E...G...L...Y...L...A...S...F...D...F...I...D...R...V...G...H...G...W...S...Y...G...G...Y...L...S...L...A...P...O...S...D...I...V...I...A...G...A...P...V...I...
 DPRP2 699 QVE...EDC...F...L...Q...F...E...K...Y...G...F...I...D...L...S...R...V...A...I...H...G...W...S...Y...G...G...Y...L...S...L...A...P...O...S...D...I...V...I...A...G...A...P...V...I...
 DPRP3 621 SVE...K...D...C...T...E...Y...K...E...L...L...P...I...S...K...E...L...F...K...G...Y...G...G...Y...L...S...L...A...P...O...S...D...I...V...I...A...G...A...P...V...I...

 DPP4 659 E...Y...S...V...Y...T...E...R...Y...M...C...H...D...N...E...G...Y...L...S...V...A...Q...A...E...F...F...S...E...P...N...R...L...I...H...F...L...D...E...N...V...H...E...A...I...
 DPRP1 768 E...Y...S...V...Y...T...E...R...Y...M...C...H...D...N...E...G...Y...L...S...V...A...Q...A...E...F...F...S...E...P...N...R...L...I...H...F...L...D...E...N...V...H...E...A...I...
 DPRP2 759 E...Y...S...V...Y...T...E...R...Y...M...C...H...D...N...E...G...Y...L...S...V...A...Q...A...E...F...F...S...E...P...N...R...L...I...H...F...L...D...E...N...V...H...E...A...I...
 DPRP3 680 LKL...A...S...V...Y...T...E...R...Y...M...C...H...D...N...E...G...Y...L...S...V...A...Q...A...E...F...F...S...E...P...N...R...L...I...H...F...L...D...E...N...V...H...E...A...I...

 DPP4 719 SSKA...DV...VD...AMW...T...D...D...G...I...A...S...T...H...E...I...Y...T...H...S...H...K...C...F...S...L...P...
 DPRP1 828 L...S...F...R...A...G...K...P...Y...D...L...Q...I...Y...F...O...E...R...H...S...I...R...V...P...E...S...G...E...H...T...E...L...H...L...L...L...Q...E...N...I...G...S...R...I...A...K...V...I...
 DPRP2 819 L...S...Q...I...R...A...G...K...E...Y...O...L...Q...I...Y...F...O...E...R...H...S...I...R...V...P...E...S...G...E...H...T...E...L...H...L...L...L...Q...E...N...I...G...S...R...I...A...K...V...I...
 DPRP3 738 L...K...H...E...A...G...V...N...E...T...D...Y...P...D...E...G...N...S...E...K...S...K...Y...H...L...Y...S...T...E...F...S...L...K...E...S...V...L...P...O...E...P...E...D...E...

FIG. 1B

hDPRP1	1	MAAAKETEQLGVETETADCELN.IESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGT
mDPRP1	1	MAAAKETEQLGVETETADCELN.IESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGT
hDPRP1	60	MAKAPHDFHEVKNIDPIGPHSDPYYLAMSGENRENTIFYSEIPKTIHRAAVLHLSWKPI
mDPRP1	61	MAKAPHDFHEVKNIDPIGPHSDPYYLAMSGENRENTIFYSEIPKTIHRAAVLHLSWKPI
hDPRP1	120	LDLEQATLDYGMYSREEELLRERKRIGTVGIASTDYHQSSGTFLEQAGSGIYHNDGSEQ
mDPRP1	121	LDLEQATLDYGMYSREEELLRERKRIGTVGIASTDYHQSSGTFLEQAGSGIYHNDGSEH
hDPRP1	180	GFTQQLRPPLVETSCPNIRMDPKLCPADPDWIAFIHSNDIWSHVTREERTYVHNT
mDPRP1	181	GFTQQLRPPLVETSCPNIRMDPKLCPADPDWIAFIHSNDIWSHVTREERTYVHNT
hDPRP1	240	LANMEEDARSAGVATFVLQEEFDRYSGYWWCFKALTTPSGGKILRILYEENDESEVEITH
mDPRP1	241	LANMEEDARSAGVATFVLQEEFDRYSGYWWCFKALTTPSGGKILRILYEENDESEVEITH
hDPRP1	300	VTSPMLETRRADSFYRYPKTGTANPKVTFKMSEIADAEGRIDVIDKEIOPFEILFEG
mDPRP1	301	VTSPMLETRRADSFYRYPKTGTANPKVTFKMSEIADAEGRIDVIDKEIOPFEILFEG
hDPRP1	360	EYIARAGWTPEGHYAWSILLDRSQTLOIVLISPELFIPVEDVWRORLIESVPDSVTE
mDPRP1	361	EYIARAGWTPEGHYAWSILLDRSQTLOIVLISPELFIPVEDVWRORLIESVPDSVTE
hDPRP1	420	LIIYEETTDIWINIHDIHFVFPQHEEIEFIFASECKTGERHLYKITSILKESKYKRSS
mDPRP1	421	LIIYEETTDIWINIHDIHFVFPQHEEIEFIFASECKTGERHLYKITSILKESKYKRSS
hDPRP1	480	GGLPAPSDFKCPIKEEITITSGEWEVLGRHGSNIQVDEVEFLVYFEGTKDSPLEHHLYVT
mDPRP1	481	GGLPAPSDFKCPIKEEITITSGEWEVLGRHGSNIQVDEVEFLVYFEGTKDSPLEHHLYVT
hDPRP1	540	SYVNPGEVTRLTDRGYSHSCQSRHCDFEFISKYSNQNPHCVSLYKLSSPEDDETCKTKE
mDPRP1	541	SYVNPGEVTRLTDRGYSHSCQSRHCDFEFISKYSNQNPHCVSLYKLSSPEDDETVHKTKE
hDPRP1	600	FWATILDSAGPLPDYTPPEIFSFESTTGFTLYCMLYKPHDLQPKKYPTVLFYGGPQVC
mDPRP1	601	FWATILDSAGPLPDYTPPEIFSFESTTGFTLYCMLYKPHDLQPKKYPTVLFYGGPQVC
hDPRP1	660	LVNNRFKGVKYFRINTLASLGYVVVVIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQ
mDPRP1	661	LVNNRFKGVKYFRINTLASLGYVVVVIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQ
hDPRP1	720	YLASRYDFIDLDRVGIHGWSYGGYLSMALMQRSDIFRVAIAGAPVTLWIFYDTGYTERY
mDPRP1	721	YLASRYDFIDLDRVGIHGWSYGGYLSMALMQRSDIFRVAIAGAPVTLWIFYDTGYTERY
hDPRP1	780	MGHDPQNEQGYIIGSVAMQAEKFPSEPNRLLLLHGFLDENVHFAHTSILLSFLVRAGKPY
mDPRP1	781	MGHDPQNEQGYIIGSVAMQAEKFPSEPNRLLLLHGFLDENVHFAHTSILLSFLVRAGKPY
hDPRP1	840	DLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI
mDPRP1	841	DLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI

FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C

Sequence Listing Summary

SEQ ID.	
	1. DPRP1 a.a. sequence
	2. DPRP1 DNA sequence
5	3. DPRP2 a.a. sequence
	4. DPRP2 DNA sequence
	5. DPRP-3 a.a. sequence
	6. DPRP-3 DNA sequence
	7. DPRP-1 transcript 0 a.a. sequence
10	8. DPRP-1 transcript 0 DNA sequence
	9. DPRP-1 transcript 1 a.a. sequence
	10. DPRP-1 transcript 1 DNA sequence
	11. DPRP-1 transcript 2 a.a. sequence
	12. DPRP-1 transcript 2 DNA sequence
15	13. DPRP-1 transcript 3 a.a. sequence
	14. DPRP-1 transcript 3 DNA sequence
	15. DPRP-1 transcript 4 a.a. sequence
	16. DPRP-1 transcript 4 DNA sequence
	17. DPRP-1 transcript 5 a.a. sequence
20	18. DPRP-1 transcript 5 DNA sequence
	19. DPRP-1 transcript 6 a.a. sequence
	20. DPRP-1 transcript 6 DNA sequence
	21. DPRP-1 transcript 7 a.a. sequence
	22. DPRP-1 transcript 7 DNA sequence
25	23. DPRP-2 transcript 0 a.a. sequence
	24. DPRP-2 transcript 0 DNA sequence
	25. DPRP-2 transcript 1 a.a. sequence
	26. DPRP-2 transcript 1 DNA sequence
	27. DPRP-2 transcript 2 a.a. sequence
30	28. DPRP-2 transcript 2 DNA sequence
	29. DPRP-2 transcript 3 a.a. sequence
	30. DPRP-2 transcript 3 DNA sequence
	31. DPRP-2 transcript 4 a.a. sequence
	32. DPRP-2 transcript 4 DNA sequence
35	33. DPRP-2 transcript 5 a.a. sequence

34. DPRP-2 transcript 5 DNA sequence
35. DPRP-2 transcript 6 a.a. sequence
36. DPRP-2 transcript 6 DNA sequence
37. DPRP-2 transcript 7 a.a. sequence
- 5 38. DPRP-2 transcript 7 DNA sequence
39. DPRP-2 transcript 8 a.a. sequence
40. DPRP-2 transcript 8 DNA sequence
41. DPRP-3 transcript 0 a.a. sequence
42. DPRP-3 transcript 0 DNA. Sequence
- 10 43. DPRP-3 transcript 1 a.a. sequence
44. DPRP-3 transcript 1 DNA sequence
45. DPRP1 forward primer used for cloning
46. DPRP1 reverse primer used for cloning full length gene
47. DPRP1 reverse primer used for cloning fusion gene
- 15 48. DPRP1 forward primer used for expression profiling
49. DPRP1 reverse primer used for expression profiling
50. DPRP2 forward primer used for cloning
51. DPRP2 reverse primer used for cloning full length gene
52. DPRP2 reverse primer used for cloning fusion gene
- 20 53. DPRP2 forward primer used for expression profiling
54. DPRP2 reverse primer used for expression profiling
55. DPRP3 forward primer used for cloning
56. DPRP3 reverse primer used for cloning full length gene
57. DPRP3 forward primer used for cloning fusion gene
- 25 58. DPRP3 reverse primer used for cloning fusion gene
59. DPRP1 peptide antigen sequences
60. DPRP2 peptide antigen sequences
61. DPRP3 peptide antigen sequences

SEQUENCE LISTING

<110> Qi, Steve
 Akinsanya, Karen
 Riviere, Pierre
 Junien, Jean-Louis

<120> NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

<130> 70669

<150> US 60/240,117

<151> 2000-10-12

<160> 61

<170> Patent In version 3.1

<210> 1

<211> 882

<212> PRT

<213> Homo sapiens

<400> 1

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
          50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
          85          90          95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
          100          105          110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
          115          120          125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
          130          135          140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
145          150          155          160
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
          165          170          175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
          180          185          190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
          195          200          205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
          210          215          220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
225          230          235          240
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
          245          250          255

```

Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
 260 265 270
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
 275 280 285
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
 290 295 300
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
 305 310 315 320
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
 325 330 335
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe
 340 345 350
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
 355 360 365
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr
 370 375 380
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu
 385 390 395 400
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
 405 410 415
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn
 420 425 430
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Ile
 435 440 445
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr
 450 455 460
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly
 465 470 475 480
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile
 485 490 495
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn
 500 505 510
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys
 515 520 525
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
 530 535 540
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys
 545 550 555 560
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys
 565 570 575
 Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp
 580 585 590
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala
 595 600 605
 Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser
 610 615 620
 Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu
 625 630 635 640
 Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Pro
 645 650 655
 Gln Val Gln Leu Val Asn Asn Arg Phe Lys Gly Val Lys Tyr Phe Arg
 660 665 670
 Leu Asn Thr Leu Ala Ser Leu Gly Tyr Val Val Val Val Ile Asp Asn
 675 680 685
 Arg Gly Ser Cys His Arg Gly Leu Lys Phe Glu Gly Ala Phe Lys Tyr
 690 695 700
 Lys Met Gly Gln Ile Glu Ile Asp Asp Gln Val Glu Gly Leu Gln Tyr
 705 710 715 720

Leu Ala Ser Arg Tyr Asp Phe Ile Asp Leu Asp Arg Val Gly Ile His
 725 730 735
 Gly Trp Ser Tyr Gly Gly Tyr Leu Ser Leu Met Ala Leu Met Gln Arg
 740 745 750
 Ser Asp Ile Phe Arg Val Ala Ile Ala Gly Ala Pro Val Thr Leu Trp
 755 760 765
 Ile Phe Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met Gly His Pro Asp
 770 775 780
 Gln Asn Glu Gln Gly Tyr Tyr Leu Gly Ser Val Ala Met Gln Ala Glu
 785 790 795 800
 Lys Phe Pro Ser Glu Pro Asn Arg Leu Leu Leu Leu His Gly Phe Leu
 805 810 815
 Asp Glu Asn Val His Phe Ala His Thr Ser Ile Leu Leu Ser Phe Leu
 820 825 830
 Val Arg Ala Gly Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg
 835 840 845
 His Ser Ile Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu
 850 855 860
 Leu His Tyr Leu Gln Glu Asn Leu Gly Ser Arg Ile Ala Ala Leu Lys
 865 870 875 880
 Val Ile

<210> 2
 <211> 2671
 <212> DNA
 <213> Homo sapiens
 <400> 2

cggtaccatg gcagcagcaa tggaaacaga acagctgggt gttgagatat ttgaaactgc 60
 ggactgtgag gagaatattg aatcacagga tcggcctaaa ttggagcctt tttatgttga 120
 gcggtattcc tggagtcagc ttaaaaagct gcttgccgat accagaaaat atcatggcta 180
 catgatggct aaggcaccac atgatttcat gtttgtgaag aggaatgatc cagatggacc 240
 tcattcagac agaatctatt accttgccat gtctgggtgag aacagagaaa atacactgtt 300
 ttattctgaa attcccaaaa ctatcaatag agcagcagtc ttaatgctct cttggaagcc 360
 tcttttggat ctttttcagg caacactgga ctatggaatg tattctcgag aagaagaact 420
 attaagagaa agaaaacgca ttggaacagt cggaattgct tcttacgatt atcaccaagg 480
 aagtggaaca tttctgtttc aagccggtag tgggaatttat cacgtaaaag atggaggggc 540
 acaaggattt acgcaacaac ctttaaggcc caatctagtg gaaactagtt gtcccaacat 600
 acggatggat ccaaaattat gccctgctga tccagactgg attgctttta tacatagcaa 660
 cgatatttgg atatctaaca tcgtaaccag agaagaaagg agactcactt atgtgcacaa 720
 tgagctagcc aacatggaag aagatgccag atcagctgga gtcgctacct ttgttctcca 780
 agaagaattt gatagatatt ctggctattg gtggtgtcca aaagctgaaa caactcccag 840
 tgggtggtaaa attcttagaa ttctatatga agaaaatgat gaatctgagg tggaaattat 900
 tcatgttaca tcccctatgt tggaaacaag gagggcagat tcattccgtt atcctaaaac 960
 aggtacagca aatcctaaag tcacttttaa gatgtcagaa ataatgattg atgctgaagg 1020
 aaggatcata gatgtcatag ataaggaact aattcaacct tttgagattc tatttgaagg 1080
 agttgaatat attgccagag ctggatggac tcctgaggga aaatatgctt ggtccatcct 1140
 actagatcgc tcccagactc gcctgcagat agtgttgatc tcacctgaat tatttatccc 1200
 agtagaagat gatgttatgg aaaggcagag actcattgag tcagtgcctg attctgtgac 1260
 gccactaatt atctatgaag aaacaacaga catctggata aatatccatg acatctttca 1320
 tgtttttccc caaagtcacg aagaggaaat tgagtttatt tttgctctg aatgcaaaac 1380
 aggtttccgt catttatata aaattacatc ttttttaaag gaaagcaaat ataaacgatc 1440
 cagtgggtgg ctgcctgctc caagtgattt caagtgtcct atcaaagagg agatagcaat 1500
 taccagtggg gaatgggaag ttcttggccg gcatggatct aatatccaag ttgatgaagt 1560
 cagaaggctg gtatatattg aaggcaccaa agactcccct ttagagcatc acctgtacgt 1620
 agtcagttac gtaaatcctg gagaggtgac aaggctgact gaccgtggct actcacattc 1680
 ttgctgcatc agtcagcact gtgacttctt tataagtaag tatagtaacc agaagaatcc 1740
 aactgtgtg tccctttaca agctatcaag tcctgaagat gacccaactt gcaaaacaaa 1800
 ggaattttgg gccaccattt tggattcagc aggtcctctt cctgactata ctctccaga 1860
 aattttctct tttgaaagta ctactggatt tacattgtat gggatgctct acaagcctca 1920

tgatctacag	cctggaaaga	aatatcctac	tgtgctgttc	atatatgggtg	gtcctcaggt	1980
gcagttgggtg	aataatcgat	ttaaaggagt	caagtatttc	cgcttgaata	ccctagcctc	2040
tctaggttat	gtgggttag	tgatagacaa	caggggatcc	tgtcaccgag	ggcttaaatt	2100
tgaaggcgcc	tttaaata	aaatgggtca	aatagaaatt	gacgatcagg	tggaaggact	2160
ccaatatcta	gcttctcgat	atgatttcat	tgacttagat	cgtgtgggca	tccacggctg	2220
gtcctatgga	ggatacctct	ccctgatggc	attaatgcag	aggtcagata	tcttcagggt	2280
tgctattgct	ggggccccag	tcactctgtg	gatcttctat	gatacaggat	acacggaacg	2340
ttatatgggt	caccctgacc	agaatgaaca	gggctattac	ttaggatctg	tggccatgca	2400
agcagaaaag	ttccccctctg	aaccaaactcg	tttactgctc	ttacatgggt	tcctggatga	2460
gaatgtccat	tttgacacata	ccagtatatt	actgagtttt	ttagtgaggg	ctggaaagcc	2520
atatgattta	cagatctatc	ctcaggagag	acacagcata	agagttcctg	aatcgggaga	2580
acattatgaa	ctgcatcttt	tgcactacct	tcaagaaaac	cttggatcac	gtattgctgc	2640
tctaaaagtg	atatgagcgg	ccgcgagctc	c			2671

<210> 3
 <211> 863
 <212> PRT
 <213> Homo sapiens
 <400> 3

Met	Ala	Thr	Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala
1				5					10					15	
Thr	Asp	Asp	Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp
			20					25					30		
Gly	Leu	Arg	Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile
		35					40					45			
Val	Asn	Lys	Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu
	50					55					60				
Ser	Gly	Pro	His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly
65					70				75					80	
Ser	Arg	Glu	Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg
			85					90					95		
Lys	Glu	Ala	Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe
			100					105					110		
Gln	Ala	Thr	Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu
		115					120					125			
Arg	Glu	Arg	Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe
	130					135					140				
His	Ser	Glu	Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe
145					150				155					160	
His	Cys	Arg	Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys
			165					170						175	
Pro	Leu	Glu	Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys
		180						185					190		
Ile	Cys	Pro	Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp
	195					200						205			
Leu	Trp	Val	Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe
	210					215					220				
Cys	His	Gln	Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly
225					230				235					240	
Val	Ala	Thr	Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr
			245					250					255		
Trp	Trp	Cys	Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr
			260					265					270		
Leu	Arg	Ile	Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile
	275						280					285			
His	Val	Pro	Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg
	290					295					300				
Tyr	Pro	Arg	Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala
305					310					315				320	

Glu	Phe	Gln	Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys
				325					330					335	
Glu	Leu	Val	Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile
			340					345					350		
Ala	Arg	Ala	Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe
		355					360					365	-		
Leu	Asp	Arg	Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala
	370					375					380				
Leu	Phe	Ile	Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala
385					390					395					400
Arg	Ala	Val	Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val
			405						410					415	
Thr	Asn	Val	Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln
		420						425					430		
Ser	Glu	Gly	Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys
		435					440					445			
Thr	Gly	Phe	Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln
	450					455					460				
Gly	Tyr	Asp	Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys
465					470					475					480
Cys	Pro	Ile	Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val
			485						490					495	
Leu	Ala	Arg	His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu
		500						505					510		
Val	Tyr	Phe	Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr
	515						520					525			
Val	Val	Ser	Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro
	530					535					540				
Gly	Phe	Ser	His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val
545					550					555					560
Ser	His	Tyr	Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys
			565					570						575	
Leu	Ser	Gly	Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp
		580						585					590		
Ala	Ser	Met	Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro
		595					600					605			
Glu	Ile	Phe	His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met
	610					615					620				
Ile	Tyr	Lys	Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val
625					630					635					640
Leu	Phe	Val	Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe
			645						650					655	
Lys	Gly	Ile	Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr
		660						665					670		
Ala	Val	Val	Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg
		675					680					685			
Phe	Glu	Gly	Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp
	690					695					700				
Gln	Val	Glu	Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp
705					710					715					720
Leu	Ser	Arg	Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser
			725					730						735	
Leu	Met	Gly	Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Val	Ala	Ile	Ala
		740						745					750		
Gly	Ala	Pro	Val	Thr	Val	Trp	Met	Ala	Tyr	Asp	Thr	Gly	Tyr	Thr	Glu
		755					760					765			

Arg	Tyr	Met	Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly
770						775					780				
Ser	Val	Ala	Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu
785					790					795					800
Leu	Ile	Leu	His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	Phe	His	Thr
			805						810					815	
Asn	Phe	Leu	Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu
			820					825						830	
Gln	Ile	Tyr	Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly
		835					840					845			
Glu	His	Tyr	Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu	
850						855					860				

<210> 4
 <211> 2617
 <212> DNA
 <213> Homo sapiens
 <400> 4

caagcttacc	atggccacca	ccgggacccc	aacggccgac	cgaggcgacg	cagccgccac	60
agatgacccg	gccgcccgt	tccaggtgca	gaagcactcg	tgggacgggc	tccggagcat	120
catccacggc	agccgcaagt	actcgggcct	cattgtcaac	aaggcgcccc	acgacttcca	180
gtttgtgcag	aagacggatg	agtctgggccc	ccactcccac	cgctctact	acctgggaat	240
gccatatggc	agccgagaga	actccctcct	ctactctgag	attcccaaga	aggctccgaa	300
agaggctctg	ctgctcctgt	cctggaagca	gatgctggat	catttccagg	ccacgccccca	360
ccatggggtc	tactctcggg	aggaggagct	gctgagggag	cggaacgccc	tgggggtctt	420
cggcacaccc	tcctacgact	tccacagcga	gagtggcctc	ttcctcttcc	aggccagcaa	480
cagcctcttc	cactgtcgcg	acggcggcaa	gaacggcttc	atgggtgtccc	ctatgaaacc	540
gctggaaatc	aagacccagt	gctcagggcc	ccggatggac	cccaaatct	gccctgccga	600
ccctgccttc	ttctccttca	tcaataacag	cgacctgtgg	gtggccaaca	tcgagacagg	660
cgaggagcgg	cggtgacct	tctgccacca	aggtttatcc	aatgtcctgg	atgaccccaa	720
gtctgcgggt	gtggccacct	tcgtcataca	ggaagagttc	gaccgcttca	ctgggtactg	780
gtggtgcccc	acagcctcct	gggaagggtc	agagggcctc	aagacgctgc	gaatcctgta	840
tgaggaagtc	gatgagtcg	agggtggaggt	cattcacgtc	ccctctcctg	cgctagaaga	900
aaggaagacg	gactcgtatc	ggtaccccag	gacaggcagc	aagaatccca	agattgcctt	960
gaaactggct	gagttccaga	ctgacagcca	gggcaagatc	gtctcgaccc	aggagaagga	1020
gctggtgcag	cccttcagct	cgctgttccc	gaagggtggag	tacatcgcca	gggccgggtg	1080
gacccgggat	ggcaaatacg	cctggggcat	gttcctggac	cgccccagc	agtggctcca	1140
gctcgtcctc	ctcccccg	ccctgttcat	cccagacaca	gagaatgagg	agcagcggct	1200
agcctctgcc	agagctgtcc	ccaggaatgt	ccagccgtat	gtggtgtacg	aggaggtcac	1260
caacgtctgg	atcaatgttc	atgacatctt	ctatcccttc	ccccaatcag	aggagagagga	1320
cgagctctgc	tttctccgcg	ccaatgaatg	caagaccggc	ttctgccatt	tgtacaaagt	1380
caccgcccgt	ttaaaatccc	agggctacga	ttggagttag	cccttcagcc	ccggggaaga	1440
tgaatttaag	tgccccatta	aggaagagat	tgctctgacc	agcgggtgaat	gggaggtttt	1500
ggcgaggcac	ggctccaaga	tctgggtcaa	tgaggagacc	aagctgggtg	acttccaggg	1560
caccaaggac	acgccgctgg	agcaccacct	ctacgtggtc	agctatgagg	cggccggcga	1620
gatcgtacgc	ctcaccacgc	ccggcttctc	ccatagctgc	tccatgagcc	agaacttcga	1680
catgttcgtc	agccactaca	gcagcgtgag	cacgccgccc	tgcgtgcacg	tctacaagct	1740
gagcggcccc	gacgacgacc	ccctgcacaa	gcagccccgc	ttctgggcta	gcatgatgga	1800
ggcagccagc	tgcccccg	attatgttcc	tccagagatc	ttccatttcc	acacgcgctc	1860
ggatgtgcgg	ctctacggca	tgatctacaa	gccccacgcc	ttgcagccag	ggaagaagca	1920
ccccaccgtc	ctctttgtat	atggaggccc	ccagggtgcag	ctggtgaata	actccttcaa	1980
aggcatcaag	tacttgccgc	tcaacacact	ggcctccctg	ggctacgccg	tggttgtgat	2040
tgacggcagg	ggctcctgtc	agcgagggct	tcggttcgaa	ggggccctga	aaaaccaaat	2100
gggcccagggtg	gagatcgagg	accagggtgga	gggcctgcag	ttcgtggccg	agaagtatgg	2160
cttcacgcac	ctgagccgag	ttgccatcca	tggttggtcc	tacgggggct	tcctctcgct	2220
catggggcta	atccacaagc	cccagggtgtt	caagggtggcc	atcgcggtg	ccccggtcac	2280
cgtctggatg	gcctacgaca	cagggtacac	tgagcgctac	atggacgtcc	ctgagaacaa	2340
ccagcacggc	tatgaggcgg	gttccgtggc	cctgcacgtg	gagaagctgc	ccaatgagcc	2400
caaccgcttg	cttatcctcc	acggcttcc	ggacgaaaac	gtgcactttt	tccacacaaa	2460

```
cttcctcgtc tcccaactga tccgagcagg gaaaccttac cagctccaga tctaccccaa 2520
cgagagacac agtatctcgt gccccgagtc gggcgagcac tatgaagtca cgttgctgca 2580
ctttctacag gaatacctct gagcggccgc ggatccg 2617
```

```
<210> 5
<211> 796
<212> PRT
<213> Homo sapiens
<400> 5
```

Met 1	Asn	Gln	Thr	Ala 5	Ser	Val	Ser	His 10	His	Ile	Lys	Cys	Gln	Pro 15	Ser
Lys	Thr	Ile	Lys 20	Glu	Leu	Gly	Ser	Asn 25	Ser	Pro	Pro	Gln	Arg 30	Asn	Trp
Lys	Gly	Ile 35	Ala	Ile	Ala	Leu	Leu 40	Val	Ile	Leu	Val	Val 45	Cys	Ser	Leu
Ile	Thr 50	Met	Ser	Val	Ile	Leu 55	Leu	Ser	Pro	Asp	Glu 60	Leu	Thr	Asn	Ser
Ser 65	Glu	Thr	Arg	Leu 70	Ser	Leu	Glu	Asp	Leu	Phe 75	Arg	Lys	Asp	Phe	Val
Leu	His	Asp	Pro 85	Glu	Ala	Arg	Trp	Ile	Asn 90	Asp	Thr	Asp	Val 95	Val	Tyr
Lys	Ser	Glu	Asn 100	Gly	His	Val	Ile 105	Lys	Leu	Asn	Ile	Glu	Thr 110	Asn	Ala
Thr	Thr 115	Leu	Leu	Leu	Glu	Asn 120	Thr	Thr	Phe	Val	Thr	Phe 125	Lys	Ala	Ser
Arg	His 130	Ser	Val	Ser	Pro	Asp 135	Leu	Lys	Tyr	Val	Leu	Leu 140	Ala	Tyr	Asp
Val 145	Lys	Gln	Ile	Phe 150	His	Tyr	Ser	Tyr	Thr	Ala 155	Ser	Tyr	Val	Ile	Tyr
Asn	Ile	His	Thr 165	Arg	Glu	Val	Trp	Glu	Leu 170	Asn	Pro	Pro	Glu 175	Val	Glu
Asp	Ser	Val	Leu 180	Gln	Tyr	Ala	Ala 185	Trp	Gly	Val	Gln	Gly	Gln 190	Gln	Leu
Ile	Tyr 195	Ile	Phe	Glu	Asn	Asn 200	Ile	Tyr	Tyr	Gln	Pro	Asp 205	Ile	Lys	Ser
Ser 210	Ser	Leu	Arg	Leu	Thr	Ser 215	Ser	Gly	Lys	Glu	Glu	Ile 220	Ile	Phe	Asn
Gly 225	Ile	Ala	Asp	Trp	Leu 230	Tyr	Glu	Glu	Glu	Leu	Leu	His 235	Ser	His	Ile
Ala	His	Trp	Trp 245	Ser	Pro	Asp	Gly	Glu	Arg	Leu	Ala	Phe 250	Leu	Met	Ile
Asn	Asp	Ser	Leu 260	Val	Pro	Thr	Met	Val 265	Ile	Pro	Arg	Phe 270	Thr	Gly	Ala
Leu	Tyr 275	Pro	Lys	Gly	Lys	Gln 280	Tyr	Pro	Tyr	Pro	Lys	Ala 285	Gly	Gln	Val
Asn 290	Pro	Thr	Ile	Lys	Leu	Tyr 295	Val	Val	Asn	Leu	Tyr	Gly 300	Pro	Thr	His
Thr 305	Leu	Glu	Leu	Met 310	Pro	Pro	Asp	Ser	Phe	Lys 315	Ser	Arg	Glu	Tyr	Tyr
Ile	Thr	Met	Val 325	Lys	Trp	Val	Ser	Asn 330	Thr	Lys	Thr	Val 335	Val	Arg	Trp
Leu	Asn	Arg	Pro 340	Gln	Asn	Ile	Ser	Ile 345	Leu	Thr	Val	Cys 350	Glu	Thr	Thr
Thr	Gly 355	Ala	Cys	Ser	Lys	Lys 360	Tyr	Glu	Met	Thr	Ser	Asp 365	Thr	Trp	Leu
Ser 370	Gln	Gln	Asn	Glu	Glu	Pro 375	Val	Phe	Ser	Arg	Asp	Gly 380	Ser	Lys	Phe
Phe 385	Met	Thr	Val	Pro	Val	Lys 390	Gln	Gly	Gly	Arg	Gly	Glu 395	Phe	His	His

Ile Ala Met Phe Leu Ile Gln Ser Lys Ser Glu Gln Ile Thr Val Arg
 405 410 415
 His Leu Thr Ser Gly Asn Trp Glu Val Ile Lys Ile Leu Ala Tyr Asp
 420 425 430
 Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser Thr Glu Ser Ser Pro Arg
 435 440 445
 Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu Gly Leu Leu Asn Arg Gln
 450 455 460
 Cys Ile Ser Cys Asn Phe Met Lys Glu Gln Cys Thr Tyr Phe Asp Ala
 465 470 475 480
 Ser Phe Ser Pro Met Asn Gln His Phe Leu Leu Phe Cys Glu Gly Pro
 485 490 495
 Arg Val Pro Val Val Ser Leu His Ser Thr Asp Asn Pro Ala Lys Tyr
 500 505 510
 Phe Ile Leu Glu Ser Asn Ser Met Leu Lys Glu Ala Ile Leu Lys Lys
 515 520 525
 Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu His Ile Asp Asp Tyr Glu
 530 535 540
 Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp Phe Met Asp Arg Asn Gln
 545 550 555 560
 Tyr Ala Leu Leu Leu Ile Met Asp Glu Glu Pro Gly Gly Gln Leu Val
 565 570 575
 Thr Asp Lys Phe His Ile Asp Trp Asp Ser Val Leu Ile Asp Met Asp
 580 585 590
 Asn Val Ile Val Ala Arg Phe Asp Gly Arg Gly Ser Gly Phe Gln Gly
 595 600 605
 Leu Lys Ile Leu Gln Glu Ile His Arg Arg Leu Gly Ser Val Glu Val
 610 615 620
 Lys Asp Gln Ile Thr Ala Val Lys Phe Leu Leu Lys Leu Pro Tyr Ile
 625 630 635 640
 Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys Gly Tyr Gly Gly Tyr Ile
 645 650 655
 Ala Ser Met Ile Leu Lys Ser Asp Glu Lys Leu Phe Lys Cys Gly Ser
 660 665 670
 Val Val Ala Pro Ile Thr Asp Leu Lys Leu Tyr Ala Ser Ala Phe Ser
 675 680 685
 Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu Glu Ser Thr Tyr Gln Ala
 690 695 700
 Ala Ser Val Leu His Asn Val His Gly Leu Lys Glu Glu Asn Ile Leu
 705 710 715 720
 Ile Ile His Gly Thr Ala Asp Thr Lys Val His Phe Gln His Ser Ala
 725 730 735
 Glu Leu Ile Lys His Leu Ile Lys Ala Gly Val Asn Tyr Thr Met Gln
 740 745 750
 Val Tyr Pro Asp Glu Gly His Asn Val Ser Glu Lys Ser Lys Tyr His
 755 760 765
 Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser Asp Cys Leu Lys Glu Glu
 770 775 780
 Ile Ser Val Leu Pro Gln Glu Pro Glu Glu Asp Glu
 785 790 795

<210> 6
 <211> 2583
 <212> DNA
 <213> Homo sapiens
 <400> 6

gcctgggatt gtgcactgtc cagggtcctg aaacatgaac caaactgcca gcgtgtccca 60
 tcacatcaag tgtcaaccct caaaaacaat caaggaactg ggaagtaaca gccctccaca 120
 gagaaactgg aagggaattg ctattgctct gctgggtgatt ttagttgtat gctcactcat 180

```

cactatgtca gtcacccctct taagcccaga tgaactcaca aattcgtcag aaaccagatt 240
gtcttttgaa gacctcttta ggaaagactt tgtgcttcac gatccagagg ctcggtggat 300
caatgatata gatgtggtgt ataaaagcga gaatggacat gtcattaaac tgaatataga 360
aacaatgct accacattat tattggaaaa cacaactttt gtaaccttca aagcatcaag 420
acattcagtt tcaccagatt taaaatatgt ccttctggca tatgatgtca aacagatttt 480
tcattattcg tatactgctt catatgtgat ttacaacata cacactaggg aagtttgagg 540
gttaaactct ccagaagtag aggactccgt cttgcagtac gcggcctggg gtgtccaagg 600
gcagcagctg atttatatatt ttgaaaataa tatctactat caacctgata taaagagcag 660
ttcattgcga ctgacatctt ctggaaaaga agaaataatt tttaatggga ttgctgactg 720
gttatatgaa gaggaactcc tgcattctca catcgccac tgggtggtcac cagatggaga 780
aagacttgcc ttctgatga taaatgactc tttggtagcc accatgggta tccctcggtt 840
tactggagcg ttgtatccca aaggaaagca gtatccgtat cctaaggcag gtcaagtga 900
cccaacaata aaattatatg ttgtaaacct gtatggacca actcacactt tggagctcat 960
gccacctgac agcttttaat caagagaata ctatatcact atgggttaaat gggtaagcaa 1020
taccaagact gtggtaagat ggttaaaccg acctcagaac atctccatcc tcacagtctg 1080
tgagaccact acaggtgctt gtagtaaaaa atatgagatg acatcagata cgtggctctc 1140
tcagcagaat gaggagcccg tgttttctag agacggcagc aaattcttta tgacagtgcc 1200
tgttaagcaa gggggacgtg gagaatttca ccacatagct atgttcctca tccagagtaa 1260
aagtgaagcaa attaccgtgc ggcactctgac atcaggaaac tgggaagtga taaagatctt 1320
ggcatacgtat gaaactactc aaaaaattta ctttctgagc actgaatctt ctcccagagg 1380
aaggcagctg tacagtgtct ctactgaagg attattgaat cgccaatgca tttcatgtaa 1440
tttcatgaaa gaacaatgta catattttga tgccagtttt agtcccatga atcaacattt 1500
cttattatct tgtgaaggct caaggggtccc agtgggtcagc ctacatagta cggacaaccc 1560
agcaaaatat tttatatagg aaagcaattc tatgctgaag gaagctatcc tgaagaagaa 1620
gataggaaag ccagaaatta aaatccttca tattgacgac tatgaacttc ctttacagtt 1680
gtcccttccc aaagatttta tggaccgaaa ccagtatgct cttctgttaa taatggatga 1740
agaaccagga ggccagctgg ttacagataa gtcccatatt gactgggatt ccgtactcat 1800
tgacatggat aatgtcattg tagcaagatt tgatggcaga ggaagtggat tccagggctc 1860
gaaaattttg caggagattc atcgaagatt aggttcagta gaagtaaagg accaaataac 1920
agctgtgaaa tttttgctga aactgcctta cattgactcc aaaagattaa gcatttttgg 1980
aaagggttat ggtggctata ttgcatcaat gatcttaaaa tcagatgaaa agctttttta 2040
atgtggatcc gtggttgac ctatcacaga cttgaaattg tatgcctcag ctttctctga 2100
aagatacctt gggatgccat ctaaggaaga aagcacttac caggcagcca gtgtgctaca 2160
taatgttcat ggcttgaaag aagaaaatat attaataatt catggaactg ctgacacaaa 2220
agttcatttc caacactcag cagaattaat caagcaccta ataaaagctg gagtgaatta 2280
tactatgcag gtctacccag atgaagggtca taacgtatct gagaagagca agtatcatct 2340
ctacagcaca atcctcaaat tcttcagtga ttgtttgaag gaagaaatat ctgtgctacc 2400
acaggaacca gaagaagatg aataatggac cgtatttata cagaactgaa gggaatattg 2460
aggctcaatg aaacctgaca aagagactgt aatattgtag ttgctccaga atgtcaaggg 2520
cagcttacgg agatgtcact ggagcagcac gctcagagac agtgaactag catttgaata 2580
cac

```

```

<210> 7
<211> 690
<212> PRT
<213> Homo sapiens
<400> 7

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
          50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
          85          90          95

```


Leu	Phe	Tyr	Ser	Glu	Ile	Pro	Lys	Thr	Ile	Asn	Arg	Ala	Ala	Val	Leu
			100					105					110		
Met	Leu	Ser	Trp	Lys	Pro	Leu	Leu	Asp	Leu	Phe	Gln	Ala	Thr	Leu	Asp
		115					120					125			
Tyr	Gly	Met	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	Lys	Arg
	130					135					140				
Ile	Gly	Thr	Val	Gly	Ile	Ala	Ser	Tyr	Asp	Tyr	His	Gln	Gly	Ser	Gly
145				150					155						160
Thr	Phe	Leu	Phe	Gln	Ala	Gly	Ser	Gly	Ile	Tyr	His	Val	Lys	Asp	Gly
			165					170						175	
Gly	Pro	Gln	Gly	Phe	Thr	Gln	Gln	Pro	Leu	Arg	Pro	Asn	Leu	Val	Glu
		180						185					190		
Thr	Ser	Cys	Pro	Asn	Ile	Arg	Met	Asp	Pro	Lys	Leu	Cys	Pro	Ala	Asp
	195						200					205			
Pro	Asp	Trp	Ile	Ala	Phe	Ile	His	Ser	Asn	Asp	Ile	Trp	Ile	Ser	Asn
	210					215					220				
Ile	Val	Thr	Arg	Glu	Glu	Arg	Arg	Leu	Thr	Tyr	Val	His	Asn	Glu	Leu
225				230						235					240
Ala	Asn	Met	Glu	Glu	Asp	Ala	Arg	Ser	Ala	Gly	Val	Ala	Thr	Phe	Val
			245						250					255	
Leu	Gln	Glu	Glu	Phe	Asp	Arg	Tyr	Ser	Gly	Tyr	Trp	Trp	Cys	Pro	Lys
		260					265						270		
Ala	Glu	Thr	Thr	Pro	Ser	Gly	Gly	Lys	Ile	Leu	Arg	Ile	Leu	Tyr	Glu
	275					280						285			
Glu	Asn	Asp	Glu	Ser	Glu	Val	Glu	Ile	Ile	His	Val	Thr	Ser	Pro	Met
	290					295					300				
Leu	Glu	Thr	Arg	Arg	Ala	Asp	Ser	Phe	Arg	Tyr	Pro	Lys	Thr	Gly	Thr
305				310						315					320
Ala	Asn	Pro	Lys	Val	Thr	Phe	Lys	Met	Ser	Glu	Ile	Met	Ile	Asp	Ala
			325						330					335	
Glu	Gly	Arg	Ile	Ile	Asp	Val	Ile	Asp	Lys	Glu	Leu	Ile	Gln	Pro	Phe
		340						345					350		
Glu	Ile	Leu	Phe	Glu	Gly	Val	Glu	Tyr	Ile	Ala	Arg	Ala	Gly	Trp	Thr
	355					360					365				
Pro	Glu	Gly	Lys	Tyr	Ala	Trp	Ser	Ile	Leu	Leu	Asp	Arg	Ser	Gln	Thr
	370					375					380				
Arg	Leu	Gln	Ile	Val	Leu	Ile	Ser	Pro	Glu	Leu	Phe	Ile	Pro	Val	Glu
385				390						395					400
Asp	Asp	Val	Met	Glu	Arg	Gln	Arg	Leu	Ile	Glu	Ser	Val	Pro	Asp	Ser
			405						410					415	
Val	Thr	Pro	Leu	Ile	Ile	Tyr	Glu	Glu	Thr	Thr	Asp	Ile	Trp	Ile	Asn
			420					425					430		
Ile	His	Asp	Ile	Phe	His	Val	Phe	Pro	Gln	Ser	His	Glu	Glu	Glu	Ile
	435						440					445			
Glu	Phe	Ile	Phe	Ala											

Asn	Pro	His	Cys	Val	Ser	Leu	Tyr	Lys	Leu	Ser	Ser	Pro	Glu	Asp	Asp
			580					585					590		
Pro	Thr	Cys	Lys	Thr	Lys	Glu	Phe	Trp	Ala	Thr	Ile	Leu	Asp	Ser	Ala
		595					600					605			
Gly	Pro	Leu	Pro	Asp	Tyr	Thr	Pro	Pro	Glu	Ile	Phe	Ser	Phe	Glu	Ser
	610					615					620				
Thr	Thr	Gly	Phe	Thr	Leu	Tyr	Gly	Met	Leu	Tyr	Lys	Pro	His	Asp	Leu
625					630					635				640	
Gln	Pro	Gly	Lys	Lys	Tyr	Pro	Thr	Val	Leu	Phe	Ile	Tyr	Gly	Gly	Arg
			645						650					655	
Leu	Leu	Leu	Leu	Gly	Pro	Gln	Ser	Leu	Cys	Gly	Ser	Ser	Met	Ile	Gln
			660					665					670		
Asp	Thr	Arg	Asn	Val	Ile	Trp	Val	Thr	Leu	Thr	Arg	Met	Asn	Arg	Ala
		675					680					685			
Ile	Thr														
	690														

<210> 8
 <211> 4523
 <212> DNA
 <213> Homo sapiens
 <400> 8

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgct	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtggaggc	ggcgcagcat	gaagcggcgc	aggcccgcct	catagcgcac	gtcgggacgg	180
tccgggcccgg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtagtgga	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgat	atgttgatat	ctaactcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaadc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggaggt	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggaggt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgcct	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttccccaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataata	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtgggtgaat	gggaagtctt	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctgggat	atthtgaagg	caccaaagac	1800
tcccctttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatacgtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagcaggt	2040
cctcttcctg	actatactcc	tccagaaatt	ttctcttttg	aaagtactac	tggatttaca	2100
ttgtatggga	tgctctacaa	gcctcatgat	ctacagcctg	gaaagaaata	tcctactgtg	2160

```

ctgttcatat atggtggtcg gttgctattg ctggggccccc agtcactctg tggatcttct 2220
atgatacagg atacacggaa cgttatatgg gtcaccctga ccagaatgaa cagggtctatt 2280
acttaggatac tgtggccatg caagcagaaa agttcccctc tgaaccaaata cgtttactgc 2340
tcttacatgg tttcctggat gagaatgtcc attttgcaca taccagtata ttactgagtt 2400
ttttagttag ggctggaaag ccatatgatt tacagatcta tcctcaggag agacacagca 2460
taagagtccc tgaatcggga gaacattatg aactgcatct tttgcactac cttcaagaaa 2520
accttggatc acgtattgct gctctaaaag tgatataatt ttgacctgtg tagaactctc 2580
tggtatacac tggctattta accaaatgag gaggtttaat caacagaaaa cacagaattg 2640
atcatcacat tttgatacct gccatgtaac atctactcct gaaaataaat gtggtgccat 2700
gcaggggtct acggtttgtg gtagtaatct aataccttaa ccccatatgc tcaaaatcaa 2760
atgatacata ttcctgagag acccagcaat accataagaa ttactaaaaa aaaaaaaaaa 2820
aaaaagacat tagcaccatg tattcatact accctatttt cacttttaat agtattataa 2880
acttcatgaa cttaattagt gtatttttac agtatacttt tgagtttgtt aaaatatgat 2940
gatattagtg attggttttg ttcagttcca gaatctttga ctagttacag atttgatagc 3000
acttaaagt aattgaatag cttatgcttc attgcttggg catatccagc atgttatgaa 3060
ctaataacta ttaaacttga cttaaccagt cattcattaa taatttttca aggataactt 3120
agtggcctcc taaagacact tgttttggca ctgaccagtt tttagccaat ttaatctgta 3180
tctagtataa ataattctca tttttctttg atgatattaa cagagtgggc ttttctttt 3240
gcataaaggc tagtaactgt atatgtagca tggatttaat tagtcatgat attgataatt 3300
acaggcagaa aatttttaat caaatgatta gagcttaaat atttgcaggc aagttttttt 3360
ttttctttta agaaaaggaa aaagtacaca ttcactagaa ttcttcagaa aatttagtgg 3420
tgccagtttc catttggtat ttccttatta aaatattcta gaattttaag gagattgaag 3480
ggaatcacag tggggtgggg agacctgggt ttgggggaatg acagagagaa gaggtggtga 3540
gggcctgatt aaaaactaag cagaagtagt ttaacaaaa atactcatga aaatgtttgg 3600
aaactgaaat ttaacaact gtaatattaa ggaaaccaga atcaataaat cactgtcttg 3660
ccagcacagc tacagagtaa catgattcag gggaggaaaa gtctcttaga gttactttta 3720
taattctttt ttttttctt cttaggttta gaaatcttac aaatttaaac tttatccttt 3780
taaaattatt tgaacataat ttagatattg taagcttaaa atacaaatgt ttatagataa 3840
cctctttacc ataaactaat ccttggaag ccatggctct cttttttttt ttggtgttta 3900
aagcctgtaa acagtttttc tgaatgatca tgaacttttc ttggttttagc actaggattt 3960
agctatgaag agagctcata ggctttcagg tgctaattga gatctgccct gttagagtct 4020
tggggtgcta gattggtcac attgacacca gtggcaggga aggcattctat gattttgatg 4080
ctttttatca cacacttcag tgttttagaa gttattacca atacttttaa acaacactcc 4140
aagaaaattt gctatatttc tttctcatca ctacagagag agtagatttc cccatagaga 4200
gcacagcctc cattagtaag gttggtgact attggttaaga ggtggacttc attgacacca 4260
agtgggaggt agggaaagcc cagaaatggc aggatgatat ggtggttctg tcgttgggaa 4320
aggtattggg ttttgctgtt tgtatttata ctgtataata gataccacgc tttttcttat 4380
tatctgtata tgtattgctt ttcattgttg atattttccc atgccaagat ttgtttatat 4440
atattttcaa tgttaaatta aattgatttg ggtaactttc tcccccaaga aagtattttc 4500
ccccttaagt ataaatctga ctg 4523

```

```

<210> 9
<211> 241
<212> PRT
<213> Homo sapiens
<400> 9

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
          50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
          85          90          95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu

```

```
<210> 10
<211> 1356
<212> DNA
<213> Homo sapiens
<400> 10
```

```
<210> 11
<211> 661
<212> PRT
<213> Homo sapiens
<400> 11
```

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5					10					15	
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
			20					25					30		
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu

35	40	45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro		
50	55	60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser		
65	70	75
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr		80
85	90	95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu		
100	105	110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp		
115	120	125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg		
130	135	140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly		
145	150	155
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly		
165	170	175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu		
180	185	190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp		
195	200	205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn		
210	215	220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu		
225	230	235
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val		
245	250	255
Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys		
260	265	270
Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu		
275	280	285
Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met		
290	295	300
Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr		
305	310	315
Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala		
325	330	335
Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe		
340	345	350
Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr		
355	360	365
Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr		
370	375	380
Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu		
385	390	395
Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser		
405	410	415
Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn		
420	425	430
Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile		
435	440	445
Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr		
450	455	460
Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly		
465	470	475
Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile		
485	490	495
Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn		
500	505	510
Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys		

515	520	525
Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro		
530	535	540
Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys		
545	550	555
Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys		
565	570	575
Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp		
580	585	590
Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala		
595	600	605
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser		
610	615	620
Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu		
625	630	635
Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Leu		
645	650	655
Leu Arg Cys Ser Trp		
660		

<210> 12
 <211> 4829
 <212> DNA
 <213> Homo sapiens
 <400> 12

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggtgtgc	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtgagggc	ggcgagcat	gaagcggcgc	aggcccgcctc	catagcgcac	gtcgggacgg	180
tccgggaggg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgaggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaagggaagt	ggaacatttc	tgtttcaagc	cggtagtgga	720
atztatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagtgtgcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgat	atgtggatat	ctaactcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaatac	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggaggt	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggaggt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgctt	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggtataata	tccatgacat	ctttcatggt	tttcccaaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataata	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgctctatca	aagaggagat	agcaattacc	agtgggtgaat	gggaagttct	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctggtat	atthtgaagg	caccaaagac	1800
tcccccttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatcagtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagcaggt	2040

```

cctcttcctg actataactcc tccagaaatt ttctcttttg aaagtactac tggatttaca 2100
ttgtatggga tgctctacaa gcctcatgat ctacagcctg gaaagaaata tcctactgtg 2160
ctgttcatat atggtggtct cctcaggtgc agttggtgaa taatcggttt aaaggagtca 2220
agtatttccg cttgaatacc ctacgctctc taggttatgt gggtgtagtg atagacaaca 2280
ggggatcctg tcaccgaggg cttaaatttg aaggcgctt taaatataaa atgggtcaaa 2340
tagaaattga cgatcaggtg gaaggactcc aatatctagc ttctcgatat gatttcattg 2400
acttagatcg tgtgggcatc cacggctggt cctatggagg atacctctcc ctgatggcat 2460
taatgcagag gtcagatate ttcagggttg ctattgctgg ggccccagtc actctgtgga 2520
tcttctatga tacaggatac acggaacggt atatgggtca ccttgaccag aatgaacagg 2580
gctattactt aggatctgtg gccatgcaag cagaaaagtt cccctctgaa ccaaactggt 2640
tactgctctt acatggtttc ctggatgaga atgtccattt tgcacatacc agtatattac 2700
tgagtttttt agtgagggct ggaaagccat atgatttaca gatctatcct caggagagac 2760
acagcataag agttcctgaa tcggggagaac attatgaact gcactctttg cactaccttc 2820
aagaaaacct tggatcacgt attgctgctc taaaagtgat ataattttga cctgtgtaga 2880
actctctggt atacactggc tatttaacca aatgaggagg tttaatcaac agaaaacaca 2940
gaattgatca tcacattttg atacctgcca tgtaacatct actcctgaaa ataatgtgg 3000
tgccatgcag gggctctacg tttgtggtag taatctaata ccttaacccc acatgctcaa 3060
aatcaaatga tacatatctc tgagagaccc agcaatacca taagaattac taaaaaaaaa 3120
aaaaaaaaaa agacattage accatgtatt catactacce tatttttact tttaatagta 3180
ttataaactt catgaactta attagtgtat ttttacagta tacttttgag tttgttaaaa 3240
catgatgata ttagtgattg gtttggttca gttccagaat ctttgactag ttacagattt 3300
gatagcactt aaatgtaatt gaatagctta tgcttcattg cttgggcata tccagcatgt 3360
tatgaactaa taactattaa acttgactta accagtcatt cattaataat ttttcaagga 3420
taacttagtg gcctcctaaa gacacttggt ttggcactga ccagttttta gccaatttaa 3480
tctgtatcta gtataaataa ttctcatttt tctttgatga tattaacaga gtgggctttt 3540
ccttttgcat aaaggctagt aactgtatat gtagcatgga tttaattagt catgatattg 3600
ataattacag gcagaaaatt tttaatcaaa tgattagagc ttaaatattt gcaggcaagt 3660
tttttttttt cctttaagaa aaggaaaaag tacacattca ctagaattct tcagaaaatt 3720
tagtggtgcc agtttccatt tggatatttc ttattaaaaa attctagaat tttaaggaga 3780
ttgaagggaa tcacagtggg gtggggagac ctgggttttg ggaatgacag agagaagagg 3840
tggtgagggc ctgattaaaa actaagcaga agtagtttta acaaaaatac tcatgaaaat 3900
gtttggaaac tgaaatttaa acaactgtaa tattaaggaa accagaatca ataatcact 3960
gtcttgccag cacagctaca gagtaacatg attcagggga ggaaaagttc cttagagtta 4020
cttttataat tctttttttt ttctctctta ggttttagaaa tcttacaat tttaacttta 4080
tcctttttaa attatttgaa cataatttag atattgtaag cttaaaatac aaatgtttat 4140
agataacctc ttaccataa actaatccct ggcaagccat ggctctcttt ttttttttg 4200
tgtttaaagc ctgtaaacag ttttctgaa tgatcatgaa cttttcttgg tttagcacta 4260
ggatttagct atgaagagag ctcataggtt tttaggtgct aattgagatc tgccctgtta 4320
gagtcctggg gtgctagatt ggtcacattg acaccagtgg cagggaaggc atctatgagt 4380
ttgatgcttt ttatcacaca cttcagtgtt tagaaagtta ttaccaatac ttttaaaca 4440
cactccaaga aaatttgcta tatttctttc tcatcactac agagagagta gatttcccca 4500
tagagagcac agcctccatt agtaagggtg gtgactattg gtaagagggtg gacttcattg 4560
acaccaagtg ggaggtaggg aaagcccaga aatggcagga tgatatggtg gttctgtcgt 4620
tgggaaaggt attgggtttt gctgtttgta tttatactgt ataatagata ccacgctttt 4680
tcttattatc tgtatatgta ttgcttttca tgtttgatat tttcccatgc caagatttgt 4740
ttatatatat tttcaatggt aaattaaatt gatttgggta actttcttcc ccaagaaagt 4800
attttcccc ttaagtataa atctgactg

```

```

<210> 13
<211> 358
<212> PRT
<213> Homo sapiens
<400> 13

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35          40          45

```

Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
 50 55 60
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
 65 70 75 80
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
 85 90 95
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
 100 105 110
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
 115 120 125
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
 130 135 140
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
 145 150 155 160
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
 165 170 175
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
 180 185 190
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
 195 200 205
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
 210 215 220
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
 225 230 235 240
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
 245 250 255
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
 260 265 270
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
 275 280 285
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
 290 295 300
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
 305 310 315 320
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
 325 330 335
 Glu Gly Arg Ser Lys Leu Met Lys Ser Glu Gly Trp Tyr Ile Leu Lys
 340 345 350
 Ala Pro Lys Thr Pro Leu
 355

<210> 14
 <211> 4309
 <212> DNA
 <213> Homo sapiens
 <400> 14

aagtgcataa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt cttagtgccg 60
 cgttcgccgc ctgggtgtgc accggcgccg ccgcccaggga agccactgca accaggaccg 120
 gagtggaggc ggcgcagcat gaagcggcgc agggccgctc catagcgcac gtcgggacgg 180
 tccgggcggg gccgggggga aggaaaatgc aacatggcag cagcaatgga aacagaacag 240
 ctgggtgttg agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg 300
 cctaaattgg agccttttta tggtgagcgg tattcctgga gtcagcttaa aaagctgctt 360
 gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga tttcatgttt 420
 gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tgccatgtct 480
 ggtgagaaca gagaaaatac actgttttat tctgaaattc ccaaaactat caatagagca 540
 gcagtcttaa tgctctcttg gaagcctctt ttggatcttt ttcaggcaac actggactat 600
 ggaatgtatt ctcgagaaga agaactatta agagaaagaa aacgcattgg aacagtcgga 660
 attgcttctt acgattatca ccaaggaagt ggaacatttc tgtttcaagc cggtagtgga 720
 atttatcacg taaaagatgg agggccacaa ggatttacgc aacaaccttt aaggcccaat 780

ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttatata	tagcaacgat	atttggatat	ctaacatcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaadc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggaaga	tccaagttga	tgaagtcaga	aggctggtat	1260
attttgaagg	caccaaagac	tccccttttag	agcatcacct	gtacgtagtc	agttacgtaa	1320
atcctggaga	ggtgacaagg	ctgactgacc	gtggctactc	acattcttgc	tgcacagtc	1380
agcactgtga	cttctttata	agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	1440
tttacaagct	atcaagtcct	gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	1500
ccattttgga	ttcagcaggt	cctcttcttg	actatactcc	tccagaaatt	ttctcttttg	1560
aaagtactac	tggatttaca	ttgtatggga	tgtcttacia	gcctcatgat	ctacagcctg	1620
gaaagaaata	tcctactgtg	ctgttcatat	atgggtggtct	cctcaggtgc	agttggtgaa	1680
taatcggttt	aaaggagtca	agtatttccg	cttgaatacc	ctagcctctc	taggttatgt	1740
ggttgtagtg	atagacaaca	ggggatcctg	tcaccgaggg	cttaaatttg	aaggcgctt	1800
taaatataaa	atgggtcaaa	tagaaattga	cgatcaggtg	gaaggactcc	aatatctagc	1860
ttctcgatat	gatttcatth	acttagatcg	tgtgggcatc	cacggctggt	cctatggagg	1920
atacctctcc	ctgatggcat	taatgcagag	gtcagatate	ttcagggttg	ctattgctgg	1980
ggccccagtc	actctgtgga	tcttctatga	tacaggatac	acggaacgtt	atatgggtca	2040
ccctgaccag	aatgaacagg	gctattactt	aggatctgtg	gccatgcaag	cagaaaagtt	2100
cccctctgaa	ccaaatcgtt	tactgctctt	acatggtttc	ctggatgaga	atgtccattt	2160
tgcacatacc	agtatattac	tgagtttttt	agtgagggct	ggaaagccat	atgatttaca	2220
gatctatcct	caggagagac	acagcataag	agttcctgaa	tcggggagaac	attatgaact	2280
gcattctttg	cactaccttc	aagaaaacct	tggatcacgt	attgctgctc	taaaagtgat	2340
ataattttga	cctgtgtaga	actctctggt	atacactggc	tatttaacca	aatgaggagg	2400
tttaatcaac	agaaaacaca	gaattgatca	tcacattttg	atacctgcca	tgtaacatct	2460
actcctgaaa	ataaatgtgg	tgccatgcag	gggtctacgg	tttgtggtag	taatctaata	2520
ccttaacccc	acatgctcaa	aatcaaataa	tacatattcc	tgagagaccc	agcaatacca	2580
taagaattac	taaaaaaaaa	aaaaaaaaaa	agacattagc	accatgtatt	catactaccc	2640
tatttttact	tttaatagta	ttataaactt	catgaactta	attagtgtat	ttttacagta	2700
tacttttgag	tttgttaaaa	tatgatgata	ttagtgattg	gtttggttca	gttccagaat	2760
ctttgactag	ttacagattt	gatagcactt	aaatgtaatt	gaatagetta	tgcttcattg	2820
cttgggcata	tccagcatgt	tatgaactaa	taactattaa	acttgactta	accagtcatt	2880
cattaataat	ttttcaagga	taacttagtg	gcctcctaaa	gacacttggt	ttggcactga	2940
ccagttttta	gccaatttaa	tctgtatcta	gtataaataa	ttctcathtt	tctttgatga	3000
tattaacaga	gtgggctttt	ccttttgcat	aaaggctagt	aactgtatat	gtagcatgga	3060
tttaattagt	catgatattg	ataattacag	gcagaaaatt	tttaatcaaa	tgattagagc	3120
ttaaatattt	gcaggcaagt	tttttttttt	cctttaagaa	aaggaaaaag	tacacattca	3180
ctagaattct	tcagaaaatt	tagtggtgcc	agtttccatt	tggtatttcc	ttattaaaat	3240
attctagaat	tttaaggaga	ttgaaggga	tcacagtggt	gtggggagac	ctgggtttgg	3300
ggaatgacag	agagaagagg	tgggtgagggc	ctgattaaaa	actaagcaga	agtagtttta	3360
acaaaaatac	tcatgaaaat	gtttggaaac	tgaaatttaa	acaactgtaa	tattaaggaa	3420
accagaatca	ataaatcact	gtcttgccag	cacagctaca	gagtaacatg	attcagggga	3480
ggaaaagttc	cttagagtta	ctttttataat	tctttttttt	tttccctcta	ggtttagaaa	3540
tcttacaaat	ttaaacttta	tcctttttaaa	attatttgaa	cataatttag	atattgtaag	3600
cttaaaatac	aatgttttat	agataacctc	tttaccataa	actaatccct	ggcaagccat	3660
ggctctcttt	tttttttttg	tgttttaaagc	ctgtaaacag	tttttctgaa	tgatcatgaa	3720
cttttcttgg	tttagactta	ggatttagct	atgaagagag	ctcataggct	ttcaggtgct	3780
aattgagatc	tgccctgtta	gagtccttggg	gtgctagatt	ggtcacattg	acaccagtgg	3840
cagggaaggc	atctatgagt	ttgatgcttt	ttatcacaca	cttcagtggt	tagaaagtta	3900
ttaccaatac	ttttaaacaa	cactccaaga	aaatttgcta	tatttctttc	tcactactac	3960
agagagagta	gatttcccca	tagagagcac	agcctccatt	agtaagggtg	gtgactattg	4020
gtaagagggtg	gacttcattg	acaccaagtg	ggaggtaggg	aaagcccaga	aatggcagga	4080
tgatatgggtg	gttctgtcgt	tgggaaaggt	attgggtttt	gctgttttga	tttatactgt	4140
ataatagata	ccacgctttt	tcttattatc	tgtatatgta	ttgcttttca	tgtttgatat	4200
tttcccatgc	caagatttgt	ttatatatat	tttcaatgtt	aaattaaatt	gatttgggta	4260
actttcttcc	ccaagaaagt	attttcccc	ttaagtataa	atctgactg		4309

<210> 15
 <211> 108
 <212> PRT
 <213> Homo sapiens
 <400> 15

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
          50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Gly Asn Lys Ser Leu Ile Asp His Asp Arg
          85          90          95
Phe Ser Lys Ser Lys Met Pro Glu Ile Ala Ser Ser
          100          105

```

<210> 16
 <211> 620
 <212> DNA
 <213> Homo sapiens
 <400> 16

```

aagtgctaaa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt cttagtgccg      60
cgttcgccgc ctgggttgct accggcgccg ccgccgagga agccactgca accaggaccg      120
gagtggaggc ggcgagcat gaagcggcgc agggccgctc catagcgcac gtcgggacgg      180
tccgggaggc gccgggggga aggaaaatgc aacatggcag cagcaatgga aacagaacag      240
ctgggtgttg agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg      300
cctaaattgg agccttttta tgttgagcgg tattcctgga gtcagcttaa aaagctgctt      360
gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga ttcatgttt      420
gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tggtaacaag      480
tcattaattg atcatgatcg tttttcaaaa tcgaagatgc cagaaattgc ttcttcctaa      540
agctagcttg aaatgccttt ctttagatgg tctgattagg aaaacaaaca ataaaaccat      600
tagtttgttc ccactcaaca

```

<210> 17
 <211> 194
 <212> PRT
 <213> Homo sapiens
 <400> 17

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
 1 5 10 15
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
 20 25 30
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
 35 40 45
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
 50 55 60
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
 65 70 75 80
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
 85 90 95
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
 100 105 110
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
 115 120 125
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
 130 135 140
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
 145 150 155 160
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
 165 170 175
 Gly Pro Gln Gly Phe Thr Gln Pro Leu Arg Pro Asn Leu Val Glu Thr
 180 185 190
 Cys Ala

<210> 18
 <211> 832
 <212> DNA
 <213> Homo sapiens
 <400> 18

aagtgctaaa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt cttagtgccg 60
 cgttcgccgc ctgggttgct accggcgccg ccgcccaggga agccactgca accaggaccg 120
 gagtggaggc ggcgcagcat gaagcggcgc aggcccgctc catagcgcac gtcgggacgg 180
 tccgggaggc gccgggggga aggaaaatgc aacatggcag cagcaatgga aacagaacag 240
 ctgggtgttg agatatattga aactgcggac tgtgaggaga atattgaatc acaggatcgg 300
 cctaaattgg agccttttta tgttgagcgg tttcctgga gtcagcttaa aaagctgctt 360
 gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga tttcatgttt 420
 gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tgccatgtct 480
 ggtgagaaca gagaaaatac actgttttat tctgaaattc ccaaaactat caatagagca 540
 gcagtcttaa tgctctcttg gaagcctctt ttggatcttt ttcaggcaac actggactat 600
 ggaatgtatt ctcgagaaga agaactatta agagaaagaa aacgcattgg aacagtcgga 660
 attgcttctt acgattatca ccaaggaagt ggaacatttc tgtttcaagc cggtagtgga 720
 atttatcacg taaaagatgg agggccacaa ggatttacgc wacaaccttt aaggcccaat 780
 ctagtggaat ctasttgtsc caracytgca tgacccaatc agatcctgta ga 832

<210> 19
 <211> 658
 <212> PRT
 <213> Homo sapiens
 <400> 19

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
 1 5 10 15
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
 20 25 30
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
 35 40 45
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro

50	55	60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser		
65	70	75
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr		80
	85	90
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu		95
	100	105
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp		110
	115	120
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg		125
	130	135
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly		140
	145	150
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly		155
	165	170
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu		175
	180	185
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp		190
	195	200
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn		205
	210	215
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu		220
	225	230
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val		235
	245	250
Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys		255
	260	265
Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu		270
	275	280
Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met		285
	290	295
Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr		300
	305	310
Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala		315
	325	330
Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe		335
	340	345
Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr		350
	355	360
Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr		365
	370	375
Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu		380
	385	390
Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser		395
	405	410
Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn		415
	420	425
Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile		430
	435	440
Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr		445
	450	455
Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly		460
	465	470
Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile		475
	485	490
Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn		495
	500	505
Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys		510
	515	520
Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro		525

530		535		540
Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys				
545		550		555
Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys				560
		565		570
Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp				575
		580		585
Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala				590
		595		600
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser				605
		610		615
Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu				620
625		630		635
Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Arg				640
		645		650
				655

Val Lys

<210> 20
 <211> 4676
 <212> DNA
 <213> Homo sapiens
 <400> 20

aagtgcataa	gcctccgagg	ccaaggccgc	tgtactgcc	gccgctgctt	cttagtgccg	60
cggtcgccgc	ctgggttgct	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtgagggc	ggcgcagcat	gaagcggcgc	aggcccgtct	catagcgcac	gtcgggacgg	180
tccgggcggg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtagtggg	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagtgtgcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttatata	tagcaacgat	atttgatat	ctaaccatcg	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattgggtg	1020
tgtccaaaag	ctgaaacaac	tcccagtggg	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgtttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaatc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catectacta	gatcgctccc	agactcgcct	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttcccaaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataata	acgatccagt	gggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtgggtgaat	gggaagtctt	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctgggat	atthttgaag	caccaagac	1800
tccccttttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatacagtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagcaggt	2040
cctcttcctg	actatactcc	tccagaaatt	ttctcttttg	aaagtactac	tggatttaca	2100
ttgtatggga	tgctctacaa	gcctcatgat	ctacagcctg	gaaagaaata	tcctactgtg	2160
ctgttcatat	atggtggtcg	ggtcaaatag	aaattgacga	tcaggtggaa	ggactccaat	2220

```

atctagcttc tcgatatgat ttcattgact tagatcgtgt gggcatccac ggctgggcct 2280
atggaggata cctctccctg atggcattaa tgcagagggtc agatatcttc aggggttgcta 2340
ttgctggggc cccagtcact ctgtggatct tctatgatac aggatacacg gaacggtata 2400
tgggtcaccc tgaccagaat gaacaggggtc attacttagg atctgtggcc atgcaagcag 2460
aaaagttccc ctctgaacca aatcgtttac tgctcttaca tgggttcctg gatgagaatg 2520
tccattttgc acataccagt atattactga gtttttttagt gagggctgga aagccatatg 2580
atttacagat ctatcctcag gagagacaca gcataagagt tcctgaatcg ggagaacatt 2640
atgaactgca tcttttgacac taccttcaag aaaaccttgg atcacgtatt gctgctctaa 2700
aagtgatata attttgacct gtgtagaact ctctgggtata cactgggtat ttaaccaaatt 2760
gaggagggtt aatcaacaga aaacacagaa ttgatcatca catttttgata cctgccatgt 2820
aacatctact cctgaaaata aatgtgggtgc catgcagggg tctacgggtt gtggtagtaa 2880
tctaatacct taaccccaca tgctcaaaat caaatgatac atattcctga gagaccagc 2940
aataccataa gaattactaa aaaaaaaaaa aaaaaaaga cattagcacc atgtattcat 3000
actaccctat tttcactttt aatagtatta taaacttcat gaacttaatt agtgtatttt 3060
tacagtatac ttttgagttt gttaaaatat gatgatatta gtgattgggt tggttcagtt 3120
ccagaatctt tgactagtta cagatttgat agcacttaaa tgtaattgaa tagcttatgc 3180
ttcattgctt gggcatatcc agcatgttat gaactaataa ctattaaact tgacttaacc 3240
agtcattcat taataatttt tcaaggataa cttagtggcc tcctaaagac acttgttttg 3300
gcactgacca gtttttagcc aatttaattc gtatctagta taaataattc tcatttttct 3360
ttgatgatat taacagagtg ggcttttcct tttgcataaa ggctagtaac tgtatatgta 3420
gcatggattt aattagtcac gatattgata attacaggca gaaaattttt aatcaaata 3480
ttagagctta aatatttgca ggcaagtttt tttttttcct ttaagaaaag gaaaaagtac 3540
acattcacta gaattcttca gaaaatttag tgggtgccagt ttccatttgg tatttcctta 3600
ttaaaatatt ctagaatttt aaggagattg aagggaatca cagtggggtg gggagacctg 3660
ggtttgggga atgacagaga gaagagggtg tgagggcctg attaaaaact aagcagaagt 3720
agttttaaca aaaatactca tgaaaatgtt tggaaactga aatttaaaca actgtaatat 3780
taaggaaacc agaatacata aatcactgtc ttgccagcac agctacagag taacatgatt 3840
caggggagga aaagttcctt agagttactt ttataattct tttttttttt cctcttaggt 3900
ttagaaatct taaaaattta aactttatcc ttttaaaatt atttgaacat aatttagata 3960
ttgtaagctt aaaatacaaa tgtttataga taacctctt accataaact aatccctggc 4020
aagccatggc tctctttttt tttttgggtg ttaaagcctg taaacagttt ttctgaatga 4080
tcatgaactt ttcttggtt agcactagga tttagctatg aagagagctc ataggcttct 4140
aggtgctaat tgagatctgc cctgttagag tcttgggggtg ctgattgggt cacattgaca 4200
ccagtggcag ggaaggcatc tatgagtttg atgcttttta tcacacactt cagtgttag 4260
aaagttatta ccaatacttt taaacaacac tccaagaaaa tttgctatat ttctttctca 4320
tcactacaga gagagtagat ttccccatag agagcacagc ctccattagt aagggttggtg 4380
actattggta agaggtggac ttcattgaca ccaagtggga ggtagggaaa gccagaaat 4440
ggcaggatga tatgggtggt ctgtcgttgg gaaaggtatt gggttttgct gtttgatatt 4500
atactgtata atagatacca cgctttttct tattatctgt atatgtattg cttttcatgt 4560
ttgatatttt cccatgccaa gatttgttta tatatatatt caatgttaaa ttaaattgat 4620
ttgggtaact ttcttcccca agaaagtatt ttccccctta agtataaatc tgactg 4676

```

<210> 21

<211> 613

<212> PRT

<213> Homo sapiens

<400> 21

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1           5           10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
85          90          95

```

```

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
      100                      105                      110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
      115                      120                      125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
      130                      135                      140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
145                      150                      155                      160
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
      165                      170                      175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
      180                      185                      190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
      195                      200                      205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
      210                      215                      220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
225                      230                      235                      240
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
      245                      250                      255
Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
      260                      265                      270
Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
      275                      280                      285
Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
      290                      295                      300
Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
305                      310                      315                      320
Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
      325                      330                      335
Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe
      340                      345                      350
Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
      355                      360                      365
Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr
      370                      375                      380
Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu
385                      390                      395                      400
Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
      405                      410                      415
Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn
      420                      425                      430
Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile
      435                      440                      445
Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr
      450                      455                      460
Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly
465                      470                      475                      480
Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile
      485                      490                      495
Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn
      500                      505                      510
Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys
      515                      520                      525
Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
      530                      535                      540
Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys
545                      550                      555                      560
Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys
      565                      570                      575

```


Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp
 580 585 590
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Val
 595 600 605
 Leu Arg Cys Ser Trp
 610

<210> 22
 <211> 4685
 <212> DNA
 <213> Homo sapiens
 <400> 22

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtggaggc	ggcgcagcat	gaagcggcgc	agggccgctc	catagcgcac	gtcgggacgg	180
tccgggcggg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtagtgga	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagtgtgcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgat	atttggatat	ctaacatcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaatc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgctt	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcttgatcc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttcccaaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaatataa	acgatccagt	ggtagggctg	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtgggtgaat	gggaagttct	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctgggat	attttgaagg	caccaagac	1800
tcccctttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcacagtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagtcctc	2040
aggtgcagtt	ggtgaataat	cggtttaaa	gagtcaagta	tttccgcttg	aataccctag	2100
cctctctagg	ttatgtgggt	gtagtgatag	acaacagggg	atcctgtcac	cgagggttta	2160
aatttgaagg	cgccttttaa	tataaaatgg	gtcaaataga	aattgacgat	caggtggaag	2220
gactccaata	tctagcttct	cgatatgatt	tcattgactt	agatcgtgtg	ggcatccacg	2280
gctggtccta	tggaggatac	ctctccctga	tggcattaat	gcagaggtca	gatattctca	2340
gggttgctat	tgctggggcc	ccagtcactc	tgtggatctt	ctatgataca	ggatacacgg	2400
aacgttatat	gggtcaccct	gaccagaatg	aacagggcta	ttacttagga	tctgtggcca	2460
tgcaagcaga	aaagttcccc	tctgaaccaa	atcgtttact	gctcttacat	ggtttcctgg	2520
atgagaatgt	ccattttgca	cataccagta	tattactgag	tttttttagt	agggctggaa	2580
agccatatga	tttacagatc	tatcctcagg	agagacacag	cataagagtt	cctgaatcgg	2640
gagaacatta	tgaactgcat	cttttgcact	accttcaaga	aaaccttgga	tcacgtattg	2700
ctgctctaaa	agtgatataa	ttttgacctg	tgtagaactc	tctgggtatac	actggctatt	2760
taaccaaatg	aggaggttta	atcaacagaa	aacacagaat	tgatcatcac	attttgatac	2820

```

ctgccatgta acatctactc ctgaaaataa atgtggtgcc atgcaggggt ctacggtttg 2880
tggtagtaat ctaatacctt aacccacat gctcaaaatc aaatgataca tattcctgag 2940
agaccagca ataccataag aattactaaa aaaaaaaaaa aaaaaaagac attagcacca 3000
tgtattcata ctaccctatt ttcactttta atagtattat aaacttcatg aacttaatta 3060
gtgtattttt acagtatact tttgagtttg ttaaaatatg atgatattag tgattggttt 3120
ggttcagttc cagaatcttt gactagttac agatttgata gcacttaa at gtaattgaat 3180
agcttatgct tcattgcttg ggcataatcca gcatgttatg aactaataac tattaactt 3240
gacttaacca gtcattcatt aataattttt caaggataac ttagtggcct cctaaagaca 3300
cttgttttgg cactgaccag ttttttagcca atttaactctg tatctagtat aaataattct 3360
catttttctt tgatgatatt aacagagtgg gcttttcctt ttgcataaag gctagtaact 3420
gtatatgtag catggattta attagtcag atattgataa ttacaggcag aaaattttta 3480
atcaaatgat tagagcttaa atatttgcag gcaagttttt ttttttcctt taagaaaagg 3540
aaaaagtaca cattcactag aattcttcag aaaatttagt ggtgccagtt tccatttggg 3600
atttccttat taaaatatct tagaatttta aggagattga agggaatcac agtgggggtg 3660
ggagacctgg gtttggggaa tgacagagag aagaggtggg gagggcctga ttaaaaaacta 3720
agcagaagta gttttaacaa aaatactcat gaaaatgttt ggaaactgaa atttaacaa 3780
ctgtaatatt aaggaaacca gaatcaataa atcactgtct tgccagcaca gctacagagt 3840
aacatgattc aggggaggaa aagttcctta gagttacttt tataattctt ttttttttc 3900
ctcttaggtt tagaaatctt acaaatttaa actttatcct tttaaaatta tttgaacata 3960
atttagatat tgtaagctta aaatacaaat gtttatagat aacctcttta ccataaacta 4020
atccctggca agccatggct ctcttttttt ttttggtgtt taaagcctgt aaacagtttt 4080
tctgaatgat catgaacttt tcttggttta gcactaggat ttagctatga agagagctca 4140
taggctttca ggtgctaatt gagatctgcc ctgttagagt cttgggggtgc tagattggtc 4200
acattgacac cagtggcagg gaaggcatct atgagtttga tgctttttat cacacacttc 4260
agtgtttaga aagttattac caatactttt aaacaacact ccaagaaaat ttgctatatt 4320
tctttctcat cactacagag agagtagatt tcccataga gagcacagcc tccattagta 4380
aggttgggtga ctattggtta gaggtggact tcattgacac caagtgggag gtagggaaag 4440
cccagaaatg gcaggatgat atggtggttc tgctggtggg aaaggtattg ggttttgctg 4500
tttgtattta tactgtataa tagataccac gctttttctt attatctgta tatgtattgc 4560
ttttcatgtt tgatattttt ccattgccaa atttgtttat atatatttt aatgttaaat 4620
taaattgatt tgggtaactt tcttcccaa gaaagtattt tcccccttaa gtataaatct 4680
gactg 4685

```

```

<210> 23
<211> 892
<212> PRT
<213> Homo sapiens
<400> 23

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100          105          110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115          120          125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
          130          135          140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145          150          155          160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu

```

				165					170					175			
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg		
			180						185				190				
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu		
		195					200					205					
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro		
	210					215					220						
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val		
225					230					235					240		
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln		
			245					250					255				
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr		
		260				265						270					
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys		
	275					280					285						
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile		
	290				295						300						
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro		
305				310						315					320		
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg		
			325					330					335				
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln		
		340				345						350					
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val		
	355				360						365						
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala		
	370				375					380							
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg		
385				390				395					400				
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile		
		405				410						415					
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val		
		420				425						430					
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val		
	435				440						445						
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly		
	450				455					460							
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe		
465				470						475				480			
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp		
		485				490						495					
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile		
		500				505						510					
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg		
	515					520					525						
His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu	Val	Tyr	Phe		
	530				535						540						
Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser		
545				550						555				560			
Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	Gly	Phe	Ser		
		565				570						575					
His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	Ser	His	Tyr		
		580				585					590						
Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	Leu	Ser	Gly		
	595					600					605						
Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	Ala	Ser	Met		
	610				615						620						
Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	Glu	Ile	Phe		
625				630						635				640			
His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	Ile	Tyr	Lys		

```
<210> 24
<211> 4302
<212> DNA
<213> Homo sapiens
<400> 24
```

caggccgccg	cctgggtcgc	tcaacttcgc	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcctc	ccgccacttc	cggggtcgca	gtccccgggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaaggt	taagaaactg	300
cgcttgaca	aggagaacac	cggaagtgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgccca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttcagggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcttggaatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtcggaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtc	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320

ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgaagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cggcgagatc	1980
gtacgcctca	ccacgcccg	cttctcccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcacg	ccgccctgcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgacccct	gcacaagcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatcttcc	atttccacac	gcgctcggat	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccagggaa	gaagcacccc	2280
accgtcctct	ttgtatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgcggtcaa	cacactggcc	tccctgggct	acgcggtgg	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggtctcgg	ttcgaagggg	ccctgaaaaa	ccaaatgggc	2460
caggtggaga	tcgaggacca	ggtggagggc	ctgcagttcg	tggccgagaa	gtatggcttc	2520
atcgacctga	gccgagltgc	catccatggc	tggctctacg	ggggcttctt	ctcgctcatg	2580
gggctaatacc	acaagcccca	ggtgttcaag	gtggccatcg	cgggtgcccc	ggtcacctgc	2640
tggatggcct	acgacacagg	gtacactgag	cgctacatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcgggttc	cgtggccctg	cacgtggaga	agctgcccc	tgagcccaac	2760
cgcttgctta	tcctccacgg	cttctgggac	gaaaacgtgc	actttttcca	cacaaacttc	2820
ctcgtctccc	aactgatccg	agcagggaaa	ccttaccagc	tccagatcta	ccccaacgag	2880
agacacagta	ttcgctgccc	cgagtcgggc	gagcactatg	aagtcacgtt	gctgcacttt	2940
ctacaggaat	acctctgagc	ctgcccaccg	ggagccgcca	catcacagca	caagtggctg	3000
cagcctccgc	ggggaaccag	gcgggagggg	ctgagtggcc	cgcgggcccc	agtgaggcac	3060
tttgtcccgc	ccagcgtggt	ccagccccga	ggagccgctg	ccttcaccgc	cccagcgcct	3120
tttatccttt	tttaaagcgt	cttgggtttt	atgtccgctg	cttcttgggt	gccgagacag	3180
agagatgggt	gtctcgggce	agccctctct	ctccccgctt	tctgggagga	ggaggtcaca	3240
cgctgatggg	cactggagag	gccagaagag	actcagagga	gcgggctgcc	ttccgcctgg	3300
ggctccctgt	gacctctcag	tcccctggcc	cggccagcca	ccgtccccag	cacccaagca	3360
tgcaattgcc	tgtccccccc	ggccagcctc	cccaacttga	tgtttgtgtt	ttgtttgggg	3420
ggatatTTTT	cataattatt	taaaagacag	gccgggcgcg	gtggctcacg	tctgtaatcc	3480
cagcactttg	ggaggctgag	gcgggaggat	cacctgaggt	tgggagttca	agaccagcct	3540
ggccaacatg	gggaaacccc	gtctctacta	aaaatacaaa	aaattagccg	ggtgtggtgg	3600
cgcggtgcta	taatcccagc	tactcgggag	gctgaggcag	gagaatcgct	tgaacccggg	3660
aggtggaggt	tgcggtgagc	caagatcgca	ccattgcact	ccagcctggg	caacaagagc	3720
gaaactctgt	ctcaaaataa	ataaaaaata	aaagacagaa	agcaaggggt	gcctaaatct	3780
agacttgggg	tccacaccgg	gcagcggggg	tgcaaccag	cacctggtag	gctccatttc	3840
ttcccaagcc	cgagcagagg	gtcatgcggg	ccccacagga	gaagcggcca	gggcccgcgg	3900
ggggcaccac	ctgtggacag	ccctcctgtc	cccaagcttt	caggcaggca	ctgaaacgca	3960
ccgaacttcc	acgctctgct	ggtcagtggc	ggctgtcccc	tccccagccc	agccgcccag	4020
ccacatgtgt	ctgcctgacc	cgtacacacc	aggggttccg	gggttgggag	ctgaaccatc	4080
cccacctcag	ggttatatatt	ccctctcccc	ttccctcccc	gccaagagct	ctgccagggg	4140
cgggcaaaaa	aaaaagtaaa	aagaaaagaa	aaaaaaaaaa	aagaaacaaa	ccacctctac	4200
atattatgga	aagaaaatat	ttttgtcgat	tcttattctt	ttataattat	gcgtggaaga	4260
agtagacaca	ttaaacgatt	ccagttggaa	acatgtcacc	tg		4302

<210> 25

<211> 518

<212> PRT

<213> Homo sapiens

<400> 25

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
 1 5 10 15
 Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr

			20					25					30				
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp		
		35					40					45					
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg		
	50					55					60						
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys		
65				70						75				80			
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro		
			85						90					95			
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu		
			100					105						110			
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala		
	115						120					125					
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr		
	130					135					140						
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg		
145					150					155					160		
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu		
			165						170					175			
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg		
			180					185					190				
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu		
	195						200					205					
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro		
	210					215					220						
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val		
225					230					235					240		
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln		
			245						250					255			
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr		
			260					265					270				
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys		
	275						280					285					
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile		
	290					295					300						
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro		
305					310					315					320		
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg		
			325						330					335			
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln		
			340					345					350				
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val		
	355						360					365					
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala		
	370					375					380						
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg		
385					390					395					400		
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile		
			405					410					415				
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val		
			420					425					430				
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val		
	435						440					445					
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly		
	450					455					460						
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe		
465					470					475					480		
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp		
			485						490					495			
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Gly	Glu	Gln	Ser	Leu	Thr	Asn		

500
Ala Val Asp Ser Ser Arg
515

505

510

<210> 26
<211> 2411
<212> DNA
<213> Homo sapiens
<400> 26

caggccgccc	cctgggtcgc	tcaacttcgc	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcgc	ccgccacttc	cggggtcgca	gtcccgggca	120
tggagccgcg	accgtgaggg	gccgctggac	ccgggacgac	ctgccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgccctcct	gaggtcagct	gagcgggtta	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccc	cccgcctcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttcagttt	540
gtgcagaaqa	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcc	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaagag	660
gctctgctgc	tctgttctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttcagggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcgcc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttactagg	gtactgggtg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgctgc	agaagaaagg	1260
aagacggact	cgtatcggta	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgccct	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	tcagccccgg	ggaagggtgag	1800
cagagcctga	cgaatgctgt	cgactcatcg	cgttagtcac	gtgtgggttca	atatgctgtt	1860
tgttcattgg	tcggcccccc	cactcagcca	gcacaccctg	cgggagaagg	aacagggatc	1920
ggcaggaagc	cagccttccc	cagtgactgc	atgatctggc	agggcttaga	gcacccaact	1980
gttggcttat	tcaggcagca	gatttactga	gcacctcccc	tgtgccaggc	ccttagcaca	2040
accaggggtt	ggccacctac	ggccccacag	tcaaataccg	cccaccacct	gtgttcataa	2100
ataaagtttt	attggcactg	agccacagcc	acttgtttac	agagactgtc	tgtggctcgt	2160
tttgtgctgc	agcagcagaa	ctgggtagtc	ccagcagaaa	ctgttgtgca	aggccaagat	2220
ttactgtcta	gccctttgta	gaaacatttg	ccagctcctg	ctgtaggtag	ctgtgatgga	2280
attgttcact	gtaaataaag	aaaaaggaaa	atccctgctc	ttgggacctt	ctagtggagg	2340
aggcagtatt	ccagaaacag	ttagaggtgc	tgcctctggg	gtgctgtggg	tggcagatgc	2400
agatcctagt	c					2411

<210> 27
<211> 892
<212> PRT
<213> Homo sapiens
<400> 27

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1				5				10						15	

Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
 20 25 30
 Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp
 35 40 45
 Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
 50 55 60
 Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
 65 70 75 80
 Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
 85 90 95
 His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
 100 105 110
 Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
 115 120 125
 Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
 130 135 140
 Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
 145 150 155 160
 Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
 165 170 175
 Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
 180 185 190
 Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
 195 200 205
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
 210 215 220
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
 225 230 235 240
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
 245 250 255
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
 260 265 270
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys
 275 280 285
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile
 290 295 300
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro
 305 310 315 320
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg
 325 330 335
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln
 340 345 350
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val
 355 360 365
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala
 370 375 380
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg
 385 390 395 400
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile
 405 410 415
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val
 420 425 430
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val
 435 440 445
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly
 450 455 460
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe
 465 470 475 480
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp
 485 490 495

Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile	500	505	510
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg	515	520	525
His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu	Val	Tyr	Phe	530	535	540
Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser	545	550	555
Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	Gly	Phe	Ser	565	570	575
His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	Ser	His	Tyr	580	585	590
Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	Leu	Ser	Gly	595	600	605
Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	Ala	Ser	Met	610	615	620
Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	Glu	Ile	Phe	625	630	635
His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	Ile	Tyr	Lys	645	650	655
Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val	Leu	Phe	Val	660	665	670
Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe	Lys	Gly	Ile	675	680	685
Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr	Ala	Val	Val	690	695	700
Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg	Phe	Glu	Gly	705	710	715
Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp	Gln	Val	Glu	725	730	735
Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp	Leu	Ser	Arg	740	745	750
Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser	Leu	Met	Gly	755	760	765
Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Val	Ala	Ile	Ala	Gly	Ala	Pro	770	775	780
Val	Thr	Val	Trp	Met	Ala	Tyr	Asp	Thr	Gly	Tyr	Thr	Glu	Arg	Tyr	Met	785	790	795
Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly	Ser	Val	Ala	805	810	815
Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu	Leu	Ile	Leu	820	825	830
His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	Phe	His	Thr	Asn	Phe	Leu	835	840	845
Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu	Gln	Ile	Tyr	850	855	860

Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu His Tyr
 865 870 875 880
 Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu
 885 890

<210> 28
 <211> 4219
 <212> DNA
 <213> Homo sapiens
 <400> 28

```

caggccgccc cctgggtcgc tcaacttccg ggtcaaaggt gcctgagccg gcgggtcccc 60
tgtgtccgcc gcggctgtcg tcccccgctc ccgccacttc cggggtcgca gtcccgggca 120
tggagccgcg accgtgaggc gccgctggac ccgggacgac ctgccagtc cgcccgccgc 180
cccacgtccc ggtctgtgtc ccacgcctgc agctggaatg gaggtctctt ggacccttta 240
gaaggcaccc ctgccctcct gaggtcagct gagcggttaa tgcggaaggt taagaaactg 300
cgcttgaca aggagaacac cggaagttgg agaagcttct cgctgaattc cgagggggct 360
gagaggatgg ccaccaccgg gaccccaacg gccgaccgag gcgacgcagc cgccacagat 420
gacccggccg cccgcttcca ggtgcagaag cactcgtggg acgggtccg gagcatcatc 480
cacggcagcc gcaagtactc gggcctcatt gtcaacaagg cgccccacga cttccagttt 540
gtgcagaaga cggatgagtc tgggccccac tcccaccgcc tctactacct gggaatgcca 600
tatggcagcc gagagaactc cctcctctac tctgagattc ccaagaaggt ccggaagag 660
gctctgtgtc tctgtcctg gaagcagatg ctggatcatt tccaggccac gcccaccat 720
ggggtctact ctcgggagga ggagctgctg agggagcgga aacgcctggg ggtcttcggc 780
atcacctcct acgacttcca cagcgagagt ggcctcttcc tcttccaggc cagcaacagc 840
ctcttccact gccgcgacgg cggcaagaac ggcttcatgg tgtccctat gaaaccgctg 900
gaaatcaaga ccagtgctc agggccccgg atggacccca aaatctgccc tgccgaccct 960
gccttcttct ccttcatcaa taacagcgac ctgtgggtgg ccaacatcga gacaggcgag 1020
gagcggcggc tgaccttctg ccaccaaggt ttatccaatg tcttgatga cccaagtct 1080
gcgggtgtgg ccaccttcgt catacaggaa gagttcgacc gcttactgg gtactggtgg 1140
tgccccacag cctcctggga aggttcagag ggcctcaaga cgctgcgaat cctgtatgag 1200
gaagtcgatg agtccgaggt ggaggtcatt cacgtcccct ctctgcgct agaagaaagg 1260
aagacggact cgtatcggt cccaggaca ggcagcaaga atcccaagat tgccttgaaa 1320
ctggctgagt tccagactga cagccagggc aagatcgtct cgaccagga gaaggagctg 1380
gtgcagccct tcagctcgt gtcccgaag gtggagtaca tcgccagggc cgggtggacc 1440
cgggatggca aatacgctg ggccatgttc ctggaccggc ccagcagtg gctccagctc 1500
gtctcctcc ccccgccct gtccatccc agcacagaga atgaggagca gcggctagcc 1560
tctgccagag ctgtccccag gaatgtccag ccgtatgtgg tgtacgagga ggtcaccaac 1620
gtctggatca atgttcatga catcttctat ccttcccc aatcagaggg agaggacgag 1680
ctctgcttcc tccgcgcaa tgaatgcaag accggcttct gccatttgta caaagtcacc 1740
gccgttttaa aatcccagg ctacgattgg agtgagccct tcagccccgg ggaagatgaa 1800
tttaagtgcc ccattaagga agagattgct ctgaccagcg gtgaatggga ggttttggcg 1860
aggcacggct ccaagatctg ggtcaatgag gagaccaagc tgggtgactt ccagggcacc 1920
aaggacacgc cgctggagca ccacctctac gtggtcagct atgaggcggc cggcgagatc 1980
gtacgcctca ccacgcccgg cttctcccat agctgctcca tgagccagaa cttcgacatg 2040
ttcgtcagcc actacagcag cgtgagcacg ccgccctgcg tgcacgtcta caagctgagc 2100
ggccccgacg acgacccct gcacaagcag ccccgcttct gggctagcat gatggaggca 2160
gccagctgcc ccccgatta tgttctcca gagatcttcc atttccacac gcgctcgat 2220
gtgcggctct acggcatgat ctacaagccc cacgccttgc agccaggga gaagcacc 2280
accgtcctct ttgtatatgg agggccccag gtgcagctgg tgaataactc cttcaaaggc 2340
atcaagtact tgcggctcaa cacactggcc tccctgggct acgccgtggg tgtgattgac 2400
ggcaggggct cctgtcagcg agggcttcgg ttogaagggg ccctgaaaaa ccaaatgggc 2460
caggtggaga tcgaggacca ggtggagggc ctgcagttcg tggccgagaa gtatggcttc 2520
atcgacctga gccgagttgc catccatggc tggctctacg ggggcttcc ctcgctcatg 2580
gggctaatac acaagcccca ggtgttcaag gtggccatcg cgggtgcccc ggtcaccgtc 2640
tggtatggct acgacacagg gtacactgag cgctacatgg acgtccctga gaacaaccag 2700
cacggctatg aggcgggttc cgtggccctg cacgtggaga agctgcccaa tgagcccaac 2760
cgcttgctta tctccacgg cttcctggac gaaaacgtgc actttttcca cacaacttc 2820
ctcgtctccc aactgatccg agcagggaaa cttaccagc tccagatcta cccaacgag 2880
agacacagta ttcgctgccc cgagtcgggc gagcactatg aagtcacgtt gctgcacttt 2940

```



```

ctacaggaat acctctgagc ctgcccaccg ggagccgcca catcacagca caagtggctg 3000
cagcctccgc ggggaaccag gcgggagggg ctgagtggcc cgcgggcccc agtgaggcac 3060
tttgtccgc ccagcgctgg ccagccccga ggagccgctg ccttcaccgc cccgacgcct 3120
tttatccttt tttaaacgct cttgggtttt atgtccgctg cttcttggtt gccgagacag 3180
agagatgggtg gtctcggggc agcccctcct ctccccgcct tctgggagga ggaggtcaca 3240
cgctgatggg cactggagag gccagaagag actcagagga gcgggctgcc ttccgcctgg 3300
ggctccctgt gacctctcag tcccctggcc cggccagcca ccgtccccag cacccaagca 3360
tgcaattgcc tgtccccccc ggccagcctc cccaacttga tgtttgtgtt ttgtttgggg 3420
ggatattttt cataattatt taaaagacag gccgggcgcg gtggctcacg tctgtaatcc 3480
cagcactttg ggaggctgag gcgggaggat cacctgaggt tgggagttca agaccagcct 3540
ggccaacatg gggaaacccc gtctctacta aaaatacaaa aaattagccg ggtgtggtgg 3600
cgcgtagccta taatcccagc tactcgggag gctgaggcag gagaatcgct tgaacccggg 3660
aggtggaggt tgcggtgagc caagatcgca ccattgcact ccagcctggg caacaagagc 3720
gaaactctgt ctcaaaaata ataaaaaata aaagacagaa agcaaggggt gcctaaatct 3780
agacttgggg tccacaccgg gcagcggggg tgcaacccag cacctggtag gctccatttc 3840
ttcccaagcc cgactttcag gcaggcactg aaacgcaccg aacttccacg ctctgctggt 3900
cagtggcggc tgtcccctcc ccagcccagc cgcgccagcca catgtgtctg cctgaccctg 3960
acacaccagg ggttccgggg ttgggagctg aaccatcccc acctcagggt tatatttccc 4020
tctccccttc cctccccgcc aagagctctg ccaggggagg gcaaaaaaaaa aagtaaaaag 4080
aaaagaaaaa aaaaaaaaaa aaacaaacca cctctacata ttatggaaag aaaatatttt 4140
tgtcgattct tatlctttta taattatgcy tggaagaagt agacacatta aacgattcca 4200
gttggaaca tgtcacctg 4219

```

```

<210> 29
<211> 832
<212> PRT
<213> Homo sapiens
<400> 29

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100          105          110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115          120          125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
          130          135          140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145          150          155          160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
          165          170          175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
          180          185          190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
          195          200          205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
          210          215          220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
225          230          235          240
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln

```

				245					250					255			
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr		
			260					265						270			
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys		
		275					280					285					
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile		
	290					295					300						
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro		
305					310					315					320		
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg		
			325						330					335			
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln		
			340					345					350				
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val		
	355					360					365						
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala		
	370					375					380						
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg		
385					390					395				400			
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile		
			405					410					415				
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val		
			420					425					430				
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val		
	435					440						445					
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly		
	450					455					460						
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe		
465					470					475				480			
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp		
			485						490					495			
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile		
			500					505					510				
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg		
	515						520					525					
His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu	Val	Tyr	Phe		
	530					535					540						
Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser		
545					550					555					560		
Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	Gly	Phe	Ser		
			565					570						575		</	

	725		730		735										
Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp	Leu	Ser	Arg
	740							745					750		
Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser	Leu	Met	Gly
	755							760					765		
Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Ala	Gln	Pro	Leu	Ala	Tyr	Pro
	770							775					780		
Pro	Arg	Leu	Pro	Gly	Arg	Lys	Arg	Ala	Leu	Phe	Pro	His	Lys	Leu	Pro
	785							790					795		800
Arg	Leu	Pro	Thr	Asp	Pro	Ser	Arg	Glu	Thr	Leu	Pro	Ala	Pro	Asp	Leu
				805						810				815	
Pro	Gln	Arg	Glu	Thr	Gln	Tyr	Ser	Leu	Pro	Arg	Val	Gly	Arg	Ala	Leu
	820							825					830		

<210> 30
 <211> 4159
 <212> DNA
 <213> Homo sapiens
 <400> 30

caggccgcgcg	cctgggtcgc	tcaacttcgc	ggcacaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcgc	ccgccacttc	cggggtcgca	gtcccgggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcgcg	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgcctcct	gaggtcagct	gagcggttaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cgaaggttg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcc	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttctactg	gtactgggtg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccctgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttcc	tccgcgcaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtgcgccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920
aaggacacgc	cgtggagca	ccacctctac	gtggtcagct	atgaggcggc	cggcgagatc	1980
gtacgcctca	ccacgcccgg	cttctcccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcacg	ccgccttgcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgacccct	gcacaagcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatcttcc	atttccacac	gcgctcggat	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccagggaa	gaagcacc	2280
accgtcctct	ttgtatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgccggtcaa	cacactggcc	tccctgggct	acgccgtggg	tgtgattgac	2400

```

ggcagggggt cctgtcagcg agggcttcgg ttcgaagggg ccctgaaaaa ccaaattgggc 2460
caggtggaga tcgaggacca ggtggagggc ctgcagttcg tggccgagaa gtatggcttc 2520
atcgacctga gccgagttgc catccatggc tggctctacg ggggcttcct ctgctcatg 2580
gggctaatacc acaagcccca ggtgttcaag gcccaaccgc ttgcttatcc tccacggctt 2640
cctggacgaa aacgtgcact ttttccacac aaacttcctc gtctcccaac tgatccgagc 2700
agggaaacct taccagctcc agatctaccc caacgagaga cacagtattc gctgccccga 2760
gtcgggagag cactatgaag tcacgttgct gcactttcta caggaatacc tctgagcctg 2820
cccaccggga gccgccacat cacagcacia gtggctgcag cctccgcggg gaaccaggcg 2880
ggagggactg agtggcccgcc gggcccccagt gaggcacttt gtcccgccca gcgctggcca 2940
gccccgagga gccgctgcct tcaccgcccc gacgcctttt atcctttttt aaacgctctt 3000
gggttttatg tccgctgctt cttgggttgcc gagacagaga gatggtggtc tcggggccagc 3060
ccctcctctc cccgccttct gggaggagga ggtcacacgc tgatgggcac tggagaggcc 3120
agaagagact cagaggagcg ggctgccttc cgcctggggc tccctgtgac ctctcagtc 3180
cctggccccg ccagccaccg tccccagcac ccaagcatgc aattgcctgt cccccccggc 3240
cagcctcccc aacttgatgt ttgtgttttg tttgggggga tatttttcat aattatttaa 3300
aagacaggcc gggcgcggtg gctcacgtct gtaatcccag cactttggga ggctgaggcg 3360
ggcggatcac ctgaggttg gagttcaaga ccagcctggc caacatgggg aaaccccgctc 3420
tctactaaaa atacaaaaaa ttagccgggt gtgggtggcg gtgcctataa tcccagctac 3480
tcgggaggct gaggcaggag aatcgcttga acccgggagg tggaggttgc ggtgagccaa 3540
gatcgacca ttgcactcca gcctgggcaa caagagcgaa actctgtctc aaaataaata 3600
aaaaataaaa gacagaaagc aaggggtgct taaatctaga cttgggggtcc acaccgggca 3660
gcgggggttg aacccagcac ctggtaggct ccatttcttc ccaagcccga gcagagggtc 3720
atgcggggcc cacaggagaa gcggccaggg cccgcggggg gcaccacctg tggacagccc 3780
tcctgtcccc aagctttcag gcaggcactg aaacgcaccg aacttccacg ctctgctggt 3840
cagtggcggc tgtccctcc ccagcccagc cggccagcca catgtgtctg cctgaccctg 3900
acacaccagg ggttccgggg ttgggagctg aaccatcccc acctcagggt tatatttccc 3960
tctccccttc cctccccgcc aagagctctg ccagggggcg gcaaaaaaaa aagtaaaaag 4020
aaaagaaaaa aaaaaaaaag aaacaaacca cctctacata ttatggaaag aaaatatattt 4080
tgtcgattct tattctttta taattatgcy tggaagaagt agacacatta aacgattcca 4140
gttggaaca tgtcacctg 4159

```

```

<210> 31
<211> 832
<212> PRT
<213> Homo sapiens
<400> 31

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100          105          110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115          120          125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
          130          135          140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145          150          155          160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
          165          170          175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg

```

			180					185					190				
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu		
		195					200					205					
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro		
	210					215						220					
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val		
225					230						235				240		
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln		
			245					250					255				
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr		
		260					265						270				
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys		
	275					280						285					
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile		
	290					295					300						
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro		
305				310						315					320		
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg		
			325						330					335			
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln		
		340					345						350				
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val		
	355					360						365					
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala		
	370					375					380						
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg		
385				390						395				400			
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile		
			405					410					415				
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val		
		420					425						430				
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val		
	435					440						445					
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly		
	450				455						460						
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe		
465				470						475				480			
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp		
			485						490				495				
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile		
		500					505						510				
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg		
	515						520					525					
His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu	Val	Tyr	Phe		
	530				535						540						
Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser		
545				550						555					560		
Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	Gly	Phe	Ser		
			565					570					575				
His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	Ser	His	Tyr		
		580					585					590					
Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	Leu	Ser	Gly		
	595						600					605					
Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	Ala	Ser	Met		
	610					615					620						
Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	Glu	Ile	Phe		
625				630						635				640			
His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	Ile	Tyr	Lys		
			645					650					655				
Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val	Leu	Phe	Val		

	660		665		670										
Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe	Lys	Gly	Ile
	675		680		685										
Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr	Ala	Val	Val
	690		695		700										
Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg	Phe	Glu	Gly
705			710		715										720
Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp	Gln	Val	Glu
			725		730										735
Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp	Leu	Ser	Arg
	740		745		750										
Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser	Leu	Met	Gly
	755		760		765										
Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Ala	Gln	Pro	Leu	Ala	Tyr	Pro
770			775		780										
Pro	Arg	Leu	Pro	Gly	Arg	Lys	Arg	Ala	Leu	Phe	Pro	His	Lys	Leu	Pro
785			790		795										800
Arg	Leu	Pro	Thr	Asp	Pro	Ser	Arg	Glu	Thr	Leu	Pro	Ala	Pro	Asp	Leu
			805		810										815
Pro	Gln	Arg	Glu	Thr	Gln	Tyr	Ser	Leu	Pro	Arg	Val	Gly	Arg	Ala	Leu
	820		825		830										

<210> 32
 <211> 4076
 <212> DNA
 <213> Homo sapiens
 <400> 32

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggetgtcg	tccccgcctc	ccgccacttc	cgggggtcgca	gtccccgggca	120
tggagcccg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgcccctct	gaggtcagct	gagcgggttaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgaggggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcggg	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcgcc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactg	gtactgggtg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtg	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccc	agcacagaga	atgaggagca	gcggttagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgaacct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920

```

aaggacacgc cgctggagca ccacctctac gtgggtcagct atgaggcggc cggcgagatc 1980
gtacgcctca ccacgcccgg cttctcccat agctgctcca tgagccagaa cttcgacatg 2040
ttcgtcagcc actacagcag cgtgagcacg ccgccctgcg tgcacgtcta caagctgagc 2100
ggccccgacg acgacccccct gcacaagcag ccccgcttct gggctagcat gatggaggca 2160
gccagctgcc ccccggatta tgttcctcca gagatcttcc atttccacac gcgctcggat 2220
gtgcggctct acggcatgat ctacaagccc cagccttgc agccaggga gaagcacccc 2280
accgtcctct ttgtatatgg agggccccag gtgcagctgg tgaataactc cttcaaaggc 2340
atcaagtact tgcggctcaa cacactggcc tccctgggct acgccgtggt tgtgattgac 2400
ggcaggggct cctgtcagcg agggcttcgg ttcgaagggg ccctgaaaaa ccaaattggc 2460
caggtggaga tgcaggacca ggtggagggc ctgcagttcg tggccgagaa gtatggcttc 2520
atcgacctga gccgagttgc catccatggc tggctctacg ggggcttcct ctgcgtcatg 2580
gggctaatac acaagcccca ggtgttcaag gcccaaccgc ttgcttatcc tccacggctt 2640
cctggacgaa aacgtgcact ttttccacac aaacttcctc gtctcccaac tgatccgagc 2700
agggaaacct taccagctcc agatctaccc caacgagaga cacagtattc gctgccccga 2760
gtcggggcag cactatgaag tcacgttgct gcactttcta caggaatacc tctgagcctg 2820
cccaccggga gccgccacat cacagcacia gtggctgcag cctccgcggg gaaccaggcg 2880
ggagggactg agtggcccgc gggccccagt gaggcacttt gtcccggcca gcgctggcca 2940
gccccgagga gccgctgcct tcaccgcccc gacgcctttt atcctttttt aaacgctctt 3000
gggttttatg tccgctgctt cttgggttgc gagacagaga gatggtggtc tcgggccagc 3060
ccctcctctc cccgccttct gggaggagga ggtcacacgc tgatgggcac tggagaggcc 3120
agaagagact cagaggagcg ggctgccttc cgcctggggc tccctgtgac ctctcagtc 3180
cctggccccg ccagccaccg tccccagcac ccaagcatgc aattgcctgt cccccccggc 3240
cagcctcccc aacttgatgt ttgtgttttg tttgggggga tatttttcat aattatttaa 3300
aagacaggcc gggcgcggtg gctcacgtct gtaatcccag cactttggga ggctgaggcg 3360
ggcggatcac ctgaggttgg gagttcaaga ccagcctggc caacatgggg aaaccccgtc 3420
tctactaaaa atacaaaaaa ttagccgggt gtggtggcgc gtgcctataa tcccagctac 3480
tcgggaggct gaggcaggag aatcgcttga acccgggagg tggaggttgc ggtgagccaa 3540
gatcgacca ttgcactcca gcctgggcaa caagagcgaa actctgtctc aaaataaata 3600
aaaaataaaa gacagaaagc aaggggtgcc taaatctaga cttgggggtc acaccgggca 3660
gcgggggtgc aaccagcac ctggtaggct ccatttcttc ccaagcccga ctttcaggca 3720
ggcactgaaa cgcaccgaac ttccacgctc tgctggtcag tggcggctgt cccctcccca 3780
gcccagccgc ccagccacat gtgtctgcct gaccgtaca caccaggggt tccggggttg 3840
ggagctgaac catccccacc tcagggttat atttccctct ccccttccct ccccgccaag 3900
agctctgcca gggcggggca aaaaaaaaag taaaaagaaa agaaaaaaa aaaaaagaaa 3960
caaaccacct ctacatatta tggaagaaa atatttttgt cgattcttat tcttttataa 4020
ttatgcgtgg aagaagtaga cacattaac gattccagtt ggaaacatgt cacctg 4076

```

```

<210> 33
<211> 879
<212> PRT
<213> Homo sapiens
<400> 33

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1           5           10           15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100          105          110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115          120          125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr

```

130	135	140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg		
145	150	155
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu		160
	165	170
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg		175
	180	185
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		190
	195	200
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		205
	210	215
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		220
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		240
	245	250
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		255
	260	265
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		270
	275	280
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		285
	290	295
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		300
305	310	315
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		320
	325	330
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		335
	340	345
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		350
	355	360
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		365
	370	375
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		380
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		400
	405	410
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		415
	420	425
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		430
	435	440
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		445
	450	455
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		460
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		480
	485	490
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		495
	500	505
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		510
	515	520
His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr		525
	530	535
Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro		540
545	550	555
		560

Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val
 565 570 575
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys
 580 585 590
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp
 595 600 605
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro
 610 615 620
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met
 625 630 635 640
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val
 645 650 655
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 660 665 670
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 675 680 685
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 690 695 700
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 705 710 715 720
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 725 730 735
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala
 755 760 765
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu
 770 775 780
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly
 785 790 795 800
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu
 805 810 815
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr
 820 825 830
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu
 835 840 845
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly
 850 855 860
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu
 865 870 875

<210> 34
 <211> 4263
 <212> DNA
 <213> Homo sapiens
 <400> 34

caggccgccc cctgggtcgc tcaacttccg ggtcaaaggt gcctgagccg gcgggtcccc 60
 tgtgtccgcc gcggctgtcg tccccgcgc ccgccacttc cggggtcgca gtcccgggca 120
 tggagccgcg accgtgaggc gccgctggac ccgggacgac ctgcccagtc cggccgcccgc 180
 cccacgtccc ggtctgtgtc ccacgcctgc agctggaatg gaggtctctt ggacccttta 240
 gaaggcacc ctgccctcct gaggtcagct gagcgggttaa tgcggaaggt taagaaactg 300
 cgcttggaaca aggagaacac cggaagttag agaagcttct cgctgaattc cgaggggggt 360
 gagaggatgg ccaccaccgg gaccccaacg gccgaccgag gcgacgcagc cgccacagat 420
 gaccgggccg cccgcttcca ggtgcagaag cactcgtggg acggggtccg gagcatcatc 480
 cacggcagcc gcaagtactc gggcctcatt gtcaacaagg cgccccacga cttccagttt 540
 gtgcagaaga cggatgagtc tgggccccac tcccaccgcc tctactacct gggaatgcc 600
 tatggcagcc gagagaactc cctcctctac tctgagattc ccaagaaggt ccggaaagag 660
 gctctgtgtc tctgtctctg gaagcagatg ctggatcatt tccaggccac gccccaccat 720
 ggggtctact ctccggagga ggagctgctg agggagcgga aacgcctggg ggtcttcggc 780

atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccagge	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtccctat	gaaaccgctg	900
gaaatcaaga	cccagtgctc	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactg	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtccctc	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggta	ccccaggaca	ggcagcaaga	atcccaagat	tgctttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgcttg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttcc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggeg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtggtcagc	1920
tatgaggcgg	ccggcgagat	cgtacgcctc	accacgcccc	gcttctccca	tagctgctcc	1980
atgagccaga	acttcgacat	gttcgctcagc	cactacagca	gcgtgagcac	gccgccctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgaccccc	tgcaacaagca	gccccgcttc	2100
tgggctagca	tgatggaggc	agccagctgc	cccccgatt	atgttctctc	agagatcttc	2160
catttccaca	cgcgctcgga	tgtgcggctc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcaccc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgccgtgg	ttgtgattga	cggcaggggc	tcctgtcagc	gagggtctcg	gttcgaaggg	2400
gccctgaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggtcctac	2520
gggggcttcc	tctcgctcat	ggggctaata	cacaagcccc	aggtgttcaa	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	ggtacactga	gcgctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gaggcggggt	ccgtggccct	gcacgtggag	2700
aagctgcccc	atgagcccaa	ccgcttgctt	atcctccacg	gcttcttgga	cgaaaacgtg	2760
cactttttcc	acacaaactt	cctcgctctc	caactgatcc	gagcagggaa	accttaccag	2820
ctccagatct	acccaacga	gagacacagt	atcgtctgcc	ccgagtcggg	cgagcactat	2880
gaagtcacgt	tgctgcactt	tctacaggaa	tacctctgag	cctgcccacc	gggagccgcc	2940
acatcacagc	acaagtggct	gcagcctccg	cggggaacca	ggcgggaggg	actgagtggc	3000
ccgcgggccc	cagtgaggca	ctttgtcccc	cccagcgctg	gccagccccg	aggagccgct	3060
gccttcaccg	ccccgacgcc	ttttatcctt	ttttaaacgc	tcttgggttt	tatgtccgct	3120
gcttcttggg	tgccgagaca	gagagatggg	ggtctcgggc	cagccccctc	tctccccgcc	3180
ttctgggagg	aggaggtcac	acgctgatgg	gcactggaga	ggccagaaga	gactcagagg	3240
agcgggctgc	cttccgcctg	gggctccctg	tgacctctca	gtcccttggc	ccggccagcc	3300
accgtcccca	gcacccaagc	atgcaattgc	ctgtcccccc	cggccagcct	ccccaaactg	3360
atgttttgtg	tttggttggg	gggatatttt	tcataattat	ttaaaagaca	ggccgggcgc	3420
ggtggctcac	gtctgtaatc	ccagcacttt	gggaggctga	ggcgggcgga	tcacctgagg	3480
ttgggagttc	aagaccagcc	tggccaacat	ggggaaaccc	cgtctctact	aaaaatacaa	3540
aaaattagcc	gggtgtgggt	gcgcgtgcct	ataatcccag	ctactcggga	ggctgaggca	3600
ggagaatcgc	ttgaacccgg	gaggtggagg	ttgcgggtgag	ccaagatcgc	accattgcac	3660
tccagcctgg	gcaacaagag	cgaaactctg	tctcaaaaata	aataaaaaat	aaaagacaga	3720
aagcaagggg	tgcttaaate	tagacttggg	gtccacaccg	ggcagcgggg	ttgcaaccca	3780
gcacctggta	ggctccattt	cttcccaagc	ccgagcagag	ggtcatgcgg	gccccacagg	3840
agaagcggcc	agggccccgc	gggggcacca	cctgtggaca	gccctcctgt	ccccaaagctt	3900
tcaggcaggc	actgaaacgc	accgaacttc	cacgctctgc	tggtcagtg	cggctgtccc	3960
ctccccagcc	cagccgcccc	gccacatgtg	tctgcctgac	ccgtacacac	caggggttcc	4020
ggggttggga	gctgaaccat	ccccacctca	gggttatatt	tccctctccc	cttccctccc	4080
cgccaagagc	tctgccaggg	gcgggcaaaa	aaaaaagtaa	aaagaaaaga	aaaaaaaaaa	4140
aaagaaacaa	accacctcta	catattatgg	aaagaaaata	tttttgtcga	ttcttattct	4200
tttataatta	tgcggtggaag	aagtagacac	attaaacgat	tccagttgga	aacatgtcac	4260
ctg						4263

<210> 35
 <211> 879
 <212> PRT
 <213> Homo sapiens
 <400> 35

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	1	5	10	15
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr	20	25	30	
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp	35	40	45	
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg	50	55	60	
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys	65	70	75	80
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro	85	90	95	
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu	100	105	110	
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala	115	120	125	
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr	130	135	140	
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	145	150	155	160
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu	165	170	175	
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg	180	185	190	
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu	195	200	205	
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro	210	215	220	
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val	225	230	235	240
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln	245	250	255	
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr	260	265	270	
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys	275	280	285	
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile	290	295	300	
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro	305	310	315	320
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg	325	330	335	
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln	340	345	350	
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val	355	360	365	
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala	370	375	380	
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg	385	390	395	400
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile	405	410	415	

Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val	420	425	430
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val	435	440	445
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly	450	455	460
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe	465	470	475
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp	485	490	495
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile	500	505	510
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg	515	520	525
His	Gly	Ser	Lys	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	530	535	540
Val	Val	Ser	Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	545	550	555
Gly	Phe	Ser	His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	565	570	575
Ser	His	Tyr	Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	580	585	590
Leu	Ser	Gly	Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	595	600	605
Ala	Ser	Met	Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	610	615	620
Glu	Ile	Phe	His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	625	630	635
Ile	Tyr	Lys	Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val	645	650	655
Leu	Phe	Val	Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe	660	665	670
Lys	Gly	Ile	Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr	675	680	685
Ala	Val	Val	Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg	690	695	700
Phe	Glu	Gly	Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp	705	710	715
Gln	Val	Glu	Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp	725	730	735
Leu	Ser	Arg	Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser	740	745	750
Leu	Met	Gly	Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Val	Ala	Ile	Ala	755	760	765
Gly	Ala	Pro	Val	Thr	Val	Trp	Met	Ala	Tyr	Asp	Thr	Gly	Tyr	Thr	Glu	770	775	780
Arg	Tyr	Met	Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly	785	790	795
Ser	Val	Ala	Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu	805	810	815
Leu	Ile	Leu	His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	Phe	His	Thr	820	825	830
Asn	Phe	Leu	Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu	835	840	845
Gln	Ile	Tyr	Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly	850	855	860
Glu	His	Tyr	Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu		865	870	875

<210> 36
 <211> 4180
 <212> DNA
 <213> Homo sapiens
 <400> 36

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tcccccgctc	ccgccacttc	cggggtcgca	gtcccgggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaaagtgg	agaagcttct	cgctgaattc	cgaggggggt	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgtctcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaagag	660
gctctgctgc	tctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcttgatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactg	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtccgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggta	ccccaggaca	ggcagcaaga	atcccaagat	tgcttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cggggtggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttcc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	tcagcccccg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtggtcagc	1920
tatgaggcgg	ccggcgagat	cgtacgcctc	accacgcccc	gcttctccca	tagctgctcc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgccttgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgaccccc	tgcaacaagca	gccccgcttc	2100
tgggctagca	tgatggaggc	agccagctgc	cccccgatt	atgttcctcc	agagatcttc	2160
catttccaca	cgcgctcgga	tgtgcggtc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcacc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgccgtgg	ttgtgattga	cggcaggggc	tctgtcagc	gagggtctcg	gttcgaaggg	2400
gccctgaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggctctac	2520
gggggcttcc	tctcgctcat	ggggctaate	cacaagcccc	aggtgttcaa	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	ggtacactga	gcgctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gaggcgggtt	ccgtggccct	gcacgtggag	2700
aagctgcccc	atgagcccaa	ccgcttgctt	atcctccacg	gcttctctga	cgaaaacgtg	2760
cactttttcc	acacaaactt	cctcgtctcc	caactgatcc	gagcagggaa	accttaccag	2820
ctccagatct	accccaacga	gagacacagt	attcgtctgc	ccgagtcggg	cgagcactat	2880
gaagtcacgt	tgctgcactt	tctacaggaa	tacctctgag	cctgcccacc	gggagccgcc	2940
acatcacagc	acaagtggct	gcagcctccg	cggggaacca	ggcgggaggg	actgagtggc	3000
ccgcgggccc	cagtgaggca	ctttgtcccc	cccagcgtcg	gccagccccg	aggagccgct	3060
gccttcaccg	ccccgacgcc	ttttatcctt	ttttaaacgc	tcttgggttt	tatgtccgct	3120
gcttcttggg	tgccgagaca	gagagatggg	ggtctcgggc	cagccccctc	tctccccgcc	3180

```

ttctgggagg aggaggtcac acgctgatgg gcaactggaga ggccagaaga gactcagagg 3240
agcgggctgc cttccgcctg gggctccctg tgacctctca gtcccttggc ccggccagcc 3300
accgtcccca gcacccaagc atgcaattgc ctgtccccc cggccagcct ccccaacttg 3360
atgttttgtgt tttgtttggg gggatatttt tcataattat ttaaaagaca ggccgggagc 3420
ggtggctcac gtctgtaatc ccagcacttt gggaggctga ggccggcgga tcacctgagg 3480
ttgggagttc aagaccagcc tggccaacat ggggaaaccc cgtctctact aaaaatacaa 3540
aaaattagcc ggggtgtggtg gcgcgtgcct ataatcccag ctactcggga ggctgaggca 3600
ggagaatcgc ttgaacccgg gaggtggagg ttgcggtgag ccaagatcgc accattgcac 3660
tccagcctgg gcaacaagag cgaaactctg tctcaaaata aataaaaaat aaaagacaga 3720
aagcaagggg tgcctaaatc tagacttggg gtccacaccg ggcagcgggg ttgcaaccca 3780
gcacctggta ggctccattt cttcccaagc ccgactttca ggcaggcact gaaacgcacc 3840
gaacttccac gctctgctgg tcagtggcgg ctgtccccc cccagcccag ccgcccagcc 3900
acatgtgtct gcctgaccgg tacacaccag gggttccggg gttgggagct gaaccatccc 3960
cacctcaggg ttatatattc ctctccctt ccctccccc caagagctct gccaggggag 4020
ggcaaaaaaa aaagtaaaaa gaaaagaaaa aaaaaaaaaa gaaacaaacc acctctacat 4080
attatggaaa gaaaatattt ttgtcgattc ttattctttt ataattatgc gtggaagaag 4140
tagacacatt aaacgattcc agttggaaac atgtcacctg 4180

```

```

<210> 37
<211> 819
<212> PRT
<213> Homo sapiens
<400> 37

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100          105          110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115          120          125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
          130          135          140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145          150          155          160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
          165          170          175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
          180          185          190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
          195          200          205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
          210          215          220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
225          230          235          240
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
          245          250          255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
          260          265          270

```

Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys
	275						280					285			
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile
	290					295					300				
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro
305					310					315					320
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg
				325					330					335	
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln
			340					345					350		
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val
	355					360						365			
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala
	370					375					380				
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg
385					390					395					400
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile
				405					410					415	
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val
			420					425					430		
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val
	435					440						445			
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly
	450					455					460				
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe
465					470					475					480
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp
				485					490					495	
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile
			500					505					510		
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg
	515						520					525			
His	Gly	Ser	Lys	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr
	530					535					540				
Val	Val	Ser	Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro
545					550					555					560
Gly	Phe	Ser	His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val
				565					570					575	
Ser	His	Tyr	Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys
			580					585					590		
Leu	Ser	Gly	Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp
	595						600					605			
Ala	Ser	Met	Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro
	610					615					620				
Glu	Ile	Phe	His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met
625					630					635					640
Ile	Tyr	Lys	Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val
				645					650					655	
Leu	Phe	Val	Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe
			660				665					670			
Lys	Gly	Ile	Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr
	675						680					685			
Ala	Val	Val	Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg
	690					695					700				
Phe	Glu	Gly	Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp
705					710					715					720
Gln	Val	Glu	Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp
				725					730					735	

Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu
 755 760 765
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His
 770 775 780
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala
 785 790 795 800
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly
 805 810 815
 Arg Ala Leu

<210> 38
 <211> 4120
 <212> DNA
 <213> Homo sapiens
 <400> 38

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccc	gcgggtcccc	60
tgtgtccgcc	gcggtgtcgc	tcccøcgctc	ccgccacttc	cggggtcgca	gtcccgggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaaggt	taagaaactg	300
cgcttgaca	aggagaacac	cggaagttag	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccc	cccgtctcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgccca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tøctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tøctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactgg	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtccøct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggta	ccccaggaca	ggcagcaaga	atcccaagat	tgøcttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgøctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtøctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	ccøttccccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggøttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttgøcg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtgggtcagc	1920
tatgaggcgg	ccggcgagat	cgtacgcctc	accacgcccg	gcttctccca	tagctgctcc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgøøctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgaccccc	tgcacaagca	gccccgcttc	2100
tgggctagca	tgatggaggc	agccagctgc	cccccgøatt	atgttøctcc	agagatcttc	2160
catttccaca	cgcgctcgga	tgtgcggctc	tacggcatga	tctacaagcc	ccacgcøttg	2220
cagccaggga	agaagcaccc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	cøttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgøøgtgg	ttgtgattga	cggcaggggc	tøctgtcagc	gagggcttøg	gttcgaaggg	2400
gccctgaaaa	accaaattggg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460

```

gtggccgaga agtatggctt catcgacctg agccgagttg ccatccatgg ctggtcctac 2520
gggggcttcc tctcgctcat ggggctaata cacaagcccc aggtggttcaa ggcccaaccg 2580
cttgcttata ctccacggct tcttggaaga aaacgtgcac tttttccaca caaacttcct 2640
cgtctcccaa ctgatccgag cagggaaacc ttaccagctc cagatctacc ccaacgagag 2700
acacagtatt cgctgccccg agtcggggcg gcactatgaa gtcacgttgc tgcactttct 2760
acaggaatac ctctgagcct gccaccggg agccgccaca tcacagcaca agtggctgca 2820
gcctccgagg ggaaccaggc gggagggaact gaggggcccg cgggccccag tgaggcactt 2880
tgtcccgccc agcgctggcc agccccgagg agccgctgcc ttcaccgccc cgacgccttt 2940
tatecttttt taaacgctct tgggttttat gtccgctgct tcttggttgc cgagacagag 3000
agatgggtgt ctcgggccag cccctcctct ccccgcttc tgggaggagg aggtcacacg 3060
ctgatgggca ctggagaggc cagaagagac tcagaggagc gggctgcctt ccgcctgggg 3120
ctccctgtga cctctcagtc ccctggcccg gccagccacc gtccccagca cccaagcatg 3180
caattgcctg tcccccccg ccagcctccc caacttgatg tttgtgtttt gtttgggggg 3240
atatttttca taattattta aaagacaggc cgggcgcggt ggctcacgct tghtaatcca 3300
gcactttggg aggttgaggc gggcggaatc cctgaggttg ggagttcaag accagcctgg 3360
ccaacatggg gaaaccccgt ctctactaaa aatacaaaaa attagccggg tgtggtggcg 3420
cgtgcctata atcccagcta ctcgggaggc tgaggcagga gaatcgcttg aaccggggag 3480
gtggaggttg cggtagacca agatcgacc attgcactcc agcctgggca acaagagcga 3540
aactctgtct caaaataaat aaaaaataaa agacagaaag caaggggtgc ctaaatctag 3600
acttggggtc cacaccgggc agcgggggtg caaccagca cctggtaggc tccatttctt 3660
cccaagcccg agcagagggc catgcccggc ccacaggaga agcggccagg gcccgccggg 3720
ggcaccacct gtggacagcc ctctgtccc caagctttca ggcaggcact gaaacgcacc 3780
gaacttccac gctctgctgg tcagtggcgg ctgtcccctc cccagcccag ccgcccagcc 3840
acatgtgtct gcctgaccgg tacacaccag gggttccggg gttgggagct gaaccatccc 3900
cacctcaggg ttatatattc ctctcccctt ccctcccgc caagagctct gccaggggcg 3960
ggcaaaaaaa aaagtaaaaa gaaaagaaaa aaaaaaaaaa gaaacaaacc acctctacat 4020
attatggaaa gaaaatattt ttgtcgattc ttattctttt ataattatgc gtggaagaag 4080
tagacacatt aaacgattcc agttggaac atgtcacctg 4120

```

```

<210> 39
<211> 819
<212> PRT
<213> Homo sapiens
<400> 39

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100          105          110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115          120          125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
          130          135          140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145          150          155          160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
          165          170          175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
          180          185          190

```

Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu	195	200	205
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro	210	215	220
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val	225	230	235
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln	245	250	255
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr	260	265	270
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys	275	280	285
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile	290	295	300
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro	305	310	315
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg	325	330	335
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln	340	345	350
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val	355	360	365
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala	370	375	380
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg	385	390	395
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile	405	410	415
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val	420	425	430
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val	435	440	445
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly	450	455	460
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe	465	470	475
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp	485	490	495
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile	500	505	510
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg	515	520	525
His	Gly	Ser	Lys	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	530	535	540
Val	Val	Ser	Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	545	550	555
Gly	Phe	Ser	His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	565	570	575
Ser	His	Tyr	Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	580	585	590
Leu	Ser	Gly	Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	595	600	605
Ala	Ser	Met	Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	610	615	620
Glu	Ile	Phe	His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	625	630	635
Ile	Tyr	Lys	Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val	645	650	655

Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 660 665 670
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 675 680 685
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 690 695 700
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 705 710 715 720
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 725 730 735
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu
 755 760 765
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His
 770 775 780
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala
 785 790 795 800
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly
 805 810 815
 Arg Ala Leu

<210> 40
 <211> 4037
 <212> DNA
 <213> Homo sapiens
 <400> 40

caggccgccc cctgggtcgc tcaacttccg ggtcaaaggt gcctgagccg gcgggtcccc 60
 tgtgtccgcc gcggtgtcg tccccgctc ccgccacttc cggggtcgca gtcccgggca 120
 tggagccgcg accgtgagge gccgctggac ccgggacgac ctgcccagtc cgcccgcgc 180
 cccacgtccc ggtctgtgtc ccacgcctgc agctggaatg gaggtctctt ggacccttta 240
 gaaggcaccg ctgcccctct gaggtcagct gagcgggttaa tgcggaaggt taagaaactg 300
 cgcttgaca aggagaacac cggaagttgg agaagcttct cgctgaattc cgagggggct 360
 gagaggatgg ccaccaccgg gaccccaacg gccgaccgag gcgacgcagc cgccacagat 420
 gacccggccg cccgcttcca ggtgcagaag cactcgtggg acgggctccg gagcatcatc 480
 cacggcagcc gcaagtactc gggcctcatt gtcaacaagg cgccccacga cttccagttt 540
 gtgcagaaga cggatgagtc tgggccccac tcccaccgcc tctactacct gggaatgcca 600
 tatggcagcc gagagaactc cctcctctac tctgagattc ccaagaaggt ccggaaagag 660
 gctctgctgc tctgtctctg gaagcagatg ctggatcatt tccaggccac gccccaccat 720
 ggggtctact ctcgggagga ggagctgctg agggagcgga aacgcctggg ggtcttcggc 780
 atcacctcct acgacttcca cagcgagagt ggcctcttcc tcttccaggc cagcaacagc 840
 ctcttccact gccgcgacgg cggcaagaac ggcttcatgg tgtcccctat gaaaccgctg 900
 gaaatcaaga cccagtgtc agggccccgg atggacccca aaatctgccc tgccgacctt 960
 gccttcttct ccttcatcaa taacagcgac ctgtgggtgg ccaacatcga gacaggcgag 1020
 gagcggcgcc tgaccttctg ccaccaaggt ttatccaatg tcctggatga cccaagtct 1080
 gcgggtgtgg ccaccttcgt catacaggaa gagttcgacc gcttcaactg gtactgggtg 1140
 tgccccacag cctcctggga aggttcagag ggcctcaaga cgctgcgaat cctgtatgag 1200
 gaagtcgatg agtccgaggt ggaggtcatt cacgtcccct ctctgctgct agaagaaagg 1260
 aagacggact cgtatcggtg ccccaggaca ggcagcaaga atcccaagat tgccttgaaa 1320
 ctggctgagt tccagactga cagccagggc aagatcgtct cgaccagga gaaggagctg 1380
 gtgcagccct tcagctcgct gttcccgaag gtggagtaca tcgccagggc cgggtggacc 1440
 cgggatggca aatacgctg ggcctgttc ctggaccggc cccagcagtg gctccagctc 1500
 gtctcctcc ccccgccct gttcatcccg agcacagaga atgaggagca gcggctagcc 1560
 tctgccagag ctgtccccag gaatgtccag ccgtatgtgg tgtacgagga ggtcaccaac 1620
 gtctggatca atgttcatga catcttctat cccttcccc aatcagaggg agaggacgag 1680
 ctctgcttcc tccgcgcaa tgaatgcaag accggttct gccatttgta caaagtcacc 1740
 gccgttttaa aatcccagg ctacgattgg agtgagccct tcagccccgg ggaagatgaa 1800
 ttttaagtgcc ccattaagga agagattgct ctgaccagcg gtgaatggga ggttttggcg 1860


```

aggcacggct ccaagggcac caaggacacg ccgctggagc accacctcta cgtggtcagc 1920
tatgaggcgg ccggcgagat cgtacgcctc accacgcccc gcttctccca tagctgctcc 1980
atgagccaga acttcgacat gttcgtcagc cactacagca gcgtgagcac gccgccctgc 2040
gtgcacgtct acaagctgag cggccccgac gacgaccccc tgcacaagca gccccgcttc 2100
tgggctagca tgatggaggg agccagctgc cccccggatt atgttcctcc agagatcttc 2160
catttccaca cgcgctcgga tgtgcggctc tacggcatga tctacaagcc ccacgccttg 2220
cagccaggga agaagcaccc caccgtcctc tttgtatatg gaggccccca ggtgcagctg 2280
gtgaataact ccttcaaagg catcaagtac ttgcggtcga acacactggc ctccctgggc 2340
tacgccgtgg ttgtgattga cggcaggggc tcctgtcagc gagggttcg gttcgaagg 2400
gccctgaaaa accaaatggg ccagggtggag atcgaggacc aggtggaggg cctgcagttc 2460
gtggccgaga agtatggctt catcgacctg agccgagttg ccatccatgg ctggtcctac 2520
gggggcttcc tctcgctcat ggggctaata cacaagcccc aggtgttcaa ggcccaaccg 2580
cttgcttatc ctccacggct tcctggacga aaacgtgcac ttttccaca caaacttct 2640
cgtctcccaa ctgatccgag cagggaacc ttaccagctc cagatctacc ccaacgagag 2700
acacagtatt cgctgccccg agtcgggcga gcactatgaa gtcacgttgc tgcactttct 2760
acaggaatac ctctgagcct gccaccggg agccgccaca tcacagcaca agtggctgca 2820
gcctccgagg ggaaccaggc gggagggact gagtggcccc cgggccccag tgaggcactt 2880
tgtcccgccc agcgtggcc agccccgagg agccgctgcc ttcaccgccc cgacgccttt 2940
tattctttt taaacgctct tgggttttat gtccgctgct tcttggttgc cgagacagag 3000
agatgggtgg ctcgggccag cccctcctct ccccgcttc tgggaggagg aggtcacacg 3060
ctgatgggca ctggagaggc cagaagagac tcagaggagg gggctgcctt ccgcctgggg 3120
ctccctgtga cctctcagtc ccctggcccc gccagccacc gtccccagca cccaagcatg 3180
caattgcctg tcccccccg ccagcctccc caacttgatg tttgtgttt gtttggggg 3240
atatttttca taattattta aaagacaggc cgggcgcggt ggctcacgtc tgtaatccca 3300
gcactttggg aggttgaggc gggcggatca cctgaggttg ggagttcaag accagcctgg 3360
ccaacatggg gaaaccccgt ctctactaaa aatacaaaaa attagccggg tgtggtggcg 3420
cgtgcctata atcccagcta ctcgggaggc tgaggcagga gaatcgctg aaccggggag 3480
gtggaggttg cggtgagcca agatcgacc attgcactcc agcctgggca acaagagcga 3540
aactctgtct caaaataaat aaaaaataaa agacagaaag caaggggtgc ctaaatctag 3600
acttggggtc cacaccgggc agcgggggtg caaccagca cctggtaggc tccatttctt 3660
cccaagcccc actttcaggc aggcactgaa acgcaccgaa ctccacgct ctgctggtca 3720
gtggcggtg tcccccccc agcccagccg cccagccaca tgtgtctgcc tgaccgctac 3780
acaccagggg ttccgggggtt gggagctgaa ccatccccac ctgagggtta tatttccctc 3840
tccccttccc tccccgcaa gagctctgcc aggggcgggc aaaaaaaaaa gtaaaaagaa 3900
aagaaaaaaaa aaaaaaagaa acaaacacc tctacatatt atggaaagaa aatatttttg 3960
tcgattctta ttcttttata attatgcgtg gaagaagtag acacattaaa cgattccagt 4020
tggaacatg tcacctg 4037

```

```

<210> 41
<211> 706
<212> PRT
<213> Homo sapiens
<400> 41

```

```

Asp Thr Asp Val Val Tyr Lys Ser Glu Asn Gly His Val Ile Lys Leu
1          5          10          15
Asn Ile Glu Thr Asn Ala Thr Thr Leu Leu Leu Glu Asn Thr Thr Phe
          20          25          30
Val Thr Phe Lys Ala Ser Arg His Ser Val Ser Pro Asp Leu Lys Tyr
          35          40          45
Val Leu Leu Ala Tyr Asp Val Lys Gln Ile Phe His Tyr Ser Tyr Thr
          50          55          60
Ala Ser Tyr Val Ile Tyr Asn Ile His Thr Arg Glu Val Trp Glu Leu
65          70          75          80
Asn Pro Pro Glu Val Glu Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly
          85          90          95
Val Gln Gly Gln Gln Leu Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr
          100          105          110

```


Gln	Pro	Asp	Ile	Lys	Ser	Ser	Ser	Leu	Arg	Leu	Thr	Ser	Ser	Gly	Lys	115	120	125
Glu	Glu	Ile	Ile	Phe	Asn	Gly	Ile	Ala	Asp	Trp	Leu	Tyr	Glu	Glu	Glu	130	135	140
Leu	Leu	His	Ser	His	Ile	Ala	His	Trp	Trp	Ser	Pro	Asp	Gly	Glu	Arg	145	150	155
Leu	Ala	Phe	Leu	Met	Ile	Asn	Asp	Ser	Leu	Val	Pro	Thr	Met	Val	Ile	165	170	175
Pro	Arg	Phe	Thr	Gly	Ala	Leu	Tyr	Pro	Lys	Gly	Lys	Gln	Tyr	Pro	Tyr	180	185	190
Pro	Lys	Ala	Gly	Gln	Val	Asn	Pro	Thr	Ile	Lys	Leu	Tyr	Val	Val	Asn	195	200	205
Leu	Tyr	Gly	Pro	Thr	His	Thr	Leu	Glu	Leu	Met	Pro	Pro	Asp	Ser	Phe	210	215	220
Lys	Ser	Arg	Glu	Tyr	Tyr	Ile	Thr	Met	Val	Lys	Trp	Val	Ser	Asn	Thr	225	230	235
Lys	Thr	Val	Val	Arg	Trp	Leu	Asn	Arg	Pro	Gln	Asn	Ile	Ser	Ile	Leu	245	250	255
Thr	Val	Cys	Glu	Thr	Thr	Thr	Gly	Ala	Cys	Ser	Lys	Lys	Tyr	Glu	Met	260	265	270
Thr	Ser	Asp	Thr	Trp	Leu	Ser	Gln	Gln	Asn	Glu	Glu	Pro	Val	Phe	Ser	275	280	285
Arg	Asp	Gly	Ser	Lys	Phe	Phe	Met	Thr	Val	Pro	Val	Lys	Gln	Gly	Gly	290	295	300
Arg	Gly	Glu	Phe	His	His	Ile	Ala	Met	Phe	Leu	Ile	Gln	Ser	Lys	Ser	305	310	315
Glu	Gln	Ile	Thr	Val	Arg	His	Leu	Thr	Ser	Gly	Asn	Trp	Glu	Val	Ile	325	330	335
Lys	Ile	Leu	Ala	Tyr	Asp	Glu	Thr	Thr	Gln	Lys	Ile	Tyr	Phe	Leu	Ser	340	345	350
Thr	Glu	Ser	Ser	Pro	Arg	Gly	Arg	Gln	Leu	Tyr	Ser	Ala	Ser	Thr	Glu	355	360	365
Gly	Leu	Leu	Asn	Arg	Gln	Cys	Ile	Ser	Cys	Asn	Phe	Met	Lys	Glu	Gln	370	375	380
Cys	Thr	Tyr	Phe	Asp	Ala	Ser	Phe	Ser	Pro	Met	Asn	Gln	His	Phe	Leu	385	390	395
Leu	Phe	Cys	Glu	Gly	Pro	Arg	Val	Pro	Val	Val	Ser	Leu	His	Ser	Thr	405	410	415
Asp	Asn	Pro	Ala	Lys	Tyr	Phe	Ile	Leu	Glu	Ser	Asn	Ser	Met	Leu	Lys	420	425	430
Glu	Ala	Ile	Leu	Lys	Lys	Lys	Ile	Gly	Lys	Pro	Glu	Ile	Lys	Ile	Leu	435	440	445
His	Ile	Asp	Asp	Tyr	Glu	Leu	Pro	Leu	Gln	Leu	Ser	Leu	Pro	Lys	Asp	450	455	460
Phe	Met	Asp	Arg	Asn	Gln	Tyr	Ala	Leu	Leu	Leu	Ile	Met	Asp	Glu	Glu	465	470	475
Pro	Gly	Gly	Gln	Leu	Val	Thr	Asp	Lys	Phe	His	Ile	Asp	Trp	Asp	Ser	485	490	495
Val	Leu	Ile	Asp	Met	Asp	Asn	Val	Ile	Val	Ala	Arg	Phe	Asp	Gly	Arg	500	505	510
Gly	Ser	Gly	Phe	Gln	Gly	Leu	Lys	Ile	Leu	Gln	Glu	Ile	His	Arg	Arg	515	520	525
Leu	Gly	Ser	Val	Glu	Val	Lys	Asp	Gln	Ile	Thr	Ala	Val	Lys	Phe	Leu	530	535	540
Leu	Lys	Leu	Pro	Tyr	Ile	Asp	Ser	Lys	Arg	Leu	Ser	Ile	Phe	Gly	Lys	545	550	555
Gly	Tyr	Gly	Gly	Tyr	Ile	Ala	Ser	Met	Ile	Leu	Lys	Ser	Asp	Glu	Lys	565	570	575

Leu Phe Lys Cys Gly Ser Val Val Ala Pro Ile Thr Asp Leu Lys Leu
 580 585 590
 Tyr Ala Ser Ala Phe Ser Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu
 595 600 605
 Glu Ser Thr Tyr Gln Ala Ala Ser Val Leu His Asn Val His Gly Leu
 610 615 620
 Lys Glu Glu Asn Ile Leu Ile Ile His Gly Thr Ala Asp Thr Lys Val
 625 630 635 640
 His Phe Gln His Ser Ala Glu Leu Ile Lys His Leu Ile Lys Ala Gly
 645 650 655
 Val Asn Tyr Thr Met Gln Val Tyr Pro Asp Glu Gly His Asn Val Ser
 660 665 670
 Glu Lys Ser Lys Tyr His Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser
 675 680 685
 Asp Cys Leu Lys Glu Glu Ile Ser Val Leu Pro Gln Glu Pro Glu Glu
 690 695 700
 Asp Glu
 705

<210> 42
 <211> 4541
 <212> DNA
 <213> Homo sapiens
 <400> 42

gkctykgtkg	wtsmagatac	agatgtggtg	tataaaagcg	agaatggaca	tgtcattaaa	60
ctgaatatag	aaacaaatgc	taccacatta	ttattggaaa	acacaacttt	tgtaaccttc	120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaatatg	tccttctggc	atatgatgtc	180
aaacagattt	ttcattattc	gtatactgct	tcatatgtga	tttacaacat	acacactagg	240
gaagtgtggg	agttaaatcc	tccagaagta	gaggactccg	tcttgcagta	cgcggcctgg	300
ggtgtccaag	ggcagcagct	gatttatatt	tttgaaaata	atatctacta	tcaacctgat	360
ataaagagca	gttcattgcg	actgacatct	tctggaaaag	aagaaataat	ttttaatggg	420
attgctgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccca	ctggtggtca	480
ccagatggag	aaagacttgc	cttcctgatg	ataaatgact	ctttggtacc	caccatgggt	540
atccctcggg	ttactggagc	gttgatcccc	aaaggaaagc	agtatccgta	tcctaaggca	600
ggtcaagtga	acccaacaat	aaaattatat	gttgtaaacc	tgtatggacc	aactcacact	660
ttggagctca	tgccacctga	cagcttttaa	tcaagagaat	actatatcac	tatggttaaa	720
tgggtaagca	ataccaagac	tgtggttaaga	tgggttaaacc	gacctcagaa	catctccatc	780
ctcacagtct	gtgagaccac	tacaggtgct	tgtagtaaaa	aatatgagat	gacatcagat	840
acgtggctct	ctcagcagaa	tgaggagccc	gtgttttcta	gagacggcag	caaattcttt	900
atgacagtgc	ctgttaagca	agggggacgt	ggagaatttc	accacatagc	tatgttcctc	960
atccagagta	aaagtgagca	aattaccgtg	cggcatctga	catcaggaaa	ctgggaagtg	1020
ataaagatct	tggcatacga	tgaaactact	caaaaaattt	actttctgag	cactgaatct	1080
tctcccagag	gaaggcagct	gtacagtgct	tctactgaag	gattattgaa	tcgccaatgc	1140
atttcatgta	atttcatgaa	agaacaatgt	acatatattg	atgccagttt	tagtcccatg	1200
aatcaacatt	tcttattatt	ctgtgaaggt	ccaagggctc	cagtggtcag	cctacatagt	1260
acggacaacc	cagcaaaaata	ttttatattg	gaaagcaatt	ctatgctgaa	ggaagctatc	1320
ctgaagaaga	agataggaaa	gccagaaatt	aaaatccttc	atattgacga	ctatgaactt	1380
cctttacagt	tgtcccttcc	caaagatttt	atggaccgaa	accagtatgc	tcttctgtta	1440
ataatggatg	aagaaccagg	aggccagctg	gttacagata	agttccatat	tgactgggat	1500
tccgtactca	ttgacatgga	taatgtcatt	gtagcaagat	ttgatggcag	aggaagtgga	1560
ttccagggtc	tgaaaatttt	gcaggagatt	catcgaagat	taggttcagt	agaagtaaag	1620
gaccaaataa	cagctgtgaa	atttttgctg	aaactgcctt	acattgactc	caaaagatta	1680
agcatttttg	gaaaggggta	tgggtggctat	attgcatcaa	tgatcttaaa	atcagatgaa	1740
aagcttttta	aatgtggatc	cgtgggttga	cctatcacag	acttgaaatt	gtatgcctca	1800
gctttctctg	aaagatacct	tgggatgccca	tctaaggaag	aaagcactta	ccaggcagcc	1860
agtgtgctac	ataatgttca	tggcttgaaa	gaagaaaata	tattaataat	tcattggaact	1920
gctgacacaa	aagttcattt	ccaacactca	gcagaattaa	tcaagcacct	aataaaaagct	1980
ggagtgaatt	atactatgca	ggtctaccca	gatgaaggctc	ataacgtatc	tgagaagagc	2040

```

aagtatcatc tctacagcac aatcctcaaa ttcttcagtg attgtttgaa ggaagaaata 2100
tctgtgctac cacaggaacc agaagaagat gaataatgga ccgtatttat acagaactga 2160
agggaaatatt gaggtcaat gaaacctgac aaagagactg taatattgta gttgctccag 2220
aatgtcaagg gcagcttacg gagatgtcac tggagcagca cgctcagaga cagtgaacta 2280
gcatttgaat acacaagtcc aagtctactg tgttgctagg ggtgcagaac ccgtttcttt 2340
gtatgagaga ggtcaaaggg ttggtttcct gggagaaatt agttttgcat taaagtagga 2400
gtagtgcagtg ttttcttctg ttatccccct gtttgttctg taactagttg ctctcatttt 2460
aatttcactg gccaccatca tctttgcata taatgcacaa tctatcatct gtcctacagt 2520
ccctgatctt tcatggctga gctgcaatct aacactttac tgtaccttta taataagtgc 2580
aattctttca ttgtctatta ttatgcttaa gaaaatattc agttaataaa aaacagagta 2640
ttttatgtaa tttctgtttt taaaaagaca ttattaaatg ggtcaaagga catatagaaa 2700
tgtggatttc agcaccttcc aaagttcagc cagttatcag tagatacaat atctttaaat 2760
gaacacacga gtgtatgtct cacaatatat atacacaagt gtgcatatac agttaatgaa 2820
actatcttta aatgttattc atgctataaa gagtaaactg ttgatgaatt agaagagatg 2880
ctcttttcca agctataatg gatgctttgt ttaatgagcc aaatatgatg aaacattttt 2940
tccaattcaa attctagcta ttgctttcct ataaatgttt gggttgtgtt tggattgtt 3000
tttagtggtt aatagttttc cagttgcatt taattttttg aatatgatac cttgtcacat 3060
gtaaattaga tacttaaata ttaaattata gtttctgata aagaaatttt gttaacaatg 3120
caatgccact gagtgctatt ttgctctttt ggtggagaag gcttttttca aaactcttg 3180
tccttttact tctttctctc agtgcagaat caattctcat tttcatcgta aaagcaaata 3240
gctggattat ttcatttgcc agtttctatt tagtattcca tgcctgcccc attcatctgt 3300
tactgtttaa tttcaattct tctggtgaga attagaaatg aaatattttt tattcattgg 3360
ccaaaaagtt cacagacagc agtggttget atttactttg aattgaaggc acaaaatgca 3420
tcaattcctg tgctgtgttg acttgcaagta gtaagtaact gagagcataa aataaacctg 3480
actgtatgaa gtcaatttaa gtgatgagaa catttaactt tggtgactaa agtcagaata 3540
tcttctcact tcacttaagg gatcttcag aagatatcta aaagtctgta ataagcttag 3600
aagttcagat aaatctaggc aggatactgc atttttgtgg ttttaaaaaa gtccttagga 3660
cagactgaat tatcataact tatggcatca ggaggaaact ttaaaatatac aaggaatcac 3720
tcagtcaccc tcctgttttg ttgaaggatc aaccccaaat tctgggtatt tgagtacatg 3780
tgaatcatgg atttggattt caactttttc cctggatgct ttggaatcgt gtcttccatg 3840
ctccactggg ttcaatttaa aataggagag gctttctctt ctgaaagatc cattttaggt 3900
ctttttcaag aatagtgaac acatttttta acaaaataag ttgtaatttt aaaaggaaag 3960
ttttgcctat tttattaaga tggaaatttc tttttaggct aatttgaaat ccaactgaag 4020
ctttttaacc aatattttta atttgaacca ctagagtttt ttatgatgca aatgattatg 4080
ttgtctgaaa ggtgtggttt tattgaatgt ctatttgagt atcattttaa aagtatttgc 4140
cttttactgt catcatttct cttgttttat tattattatc aatgtttatc tatttttcaa 4200
ttaatttaat acagtttcta atgtgaaaga catttttctg gaaccctgtt tccccttaa 4260
cactaaagag acctcaagtg aaagcatatt gcttagtagg aaggtagaaa atgttaatcc 4320
ctgcgattct ttgagtttta atgacagggt cattttcagt aaaggaaatg ctcaccaaca 4380
catagtcacc aactattaaa ggaatcatgt gattggattt tcccctgtat acatgtaccc 4440
ttggtcataa tcccactatt tcatacatat ttatgcattg ctagattttc ctaggactcc 4500
aatagcatgc tttccaagtg ttattattcc cttaatgtta a 4541

```

<210> 43

<211> 691

<212> PRT

<213> Homo sapiens

<400> 43

```

Asp Thr Asp Val Val Tyr Lys Ser Glu Asn Gly His Val Ile Lys Leu
1           5           10           15
Asn Ile Glu Thr Asn Ala Thr Thr Leu Leu Leu Glu Asn Thr Thr Phe
20           25           30
Val Thr Phe Lys Ala Ser Arg His Ser Val Ser Pro Asp Leu Lys Tyr
35           40           45
Val Leu Leu Ala Tyr Asp Val Lys Gln Ile Phe His Tyr Ser Tyr Thr
50           55           60
Ala Ser Tyr Val Ile Tyr Asn Ile His Thr Arg Glu Val Trp Glu Leu
65           70           75           80

```

Asn	Pro	Pro	Glu	Val	Glu	Asp	Ser	Val	Leu	Gln	Tyr	Ala	Ala	Trp	Gly			
				85					90					95				
Val	Gln	Gly	Gln	Gln	Leu	Ile	Tyr	Ile	Phe	Glu	Asn	Asn	Ile	Tyr	Tyr			
			100					105					110					
Gln	Pro	Asp	Ile	Lys	Ser	Ser	Ser	Leu	Arg	Leu	Thr	Ser	Ser	Gly	Lys			
		115					120					125						
Glu	Glu	Ile	Ile	Phe	Asn	Gly	Ile	Ala	Asp	Trp	Leu	Tyr	Glu	Glu	Glu			
	130					135					140							
Leu	Leu	His	Ser	His	Ile	Ala	His	Trp	Trp	Ser	Pro	Asp	Gly	Glu	Arg			
145					150					155					160			
Leu	Ala	Phe	Leu	Met	Ile	Asn	Asp	Ser	Leu	Val	Pro	Thr	Met	Val	Ile			
			165						170					175				
Pro	Arg	Phe	Thr	Gly	Ala	Leu	Tyr	Pro	Lys	Gly	Lys	Gln	Tyr	Pro	Tyr			
			180					185					190					
Pro	Lys	Ala	Gly	Gln	Val	Asn	Pro	Thr	Ile	Lys	Leu	Tyr	Val	Val	Asn			
		195					200					205						
Leu	Tyr	Gly	Pro	Thr	His	Thr	Leu	Glu	Leu	Met	Pro	Pro	Asp	Ser	Phe			
	210					215					220							
Lys	Ser	Arg	Glu	Tyr	Tyr	Ile	Thr	Met	Val	Lys	Trp	Val	Ser	Asn	Thr			
225					230					235					240			
Lys	Thr	Val	Val	Arg	Trp	Leu	Asn	Arg	Pro	Gln	Asn	Ile	Ser	Ile	Leu			
				245					250					255				
Thr	Val	Cys	Glu	Thr	Thr	Thr	Gly	Ala	Cys	Ser	Lys	Lys	Tyr	Glu	Met			
			260					265					270					
Thr	Ser	Asp	Thr	Trp	Leu	Ser	Gln	Gln	Asn	Glu	Glu	Pro	Val	Phe	Ser			
		275					280					285						
Arg	Asp	Gly	Ser	Lys	Phe	Phe	Met	Thr	Val	Pro	Val	Lys	Gln	Gly	Gly			
	290					295					300							
Arg	Gly	Glu	Phe	His	His	Ile	Ala	Met	Phe	Leu	Ile	Gln	Ser	Lys	Ser			
305					310					315					320			
Glu	Gln	Ile	Thr	Val	Arg	His	Leu	Thr	Ser	Gly	Asn	Trp	Glu	Val	Ile			
			325					330					335					
Lys	Ile	Leu	Ala	Tyr	Asp	Glu	Thr	Thr	Gln	Lys	Ile	Ser	Ala	Ser	Thr			
		340						345					350					
Glu	Gly	Leu	Leu	Asn	Arg	Gln	Cys	Ile	Ser	Cys	Asn	Phe	Met	Lys	Glu			
		355				360					365							
Gln	Cys	Thr	Tyr	Phe	Asp	Ala	Ser	Phe	Ser	Pro	Met	Asn	Gln	His	Phe			
	370				375						380							
Leu	Leu	Phe	Cys	Glu	Gly	Pro	Arg	Val	Pro	Val	Val	Ser	Leu	His	Ser			
385					390					395					400			
Thr	Asp	Asn	Pro	Ala	Lys	Tyr	Phe	Ile	Leu	Glu	Ser	Asn	Ser	Met	Leu			
			405						410					415				
Lys	Glu	Ala	Ile	Leu	Lys	Lys	Lys	Ile	Gly	Lys	Pro	Glu	Ile	Lys	Ile			
		420						425					430					
Leu	His	Ile	Asp	Asp	Tyr	Glu	Leu	Pro	Leu	Gln	Leu	Ser	Leu	Pro	Lys			
		435					440					445						
Asp	Phe	Met	Asp	Arg	Asn	Gln	Tyr	Ala	Leu	Leu	Leu	Ile	Met	Asp	Glu			
	450					455					460							
Glu	Pro	Gly	Gly	Gln	Leu	Val	Thr	Asp	Lys	Phe	His	Ile	Asp	Trp	Asp			
465					470					475					480			
Ser	Val	Leu	Ile	Asp	Met	Asp	Asn	Val	Ile	Val	Ala	Arg	Phe	Asp	Gly			
			485						490					495				
Arg	Gly	Ser	Gly	Phe	Gln	Gly	Leu	Lys	Ile	Leu	Gln	Glu	Ile	His	Arg			
		500						505					510					
Arg	Leu	Gly	Ser	Val	Glu	Val	Lys	Asp	Gln	Ile	Thr	Ala	Val	Lys	Phe			
		515					520					525						
Leu	Leu	Lys	Leu	Pro	Tyr	Ile	Asp	Ser	Lys	Arg	Leu	Ser	Ile	Phe	Gly			
	530					535					540							

Lys Gly Tyr Gly Gly Tyr Ile Ala Ser Met Ile Leu Lys Ser Asp Glu
 545 550 555 560
 Lys Leu Phe Lys Cys Gly Ser Val Val Ala Pro Ile Thr Asp Leu Lys
 565 570 575
 Leu Tyr Ala Ser Ala Phe Ser Glu Arg Tyr Leu Gly Met Pro Ser Lys
 580 585 590
 Glu Glu Ser Thr Tyr Gln Ala Ala Ser Val Leu His Asn Val His Gly
 595 600 605
 Leu Lys Glu Glu Asn Ile Leu Ile Ile His Gly Thr Ala Asp Thr Lys
 610 615 620
 Val His Phe Gln His Ser Ala Glu Leu Ile Lys His Leu Ile Lys Ala
 625 630 635 640
 Gly Val Asn Tyr Thr Met Gln Val Tyr Pro Asp Glu Gly His Asn Val
 645 650 655
 Ser Glu Lys Ser Lys Tyr His Leu Tyr Ser Thr Ile Leu Lys Phe Phe
 660 665 670
 Ser Asp Cys Leu Lys Glu Glu Ile Ser Val Leu Pro Gln Glu Pro Glu
 675 680 685
 Glu Asp Glu
 690

<210> 44
 <211> 4496
 <212> DNA
 <213> Homo sapiens
 <400> 44

gkctykgtkg	wtsmagatac	agatgtggtg	tataaaagcg	agaatggaca	tggtcattaaa	60
ctgaatatag	aaacaaatgc	taccacatta	ttattggaaa	acacaacttt	tgtaaccttc	120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaatatg	tccttctggc	atatgatgtc	180
aaacagattt	ttcattattc	gtatactgct	tcatatgtga	tttacaacat	acacactagg	240
gaagtttggg	agttaaatcc	tccagaagta	gaggactccg	tcttgacagta	cgcggcctgg	300
ggtgtccaag	ggcagcagct	gatttatatt	tttgaaaata	atatctacta	tcaacctgat	360
ataaagagca	gttcattgcg	actgacatct	tctggaaaag	aagaaataat	ttttaatggg	420
attgctgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccca	ctgggtggtca	480
ccagatggag	aaagacttgc	cttcctgatg	ataaatgact	ctttggtacc	caccatgggt	540
atccctcggg	ttactggagc	gttgatatccc	aaaggaaagc	agtatccgta	tcctaaggca	600
ggtcaagtga	acccaacaat	aaaattatat	gttgtaaacc	tgtatggacc	aactcacact	660
ttggagctca	tgccacctga	cagctttaaa	tcaagagaat	actatatcac	tatgggttaa	720
tgggtaagca	ataccaagac	tgtggtaaga	tgggttaaacc	gacctcagaa	catctccatc	780
ctcacagtct	gtgagaccac	tacaggtgct	tgtagtaaaa	aatatgagat	gacatcagat	840
acgtggctct	ctcagcagaa	tgaggagccc	gtgttttcta	gagacggcag	caaattcttt	900
atgacagtgc	ctggttaagca	agggggacgt	ggagaatttc	accacatagc	tatgttcctc	960
atccagagta	aaagtgaagc	aattaccgtg	cggcatctga	catcaggaaa	ctgggaagtg	1020
ataaagatct	tggcatacga	tgaaactact	caaaaaatca	gtgcttctac	tgaaggatta	1080
ttgaatcgcc	aatgcatttc	atgtaatttc	atgaaagaac	aatgtacata	ttttgatgcc	1140
agtttttagtc	ccatgaatca	acatttctta	ttattctgtg	aagggtccaag	ggtcccagtg	1200
gtcagcctac	atagtacgga	caaccagca	aatattttta	tattggaaag	caattctatg	1260
ctgaaggaag	ctatcctgaa	gaagaagata	ggaaagccag	aaattaaaat	ccttcatatt	1320
gacgactatg	aacttccttt	acagttgtcc	cttcccaaag	attttatgga	ccgaaaccag	1380
tatgctcttc	tggttaataat	ggatgaagaa	ccaggaggcc	agctgggttac	agataagttc	1440
catattgact	gggattccgt	actcattgac	atggataatg	tcattgtagc	aagatttgat	1500
ggcagaggaa	gtggattcca	gggtctgaaa	attttgcagg	agattcatcg	aagattaggt	1560
tcagtagaag	taaaggacca	aataacagct	gtgaaatttt	tgctgaaact	gccttacatt	1620
gactccaaaa	gattaagcat	ttttggaaag	ggttatgggtg	gctatattgc	atcaatgatc	1680
ttaaaatcag	atgaaaagct	ttttaaatgt	ggatccgtgg	ttgcacctat	cacagacttg	1740
aaattgtatg	cctcagcttt	ctctgaaaga	taccttggga	tgccatctaa	ggaagaaagc	1800
acttaccagg	cagccagtgt	gctacataat	gttcatggct	tgaaagaaga	aaatatatta	1860
ataattcatg	gaactgctga	cacaaaagtt	catttccaac	actcagcaga	attaatcaag	1920

cacctaataa	aagctggagt	gaattatact	atgcaggtct	acccagatga	aggtcataac	1980
gtatctgaga	agagcaagta	tcatctctac	agcacaatcc	tcaaattctt	cagtgtattgt	2040
ttgaaggaag	aaatatctgt	gctaccacag	gaaccagaag	aagatgaata	atggaccgta	2100
tttatacaga	actgaaggga	atattgaggc	tcaatgaaac	ctgacaaaga	gactgtaata	2160
ttgtagttgc	tccagaatgt	caagggcagc	ttacggagat	gtcactggag	cagcacgctc	2220
agagacagtg	aactagcatt	tgaatacaca	agtccaagtc	tactgtgttg	ctaggggtgc	2280
agaacccgtt	tctttgtatg	agagaggtca	aagggttggt	ttcctgggag	aaattagttt	2340
tgcattaaag	taggagtagt	gcatgttttc	ttctgttatc	cccctgtttg	ttctgttaact	2400
agttgctctc	attttaattt	cactggccac	catcatcttt	gcatataatg	cacaatctat	2460
catctgtcct	acagtccctg	atctttcatg	gctgagctgc	aatctaacac	tttactgtac	2520
ctttataata	agtgcatttc	tttcattgtc	tattattatg	cttaagaaaa	tattcagtta	2580
ataaaaaaca	gagtatttta	tgtaatctct	gttttttaaaa	agacattatt	aaatgggtca	2640
aaggacatat	agaaatgtgg	atcttcagcac	cttccaaagt	tcagccagtt	atcagtagat	2700
acaatatctt	taaatgaaca	cacgagtgtg	tgtctcacia	tatatataca	caagtgtgca	2760
tatacagtta	atgaaactat	ctttaaatgt	tattcatgct	ataaagagta	aacgtttgat	2820
gaattagaag	agatgctctt	ttccaagcta	taatggatgc	tttgtttaat	gagccaaata	2880
tgatgaaaca	ttttttccaa	ttcaaattct	agctattgct	ttcctataaa	tgtttggtt	2940
gtgtttggta	ttgttttttag	tggttaatag	ttttccagtt	gcattttaatt	ttttgaatat	3000
gataccttgt	cacatgtaaa	ttagatactt	aaatattaaa	ttatagtttc	tgataaagaa	3060
attttggttaa	caatgcaatg	ccactgagtg	ctattttgct	cttttggttg	agaaggcttt	3120
tttcaaaact	cttggctcct	ttacttcttt	ctctcagtg	agaatcaatt	ctcattttca	3180
tcgtaaaagc	aaatagctgg	attatctcat	ttgccagttt	ctatttagta	ttccatgcct	3240
gccaattca	tctgttactg	tttaatttca	attcttctgg	tgagaattag	aaatgaaata	3300
ttttttattc	attggccaaa	aagttcacag	acagcagtg	ttgctattta	ctttgaattg	3360
aaggcacaaa	atgcatcaat	tcctgtgctg	tggtgacttg	cagtagtaag	taactgagag	3420
cataaaataa	acctgactgt	atgaagtcaa	tttaagtgat	gagaacattt	aactttggtg	3480
actaaagtca	gaatatcttc	tcacttcact	taagggatct	tccagaagat	atctaaaagt	3540
ctgtaataag	cttagaagtt	cagataaatc	taggcaggat	actgcatttt	tgtgggtttta	3600
aaaaagtcct	taggacagac	tgaattatca	taacttatgg	catcaggagg	aaactttaaa	3660
atatcaagga	atcactcagt	caccctcctg	ttttgttgaa	ggatcaacc	caaattctgg	3720
gtatttgagt	acatgtgaat	catggatttg	gtattcaact	ttttccctgg	atgctttgga	3780
atcgtgtcct	ccatgctcca	ctgggttcaa	tttaaaatag	gagaggcttt	ctcttctgaa	3840
agatccattt	taggtctttt	tcaagaatag	tgaacacatt	ttttaacaaa	ataagttgta	3900
attttaaaag	gaaagttttg	cctattttat	taagatggaa	atctcttttt	aggctaattt	3960
gaaatccaac	tgaagctttt	taaccaatat	tttaaatgtg	aaccactaga	gttttttatg	4020
atgcaaatga	ttatgttgtc	tgaaggtgt	ggttttattg	aatgtctatt	tgagtatcat	4080
ttaaaaagta	tttgccctttt	actgtcatca	tttctcttgt	tttattatta	ttatcaatgt	4140
ttatctattt	ttcaattaat	ttaatacagt	ttctaattgt	aaagacattt	ttctggaacc	4200
cgtttttccc	ttaaacacta	aagagacctc	aagtgaagac	atattgctta	gtaggaaggt	4260
agaaaatggt	aatccctgcg	attcttttag	ttttaatgac	agggtcattt	tcagtaaagg	4320
aatgctcac	caacacatag	tcaccaacta	ttaaaggaat	catgtgattg	gattttcccc	4380
tgtatacatg	tacccttggt	cataatccca	ctatttcata	catatttatg	cattgctaga	4440
ttttcctagg	actccaatag	catgctttcc	aagtgttatt	attcccttaa	tggttaa	4496

<210> 45
 <211> 29
 <212> DNA
 <213> Homo sapiens
 <400> 45

cggtaccatg gcagcagcaa tggaacag 29

<210> 46
 <211> 39
 <212> DNA
 <213> Homo sapiens
 <400> 46

ggagctcgcg gccgctcata tcaacttttag agcagcaat 39

<210> 47
<211> 27
<212> DNA
<213> Homo sapiens
<400> 47

caagctttat cactttttaga gcagcaa

27

<210> 48
<211> 22
<212> DNA
<213> Homo sapiens
<400> 48

cacattcttg ctgcatcagt ca

22

<210> 49
<211> 22
<212> DNA
<213> Homo sapiens
<400> 49

ttgggtcatc ttcaggactt ga

22

<210> 50
<211> 27
<212> DNA
<213> Homo sapiens
<400> 50

caagcttacc atggccacca ccgggac

27

<210> 51
<211> 37
<212> DNA
<213> Homo sapiens
<400> 51

cggatccgcg gccgctcaga ggtattcctg tagaaag

37

<210> 52
<211> 27
<212> DNA
<213> Homo sapiens
<400> 52

cggatccagg tattcctgta gaaagtg

27

<210> 53
<211> 20
<212> DNA
<213> Homo sapiens
<400> 53

tacgccgtgg ttgtgattga

20

<210> 54
<211> 20
<212> DNA

<213> Homo sapiens
<400> 54

ccatacttct cggccacgaa

20

<210> 55
<211> 19
<212> DNA
<213> Homo sapiens
<400> 55

gcctgggatt gtgcactgt

19

<210> 56
<211> 29
<212> DNA
<213> Homo sapiens
<400> 56

gtgtattcaa atgctagttc actgtctct

29

<210> 57
<211> 22
<212> DNA
<213> Homo sapiens
<400> 57

agctagcact gtccagggtc ct

22

<210> 58
<211> 25
<212> DNA
<213> Homo sapiens
<400> 58

agggcccttc atcttcttct ggttc

25

<210> 59
<211> 19
<212> PRT
<213> Homo sapiens
<400> 59

Val Glu Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro
1 5 10 15
Asp Ser Val

<210> 60
<211> 19
<212> PRT
<213> Homo sapiens
<400> 60

Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val Pro
1 5 10 15
Arg Asn Val

<210> 61
<211> 15

<212> PRT
<213> Homo sapiens
<400> 61

Lys Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys
1 5 10 15